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Abstract 
Extracellular vesicles (EV) are heterogeneous populations of small vesicles released by 
virtually all cells and are classified depending on their biogenesis and size. Microvesicles 
(MV) are a subtype of EV and are released under optimal cell conditions and/or upon 
stimuli. In this study, the influence of erythrocyte derived MV (eMV) on the growth of 
THP-1 and Jurkat cell lines was observed. HeLa cells and those infected with Human 
Rhinovirus type 16 derived MV (HRV16iHMV) were used as parallel samples for all 
experiments. This is because virus infected cell derived EV have been extensively studied 
and it is understood that viral-MV uses the virus mechanism of entry to communicate 
with neighbouring cells. Whereas the eMV mechanism is still not fully understood. 
Therefore, to understand the mechanism of eMV action on the growth of cell lines, their 
characterisation was explored. 
Flow cytometry analysis using fluorescence sub-micron particle size reference indicates 
that the samples acquired during this PhD research meet the ‘current requirements’ in the 
field, to be classified as MV according to their sizes (100-1000 nm), and that the amount 
of release of eMV increases depending on the stimulus used (CaCl2, Normal Human 
Serum), due to remodelling of the cell membrane. Immunoblotting and flow cytometry 
surface marker profiling data shows that eMV are composed of key molecules that may 
allow their survival in the extracellular environment and communication with 
neighbouring cells. CD235 surface marker confirms their parent cells and the presence of 
CD47 suggests how eMV may avoid phagocytosis. Surface receptors including CD36, 
CD58 and CD63 indicate how they may communicate and enter the neighbouring cells 
through endocytosis. The identification of proteases suggests how eMV may be capable 
of tissue remodelling and degradation, whereas the presence of miRNAs may indicate 
how eMV can have an impact on the recipient cell by downregulating gene expression. 
Fluorescence microscopy shows eMV interacting with the cell membrane and the flow 
cytometry data suggests that eMV inhibit the growth of THP-1.  
The mechanism which clarifies this impact is unknown. Nevertheless, this PhD project 
has identified key biological molecules which constitute biologically active entities and 
might therefore, help eMV to transfer information and substances to recipient cells 
displaying their potential as delivery vectors. Thus, data obtained here can positively 
contribute towards the EV field.  
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1. Literature review and general introduction 
 
 
1.1 Theoretical background of extracellular vesicles  
Extracellular Vesicles (EV) were first acknowledged when Chargaff & West (1946) 
identified a “precipitable factor” present in ultracentrifugated platelet-free plasma. They 
postulated that these fragments were capable of inducing and accelerating the generation 
of thrombin. Then, Wolf (1967) described these fragments as a residue or by-product of 
platelet activation that had no real purpose, referring to them as ‘’platelet dust’’.  
Studies in this field, particularly those conducted within the last two decades resulted in 
different nomenclature being used for these small vesicles, such as, calcifying matrix 
vesicles (Anderson, 1969), prostasomes (Stegmayr & Ronquist, 1982), plasma-membrane 
microvesicles (Holme, et al., 1994) ectosomes (Hess, et al., 1999), apoptotic bodies and 
exosomes (Théry, et al., 2001), tolerosomes (Karlsson, et al., 2001), microparticles 
(Watanabe, et al., 2003), dexosomes (Patel, et al., 2005) and shedding microvesicles 
(Cocucci, et al., 2009). 
Despite such terms having some use within a specialised field, it became difficult to 
discriminate between the different types of these vesicles, especially where generic 
terminology have a different meaning for different things to different investigators. As a 
result of expanding interest in this field, the International Society for Extracellular 
Vesicles (ISEV) met in Gothenburg-Sweden, April 2012. ISEV gathered pioneers and 
active authors in this field to chair a session on the issue of vesicle nomenclature. The 
authors considered their biogenesis, size, morphology, physical properties, and 
physiological function. As a result, authors were encouraged to use the generic term 
‘‘Extracellular vesicles’’ (EV) for all secreted vesicles, and as a keyword in all 
publications (Gould & Raposo, 2013). 
Research into EV has discovered that these membrane-coated vesicles are released by 
virtually all cells types and have been found in many biological fluids, including ascites 
(Andre, et al., 2002), breast milk (Admyre, et al., 2007), amniotic fluid (Keller, et al., 
2007), brochoalveolar lavage liquid (Prado, et al., 2008), plasma (Orozco, et al., 2009), 
urine (Conde-Vancells, et al., 2010), and saliva (Yang, et al., 2014) amongst other 
 
 
2 
biological samples. It has been suggested that EV can be characterised by antigenic 
markers exposed on their surface linked to their parent cell origin and are distinguishable 
by their biogenesis. EV vary in size, biochemical composition, and biological effects 
(Azevedo, et al., 2007; Distler, et al., 2005).  
Currently, there are three main classes of EV: exosomes, microvesicles and apoptotic 
bodies (Andaloussi, et al., 2013). Each of these types will be discussed in detail in the 
following chapters of this thesis, elucidating their differences and similarities.   
1.1.1 The biogenesis and general characteristics of exosomes 
To date, exosomes are the best characterised class of EV and they range between 30-120 
nm (Fleissner, et al., 2012; Dozio & Sanchez, 2017). When visualised by electron, 
transmission electron, and cryo-electron microscopy exosomes appear as a uniform cup-
like morphology and round vesicles (Trajkovic, et al., 2008; Conde-Vancells, et al., 2010). 
Cryo-electron tomography have been used to observe the 3D structure of platelet 
exosomes in fresh plasma revealing them to be round, electron dense and without a visible 
lipid bilayer (Yuana, et al., 2013).  
Exosomes are considered Intraluminal Vesicles (ILVs) that are known to be released from 
eukaryotic cells, and are created by inward budding of endosomal Multivesicular Bodies 
(MVBs). They are the only know secreted EV that originates from internal membrane 
(Meckes & Raab-Traub, 2011). 
Théry, et al., (2001), pioneers in the field, identified proteins including Alix and Tumour 
susceptibility gene (Tsg) 101 proteins which belong to the Endosomal Sorting Complexes 
Required for Transport (ESCRT in exosomes derived from dendritic cell (DC). This 
strongly supports the hypothesis of ESCRT-dependent exosome biogenesis. 
Current research indicates that ESCRT consists of four soluble multiprotein complexes: 
ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III which leads to the formation of MVBs. 
The ESCRT-0 complex initiates the MVB pathway by localising to endosomes though an 
interaction with an endosome-enriched phospholipid, phosphatidylinositol-3-phosphate 
(PI3P) (Schmidt & Teis, 2012). This process requires ubiquitination of the cytosolic tail 
of endocytosed receptors including Tsg101 (Katzmann, et al., 2002), which belongs to 
the ESCRT-I complex, bind the ubiquitinated  (a protein that is inactivated by attaching 
ubiquitin to it) cargo proteins and activate the ESCRT-II complex (Schmidt & Teis, 2012). 
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Then, the ESCRT-II complex commences with the oligomerization and ESCRT-III 
complex follows, MVBs proteins sequestration and recruits a deubiquitinating enzyme, 
removing the ubiquitin tag from the cargo proteins before sorting them into the ILVs 
(Mageswaran, et al., 2014). Subsequently, the ESCRT-III complex is dismantled by an 
Adenosine Triphosphate enzyme (ATPase) (Urbanelli, et al., 2013) which binds to the 
individual ESCRT-III proteins (associated with a variety of cellular activities), including 
disassembly by Vacuolar protein sorting-associated protein 4 (Vps4). This may help the 
membrane deformation permitting ILVs formation (Hanson, et al., 2008 ). An example 
of exosomes biogenesis is presented in Fig.1.1.1.1. 
 
Fig. 1.1.1.1. An example of exosomes biogenesis. Adopted from Robbins & Morelli (2014) and modified by Roberta Freezor 
using online Pixlr photo editor. After endocytosis of plasma membrane takes place, the transmembrane proteins destined for the 
lysosome lumen are sorted into the vesicles that bud from the perimeter membrane into endosomes (“early endosomes”). Then 
when the endosome that has fully developed into a late endosome intermingles with a lysosome, the vesicles in the lumen are 
sent to the lysosome lumen. MVB membrane invagination and protein sorting are achieved by the concerted function of ESCRT. 
Then the MVB may follow a degradation pathway fusing with lysosomes or are destined to release the ILVs as exosomes to the 
extracellular space by exocytosis (Simons M & Raposo, 2009; Théry, et al., 2002). 
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Some researchers (Trajkovic, et al., 2008; Urbanelli, et al., 2013) suggest that the 
exosomal sorting of proteolipid protein do not require Tsg101 or Alix, suggesting instead 
that ceramide (cell membrane proteins made up of a fatty named sphingosine) promotes 
membrane invagination of ILVs. Bianco, et al., (2009) have suggested that the ceramide 
role demonstrates an involvement of sphingomyelinases in the biogenesis of exosomes. 
This was observed in glial cells releasing exosomes and of neutral sphingomyelinase 2 
secreting micro-Ribonucleic Acid (RNA), a small non-coding RNA molecule containing 
vesicles (Kosaka, et al., 2010). 
Fang, et al., (2007) postulated that higher order-oligomerization might play a key role in 
exosome biogenesis as well as sorting proteins into exosomes. This process was 
demonstrated to be linked to Cluster of Differentiation (CD) 43 (involved in the 
physicochemical properties of the T-cell surface and in lectin binding) exosomal sorting 
in Jurkat T-cells. A similar mechanism was proposed a decade before by Johnstone, et al., 
(1989) using antibody coated (magnetic core bead), obtaining results indicating that 
exosomes contain the transferrin receptor in reticulocytes as well as other plasma 
membrane activities, such as the nucleoside transporter and acetylcholinesterase (Vidal, 
et al., 1997).  
Additionally, the Major Histocompatibility Complex (MHC) class II/peptide complexes 
has also been identified in intestinal epithelial cell derived exosomes (Muntasell, et al., 
2007; van Niel, et al., 2003).  MHC supports the production of immune responses in 
preference to the inbuilt tolerance mechanism responses in the context of a systemic 
challenge. Therefore, controlling the outcomes of the immune response to exosome 
derived epitopes requires both the mucosal microenvironment and local effector cells in 
the intestine are proposed to be key players in this.  
Exosome composition can depend on what is sorted into them when they are being formed. 
This may include proteins (ubiquitination) acting as a substrate for the recruitment 
ESCRT machinery, and the generation of the ESCRT-dependent ILVs. MVBs, for 
example undergo continuous maturation, and during the process they may lose and/or 
gain a variety of proteins and lipids (Piper, et al., 2014), small RNA’s (Nolte-'t Hoen, et 
al., 2012), lipids (Subra, et al., 2007), and a variety of proteins (Keerthikumar, et al., 
2016). Therefore, without limitations to the endosome membrane and their properties 
there are no particular restrictions to their cargo, which is dependent on their parent cell. 
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Exosome movement to the extracellular space requires the fusion of MVBs with the 
plasma membrane, and this fusion has been proposed as requiring the involvement of a 
combination of Soluble N-ethylmaleimide-sensitive factor attachment protein receptors 
(SNAREs) and vesicular SNAREs (v-SNAREs) (Urbanelli, et al., 2013).  Supporting 
evidence of this fusion was observed in an erythroleukaemia cell line (K562), where the 
vesicle (v)-SNARE complex, known as TI-VAMP/VAMP7 (vesicular-associated 
membrane proteins), has been observed as participating in the fusion of exosomes (Fader, 
et al., 2009; Urbanelli, et al., 2013). 
SNAREs and v-SNAREs localised on MVBs interact with target SNAREs (t-SNAREs) 
that are bounded on the intracellular side of the plasma membrane to form a membrane-
bridging SNARE complex (Chaineau, et al., 2009; Jena, 2009). The arrangement of a 
SNARE complex between the vesicle and the acceptor membrane tightens the facing 
membranes together and loses the fusion barrier by undermining the lipid bilayers (Cohen 
& Melikyan, 2004). The activity of SNAREs can be regulated by many proteins including 
Rab3, Guanosine Triphosphate-binding proteins that are members of the Ras superfamily, 
which arrange the initial contact between membranes intended to fuse and assures that 
only appropriate organelles are tethered (Zerial & McBride, 2001).  
Membrane fusion is then coordinated by the arrangement of a quaternary-α-helical trans-
SNARE complex (bridge two membrane compartments or vesicles), consisting of one v-
SNARE on the vesicle and two or three t-SNAREs on the target membrane. After 
membrane fusion, the cis SNARE complex (after fusion - reside in a single resultant 
membrane) is disassembled by the ATPase, which catalyses the formation of Adenosine 
Triphosphate (ATP) from Adenosine Diphosphate (ADP) and free phosphate ion - 
releasing energy. The N-ethylmaleimide-sensitive fusion (NSF) protein is commissioned 
to the cis-SNARE complex from the cytosol by N-ethylmaleimide-sensitive factor 
Attachment Protein Alpha (α-SNAP) (Sehgal & Lee, 2011). The SNARE complex is 
summarised in Fig.1.1.1.2.  
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1.1.2 Microvesicles biogenesis and general characteristics 
Microvesicles (MV) are another class of EV released from the plasma membrane with 
cytosolic content instead of internal membranes (exosomes) (Meckes & Raab-Traub, 
2011). They are suggested to be larger and more heterogeneous in size in comparison to 
exosomes, ranging from 100-1000 nm (Sims, et al., 1988; Hind, et al., 2010; György, et 
al., 2011; Grant, et al., 2011).  
The imbalance of the assortment of membrane proteins, the enhancement in cholesterol 
and diacylglycerol in the membrane asserted to a specific sorting of lipids result in the 
blebbing of the membrane and the release of MV (Hugel, et al., 2005). The bearing of 
phosphatidylserine (PS) in the outer leaflet of the membrane is another particular 
characteristic of MV (Lima, et al., 2009; Sadallah, et al., 2011). This is summarised in 
Fig 1.1.2.1.  
Fig. 1.1.1.2. The SNARE complex. Adopted from Sato, et al., (2005) and modified by Roberta Freezor using online Pixlr photo 
editor. The portrayal of the various steps involved in the exosome membrane budding and vesicle fusion (general mechanisms) 
showing the identified molecules. This is where the donor membrane participates in vesicle formation, the process is mediated 
by GTPases and coat proteins - also involved in sorting of cargo into vesicles. After uncoating, GTPases recruit tethering factors 
that help v-SNAREs on vesicles to join with specific t-SNAREs (acceptor membranes-tethering). Subsequently, v-SNAREs and 
t-SNAREs are paired, mediating the selective fusion of vesicles with the correct acceptor membrane. The SNARE complexes 
are detached by NSF and α-SNAP and then recycled (Zhao & Zhang, 2015).  
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It has been suggested that endothelial and circulating blood cells release MV when 
exposed to distinct induction agents such as complement attack, cell activation, and cell 
apoptosis (Kriebardis, et al., 2012). Monocyte derived MV can also be induced by 
bacterial cell wall components, including lipopolysaccharides and platelets MV by 
activation through thrombin (Xiong, et al., 2012). Also, the inducement of 
polymorphonuclear cells with N-formyl-methionyl-leucyl-phenylalanine or C5a (protein 
fragment released from the cleavage of complement component C5) has been observed 
(Hess, et al., 1999), where with the use of electron microscopy the formation of buds were 
visualised (diameter of 70-300 nm).  
Fig. 1.1.2.1.  An example of MV biogenesis in response to cell stimulation. Adopted from Hugel, et al., (2005) and modified 
by Roberta Freezor using online Pixlr photo editor. The process of MV biogenesis is under the control of three phospholipid 
pumps: (1) Flippase, an inward-directed pump that is a transmembrane lipid transporter protein responsible for aiding the 
movement of phospholipid molecules between the two leaflets of the cell membrane (ATPase moves phosphatidylethanolamine 
and PS from the outer to the cytosolic leaflet); (2) Floppase, an outward-directed pump which uses ATP (ATP-binding cassette 
known as ABC transporter- moves the phospholipids from the cytosolic to outer leaflet) to transport substrates such as 
phosphatidylcholine, sphingolipid and cholesterol in opposition concentration gradients in the adverse direction; And (3) a lipid 
scramblase; which facilitates the movement of lipids along concentration gradients and is responsible for a nonspecific sorting 
of lipids within the membrane (moves the lipids in either direction, towards equilibrium) (Fadeel & Xue, 2009). These enzymes 
(flippase, floppase and scramblase) along with translocase (assists in moving other molecules across a membrane usually) and 
calpain (nonlysosomal, intracellular cysteine calcium-activated neutral proteases) are involved in the microvesiculation process 
of MV (Piccin, et al., 2007). PS exposure and the presence of transient phospholipid imbalance between the external leaflet at 
the expense of the inner leaflet gives rise to MV and this is because after cell stimulation, there is a subsequent cytosolic Ca2+ 
increase promoting the loss of the phospholipid asymmetry of the plasma membrane. 
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Further evidence of MV release has been demonstrated in microglia cells, where the 
enzyme acidic sphingomyelinase, is necessary for MV release after Adenosine 
Triphosphate (ATP) inducement (Bianco, et al., 2009). This acts as a stimulus to secrete 
MV containing proinflammatory cytokines, which are signalling molecules that are 
excreted from immune cells including helper T cells and macrophages that promote 
inflammation (Cruz, et al., 2007). Generally most of the PS and 
phosphatidylethanolamine are preserved by the active ATP-dependent transport to the 
cell membrane inner leaflet (translocase) (Connor & Schroit, 1990).  
The blockade of the translocase and the activation of Calcium ions (Ca2+)-dependent 
scramblase activities (Zwaal & Schroit , 1997; Sadallah, et al., 2011) cause PS to be 
externalised to the outer leaflet at the time of cell activation. Also, it is possible that 
clustering of MV cargo into membrane micro domains drives the MV budding process. 
This is because the inclusion of membrane targeting motifs to highly oligomeric 
cytoplasmic proteins has been shown to be sufficient to motivate their secretion from the 
plasma membrane (Conde-Vancells, et al., 2010). 
The examples provided above suggest that different stimuli can differ from one cell to 
another and that the release of MV from the cell surface is a regulated process (infection, 
activation, transformation, and stress).  
MV have been found to express many of the characteristics of the parent cell, especially 
membrane components (Camussi, et al., 2010). For example, Sprague, et al, (2008) 
investigated the ability of platelet MV to communicate activation signals to the B-cell 
compartment. Their findings demonstrated for the first time that platelet-derived 
membrane vesicles present CD154, a TNF-related activation protein- expressed on 
activated human platelets. According to their research,  MV alone was sufficient to deliver 
CD154 to cells which can stimulate antigen-specific IgG production, and modulate 
germinal centre formation through cooperation with responses elicited by CD4 (+) T cells. 
Similarly to exosomes, without limitations to the cell membrane and their properties there 
are no restrictions to their cargo which may be dependent on parent the cell. 
Furthermore, MV may also serve as important reservoirs of cytokines, mediators of 
inflammatory and immune responses (Théry, et al., 2009).  In a study by Leroyer, et al., 
(2008), the direct inducement of endothelial cells with MV associated CD40 ligand 
suggested that they may aggravate angiogenic responses at the sites of atherosclerosis. 
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Another example lies on acidic pH which is generally existent in hypo-perfused areas of 
solid tumours. This might lead to localized splitting of MV and a consequent discharge 
of their pro-angiogenic and pro-inflammatory load such as vascular endothelial growth 
factor (Taraboletti, et al., 2006).  
1.1.3 Apoptotic bodies  
Apoptotic bodies are another subtype of EV, which are larger than exosomes and MV, 
ranging from 1-5µm in size (Hristov, et al., 2004; György, et al., 2011). Apoptotic bodies 
have been understudied and this is potentially as a result of them being a by-product of 
cell death. Nevertheless, they are known to consist of exposed PS and many cellular 
fragments and organelles, including fragmented Deoxyribonucleic Acid (DNA) (Théry, 
et al., 2001; Hristov M, et al., 2004).  
During apoptosis, EV release occurs in association with blebbing, which is a dynamic 
redistribution of cellular contents (VanWijk, et al., 2003). The actin cytoskeleton 
regulates the Rho (Ras Homologous family) Guanosine Triphosphate (GTP)-ases 
(hydrolase enzymes) (Rho A, B and C), which are intracellular signalling molecules (van 
Aelst & D’Souza-Schorey, 1997). This is important because Rho proteins exchange 
Guanosine Diphosphate (GDP) for GTP, transduce signal to the succeeding effector 
proteins, and decisively retreat to the inactive GDP-bound form by hydrolysing the bound 
GTP. Two isoforms of serine/threonine kinase, Rho-associated protein kinases (ROCK) I 
and ROCK II have been identified as effectors of Rho (Liao, et al., 2007).  
ROCK proteins attach to and are initiated by GTP-bound Rho and the deletion of the 
carboxyl-terminal region of ROCK trigger the amino-terminal kinase domain and the 
initiation of ROCK proteins which assigns to the stabilization of filaments actin, 
phosphorylation of myosin light chains, myosin ATPase activity and the coupling of 
actin-myosin filaments to the plasma membrane. These events lead to elevated actin-
myosin force generation and cell contractility leading to the release of apoptotic bodies 
(Fackler & Grosse, 2008; Mitra, et al., 2011). This process is summarised in Fig. 1.1.3.1. 
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Apoptotic bodies have been observed to relocate their load, including oncogenes and 
DNA, between cells, and have been shown to be important in antigen presentation and 
immunosuppression (Meckes & Raab-Traub, 2011). A specific example suggested that 
apoptotic bodies from mature endothelial cells are taken up by endothelial progenitor cells, 
increasing their number and differentiation state, suggesting that such a mechanism may 
simplify the adjustment of injured endothelium and may serve as a new signalling 
pathway between progenitor and injured somatic cells (Hristov M, et al., 2004). Thus, 
further proving apoptotic bodies to be of biological function and interest, but again a 
heterogeneous class of EV.  
Erythrocytes are probably the only cell type that does not form exosomes. In mature 
erythrocytes only membrane vesicles may be formed due to their lack of organelles and 
nucleus. Little is known about the role of these membrane vesicles, therefore, it is 
important to distinguish, characterise and understand erythrocytes derived EV.  
 
Fig. 1.1.3.1. A basic representation of apoptotic bodies biogenesis. Adopted from Martinez, et al, (2011) and Julian & Olson 
(2014) and then merged and modified by Roberta Freezor using online Pixlr photo editor. In a varety of cell types, trigger of 
Rho-associated kinase ROCK I by caspase 3-interposed cleavage intensifies phosphorylation of myosin light chain, which order 
further actin myosin contraction, membrane blebbing and the formation of apoptotic bodies. The occurrence of apoptotic 
blebbing has been reported to be dependent on the function of ROCK but not on that of Rho, specifically ROCK I being cleaved 
during apoptosis by initiated caspases, promoting a truncated kinase with elevated intrinsic activity. This cleaved form of the 
kinase is satisfactory to promote cell contraction and membrane blebbing without caspase initiation, which is dependable to a 
direct effect of ROCK-induced cell contractility on the formation of the apoptotic morphology (Coleman, et al., 2001). 
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1.2 The importance of erythrocyte in circulation  
Originating from stem cells in the bone marrow, human erythroid cells are differentiated 
through a process named erythropoiesis (controlled by erythropoietin) to become mature 
erythrocytes (see Fig. 1.2.1). Commonly termed red blood cells for their bright red colour, 
and accounting for approximately 40-45 percent of human venous blood, they are the 
most abundant cell type in the blood with a lifespan in the circulatory system of about 
100-125 days (Lodish, et al., 2000).  
 
When arterial blood arrives in peripheral capillaries erythrocytes integrate the narrow 
capillaries one by one (Hamasaki & Okubo, 1996). This is because mature erythrocytes 
are approximately 7000 nm and relatively basic and conversely unique due to the lack of 
organelles and a nucleus. These characteristics allow erythrocytes to easily change their 
shape, leading to an advantage in flexibility and movement throughout the blood stream. 
Fig. 1.2.1. Blood cells formation and development. Adopted from SEER training modules (2008), modified and expanded by 
Roberta Freezor using online Pixlr photo editor. Where, the rate of blood cell production is controlled by the body's needs. The 
development of erythrocyte (Erythropoiesis) is the process which produces erythrocytes according to the stimulation by less O2 
in circulation, which is recognised by the kidneys that then release the hormone erythropoietin that stimulates proliferation and 
differentiation of cell precursors. Additionally, the bone marrow yield and discharge more white blood cells (leukocytes) in 
reaction to infections agents, and it also discharges more platelets (thrombocytes) in response to bleeding.  
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The dominant cytoplasmic constituent is haemoglobin, which is required for binding and 
releasing Oxygen (O2) as well as Carbon Dioxide (CO2). The CO2 is immediately 
hydrated to Carbonic Acid (H2CO3) by Carbonic Anhydrase, and the H2CO3 rapidly 
estranges into Hydrogen Ion (H+) and Bicarbonate (HCO3-). Then the leading erythrocyte 
integral membrane protein Band 3, exchanges the cellular HCO3- with Chloride in plasma. 
Following the anion exchange, H2CO3 is converted to a strong acid, Hydrochloric Acid 
(HCL), and then the intracellular pH becomes acidic which generates for the dissociation 
of O2 from oxyhemoglobin (HbO2). The dissociated O2 is given to tissues that 
metabolically generate CO2. Then the protons  that were formed  are accepted  by the  
groups of  oxyhemoglobin (HbH+), and the pH level within erythrocytes is  re-established 
to  prevent continuous dissociation  of  oxygen  from  HbO2 generating more CO2. CO2 
are provided with more O2 from HbO2 in tissues (Hamasaki & Okubo, 1996; Hamasaki 
& Yamamoto, 2000; Diez-Silva, et al., 2010).Therefore, erythrocytes are essential for 
optimal homeostasis (Diez-Silva, et al., 2010).  
Due to their vital function within the human body, erythrocytes have been studied 
extensively. Their plasma membrane (De Rosa, et al., 2007), the functions of 
haemoglobin (Giardina, et al., 1995), their proteome (Kakhniashvili, et al., 2004), and 
their lipidome (Timperio, et al., 2013) are well documented.  
Also, a large part of human iron is embedded in erythrocytes (haemoglobin) and the 
regulation of iron distribution acts as an innate immune mechanism against invading 
pathogens (Cassat & Skaar, 2013). The lysis of erythrocytes by bacteria, causes their 
haemoglobin to release their contained free radicals, which have been suggested to break 
down the pathogen’s cell wall and membrane, leading to pathogen death (Jiang, et al., 
2007; Minasyan, 2014). A role in modulating T cell proliferation and survival by 
enhancing cytokine secretion and induction of the Interleukin 2 Receptors (IL2R) through 
downregulation of oxidative stress and modulation of CD4+/8+ (immune system helper 
and killer cells, that flight against infections)  ratios has also been suggested  (Fonseca, et 
al., 2003; Minasyan, 2014). 
1.2.1 Erythrocyte derived MV 
Erythrocyte derived EV are an extracellular and heterogeneous population of small 
vesicles released from the plasma membrane of erythrocytes. They have been reported as 
being smaller (from 100-400 nm) than other MV subtypes (Hind, et al., 2010). Therefore, 
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considered MV (eMV) due to their general size (100-100 nm) (Borges, et al., 2013). These 
are the EV type that forms the focus of this PhD research. 
Erythrocytes undergo a series of biochemical and physical changes known as storage 
lesions during the aging process, including lipid and protein oxidation conjointly a 
reduction in deformability and osmotic stability (Solberg, 1988). The latter results in 
noticeable haemolysis, with the discharge of free haemoglobin 14 and iron, leading to 
erythrocytes losing approximately 20 percent of their haemoglobin and membrane surface 
area over time due to the discharge of MV (Alaarg, et al., 2013).  
eMV release has been observed to increase significantly during storage, therefore patients 
receive large numbers of MV during blood transfusions, which is dependent on the age 
of the unit (Zecher, et al., 2014). This can lead to the hypothesis of transfused eMV being 
linked to post blood transfusions adverse events/complications. These may include 
Posttransfusion purpura, Transfusion-associated graft versus host disease, iron overload, 
and immune-modulation, including bacterial and viral infection complications. (Sahu, et 
al., 2014; Bosman, et al., 2008; Dellinger & Anaya, 2004).   
MV release has also been observed as significantly lower in pre-menopausal women than 
in age-matched men in a study comparing age and sex specific differences in blood-borne 
MV from apparently healthy humans (Gustafson, et al., 2015). 
Elevated levels of eMV release have also been associated with numerous diseases, 
including Paroxysmal Nocturnal Haemoglobinuria (Sloand, et al., 2004), β Thalassaemia 
intermedia (Habib, et al., 2008), Malaria (Mantel, et al., 2013), Hereditary Haemolytic 
Anaemia (Alaarg, et al., 2013), and Sickle-cell disease (Kasar, et al., 2014). Their clinical 
relevance has also been observed (Tissot, et al., 2010) in transfusion complications (Jy, 
et al., 2011), thrombin generation (Rubin, et al., 2013), cardiovascular complications 
(Tantawy, et al., 2013) and systemic inflammation by thrombin-dependent activation of 
complement (Zecher, et al., 2014).   
According to Bicalho, et al, (2013), eMV release does not disturb glycerophosphocholine 
and sphingomyelin erythrocyte membrane organisation. This was observed when 
erythrocytes and eMV were set side by side to understand the membrane compositional 
features of out of date blood bank-stored erythrocytes. Their results revealed that 
phospholipidomics could potentially provide a superior understanding of the eMV release 
process, suggesting that eMV release may not be such a negative phenomenon to the 
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erythrocytes. Additionally, it could be suggested that eMV can potentially help to clear 
certain molecules from the blood flow. This is because of the function of their parent cell, 
erythrocytes remove particular harmful agents including denatured haemoglobin, C5b-9 
complement attack complex, band 3 neo-antigens, and/or immunoglobulin G that 
accumulates during their lifespan (Willekens, et al., 2008). MV in general contain similar 
characteristics of those present in their parent cell (see page 8).  
Only recently a study of eMV characterisation (Nguyen, et al., 2016) and a summary 
review of eMV biological roles was reported, suggesting that eMV has a role in oxidative 
stress, in inflammation, Nitric Oxide (NO) homeostasis, thrombosis and foam cell 
formation (Harisa, et al., 2017). However, the role of eMV in biological functions is not 
yet fully understood.    
1.2.2 Cellular mechanisms underlying eMV release  
The mechanism leading to the release of EV is initiated by an increase in cytosolic Ca2+, 
which causes enzymatic activation (see Fig. 1.1.2.1). The introduction of Ca2+ containing 
buffer to normal erythrocytes promotes a global and transient rise in free Ca2+ 
concentration of 2µM (Bogdanova, et al., 2013). Nevertheless, the concentration 
decreases in the course of the time until it reaches its resting value, because of the 
intracellular system maintaining the Ca2+ homeostasis (Constantin, et al., 1998).  
Erythrocytes are known to shed MV in vitro under several other conditions too. For 
instance, when erythrocytes are depleted of their ATP content by incubation at 37 ℃ they 
have been observed to decrease their total ATP, glucose and water content (Nagy, et al., 
1998). The depletion of ATP leads to the assumption that they begin to produce MV due 
to the remodelling of the membrane, and this is because the membrane fluctuations have 
been ascribed to ATP-dependent phosphorylation of structural proteins associated with 
the membrane (Levin & Korenstein, 1991). The consequence of strongly buffered energy-
driven maintenance of cell integrity has been postulated to be through the dissociation of 
actin from spectrin at nodes in the cell cytoskeleton, which could contribute to the energy 
expenditure (Kuchel & Benga, 2005). Also, there is a significant lag period between the 
depletion of ATP (caused by blocking glycolysis) and gross changes in cell shape which 
could cause microvesiculation in general and probably even more from ATP-depleted 
erythrocytes (Lutz & Bogdanova, 2013). This is because ATP is necessary for 
maintaining cell shape and flexibility, repairing membrane lipids, and energizing 
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metabolic pumps (Gov & Safran, 2005). The diffusible diacylglycerol partitions into the 
outer monolayer also contributes to membrane budding (Müller, et al., 1981). 
The release of small haemoglobin-containing vesicles from human erythrocytes treated 
with Ca2+ and ionophore A23187 (mobile ion-carrier that forms stable complexes with 
divalent cations), appears to accelerate  membrane fusion events and provides a 
convenient model system that might be relevant to more general aspects of biological 
membrane fusion (Bevers, et al., 1992). It has been a while since the treatment of 
erythrocytes with Ca2+-ionophore was suggested to induce a large variety of concomitant 
biochemical changes, including calcium influx (Allan, et al., 1976). The breakdown of 
polyphosphoinositide’s (phosphatidylinositol 4-phosphate + phosphatidylinositol 4,5-
bis-phosphate) with a consequent rise in 1,2-diacylglycerol and phosphatidate 
concentrations can cause several alterations in membrane polypeptide pattern. The 
aggregation of protein components catalysed by transamidase, the conversion of 
polypeptide 2.1 molecular weight about 200kDa into lower-molecular-weight 
components, especially polypeptide 2.3 (~175kDa) and the probable proteolysis of 
polypeptide 4.1 (~78kDa) increase the intracellular free Ca2+ levels (Allan & Thomas, 
1981). 
Bevers, et al., (1992), suggested that calcium influx initiates a variety of cellular 
responses. For example, in blood platelets and erythrocytes, these responses include 
marked shape changes with evagination of the cell surface and the shedding of MV. The 
formation of MV indicated to involve fusion between opposing segments of the plasma 
membrane and may be accompanied by a local collapse of the normal asymmetric 
distribution of plasma membrane phospholipids’. Particularly if the aminophospholipid 
translocase, which restores phospholipid asymmetry by specifically translocating 
phosphatidylserine and other aminophospho-lipids to the membrane inner leaflet is 
inhibited.  
Furthermore, Antibody-Antigen binding could induce the disruption of membrane 
organisation in erythrocytes (Zimring, et al., 2005; Powers, et al., 2007), and therefore 
may cause microvesiculation (Canellini, et al., 2012). The complement activity (attack) 
is due to the antibody-mediated or otherwise initiated activation of the complement 
cascade, and the presence of complement factors such as C5b-9 MAC can stimulate the 
release of MV (Hamilton, et al., 1990).  
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The complement system is a ‘key player’ in inflammatory responses 
(antibodies attachment to a specific antigen). It provides recognition, warning signals and 
the initial fast response upon exposure to foreign organisms. Comprised of three 
activation pathways (Classical, Alternative and Lectin), it culminates in the formation of 
the convertases, which in turn generate the major effectors of the complement system 
including Opsonins (C3b, iC3b, and C3d), anaphylatoxins (C3a and C5a), and Membrane 
Attack Complex (MAC- C5b through C9) (Dunkelberger & Song, 2010) (see Appendix 
I).  
Landsteiner’s “law” explains that the reactions between the erythrocytes and serum are 
related to the presence of markers (antigens) on the erythrocytes and antibodies in the 
serum, postulating that two different antigens (A and B) are found on the surface of eryth-
rocytes. The "naturally occurring" antibodies against these antigens are found in the 
plasma of individuals. Erythrocytes of a particular person hold antigens on their surfaces 
that correlate to their blood group, and antibodies in the serum that recognise and inte-
grate with the antigen sites. Naturally occurring antibodies are therefore a result of im-
munisation; the manufacture of antibodies in response to an antigen. (Landsteiner & 
Donath, 1904; Schwarz & Dorner, 2003; Berkman & Lawler, 2018).   
Spalter, et al, (1999) suggested that Normal Human Serum (NHS) contains naturally 
occurring antibodies and therefore complement when IgM and IgG antibodies reactive 
with autologous blood group antigens were present in the immunoglobulin (Ig) fraction 
of NHS. That is because natural IgG anti-A antibodies purified from IgG of individuals 
of blood group A exhibited an affinity for A trisaccharide antigen. Therefore, it is 
reasonable to speculate that NHS may be used as an inducer for microvesiculation in 
erythrocytes (Canellini, et al., 2012).  
In contrast to erythrocytes, general viral derived EV have been extensively studied. It is 
well understood that viral-EV use the virus mechanism of entry to communicate with and 
enter neighbouring cells (receptor-mediated endocytosis), and it is well known that viral 
infection also induces the release of EV (Meckes Jr, 2015; van Dongen, et al., 2016). 
Whereas with eMV such a mechanism is still not understood. Nevertheless, there have 
not been any reported articles that analyse MV release from Human Rhinoviruses type 16 
(HRV16) infection, thus HRV16 is the HRV type used for this research as a parallel sam-
ple for all experiments. 
 
 
 
17 
1.3 Introduction to Human Rhinovirus  
Human Rhinoviruses (HRV) are prevalent respiratory pathogens related with mild and 
self-limited upper respiratory tract infections. They are understood to be associated with 
the exacerbation of respiratory diseases such as asthma and chronic obstructive 
pulmonary disease (Khetsuriani, et al., 2008), and are answerable for serious disease 
manifestations such as bronchiolitis in young children and the immunosuppressed (Miller, 
et al., 2007).  
HRVs are responsible for more than 50 % of upper respiratory tract infections and it is 
considered to be the common cold that commonly fades away within seven days. The 
symptoms usually include nasal stuffiness, sneezing, coughing, and a sore throat but 
about 12–32 % of HRV infections in children of less than 4 years of age are asymptomatic 
(Jacobs, et al., 2013). A variety of polymorphisms in cytokine genes have been shown to 
impact the severity of HRV infection, implying a genetic predisposition (Tregoning & 
Schwarze, 2010). 
Up to date, only palliative (drugs without side effects will be accepted by otherwise 
healthy patients) treatment is offered, and vaccination as well as approved antivirals are 
still not available (Blaas & Fuchs, 2016), despite HRVs being seemingly the world’s most 
causative factor of respiratory diseases.  
HRVs are unusually disinclined transmitters, infecting about 50% those of susceptible in 
family environments (including day care and the home). Peltola, et al., (2008), suggested 
that HRV are spread mainly by aerosol, rather than by fomites or personal contact because 
it requires close contacts between virus donors and recipients. Rhinoviral infection of a 
minuscule fraction of airway epithelial cells motivates the creation of an array of 
cytokines and chemokines, which leads to the enrolment of immune cells to the airways 
and increases airway inflammation (Stokes, et al., 2011). 
Numerous serotypes exist and molecular methods have described more than 150 complete 
or partial genome sequences of all known HRV, that have been published (Fuchs & Blaas, 
2012; McIntyre, et al., 2013). 
Phylogenetic analyses have grouped HRV into three species: 
1. HRV-A;  
2. HRV-B; and  
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3. HRV-C.  
 
HRV can be divided into major (HRV-A) or minor (HRV-B) group strains. The division 
is determined by their recognition via Intercellular Adhesion Molecule-1 (ICAM-1) or 
the Low-Density Lipoprotein (LDL) receptor (Fuchs & Blaas, 2012). The newest and 
most distinct group of HRV (HRV-C),  has been suggested to use human cadherin-related 
family member 3, a transmembrane protein that enables HRV-C binding and replication 
in normally unsusceptible host cells (Bochkov, et al., 2015). 
HRV are non-enveloped, single-stranded RNA (ssRNA) with a (+) RNA genome, of 
approximately 7100 base viruses that belong to the Picornaviridae family, genus 
Enterovirus. They are composed of 60 copies, each of four polyomavirus (natural hosts 
are primarily mammals and birds) capsid proteins. Viral Protein (VP) 1, VP2, VP3, and 
the small myristoylated (lipidation modification) VP4 are arranged on an icosahedral (30 
nm in diameter) triangulation number 1, and lattice point 3 (Harutyunyan, et al., 2013). 
The VP1, VP2, and VP3 proteins elucidate the virus antigenic distinctiveness, whereas 
VP4 anchors the RNA core to the capsid. Each of the four capsid proteins has 60 copies, 
which contributes to the virion an icosahedral structure, with a canyon in VP1 that acts 
as the site of attachment to cell surface receptors for the major group through ICAM-1 
only (Jacobs, et al., 2013).  
Virus uptake occurs via clathrin-dependent, independent endocytosis or micropinocytosis, 
which is dependent upon the receptor type. This is where the virions experience 
conformational changes and promote hydrophobic subviral particles, an action that is 
originated by ICAM-1 (major group) and/or the low-pH environment in endosomes 
(Blaas & Fuchs, 2016). The RNA genome passes through the endosome membrane into 
the cytosol via a pore organised by viral proteins or succeeding membrane rupture. While 
in the cytosol, the host cell ribosome translates the positive-sense, single-stranded RNA 
into a polyprotein that is refined into its assorted components. The decrease in pH 
promotes viral uncoating (first stages of the viral replication cycle- transcription) (Fuchs 
& Blaas, 2010).  
Negative-strand (parental) RNA is replicated along as being translated into structural 
(capsid) and non-structural proteins. The virion is then assembled and confined before 
cellular export via cell lysis takes place (Jacobs, et al., 2013). The viral double-stranded 
RNA (dsRNA) formed at the time of HRV replication is identified by the host pattern 
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recognition receptor, called the Toll-like receptor 3, along with melanoma differentiation-
associated gene 5 and retinoic acid-inducible gene I (Kato, et al., 2008; Wang, et al., 
2009).  
1.3.1 Viral-derived MV 
Belonging to group A, HRV16 uses the  receptor Intercellular Adhesion Molecule (ICAM) 
1 to enter cells and are referred to as the major group (Palmenberg, et al., 2009; Oliveira, 
et al., 1993).  The release of exosomes and MV has been observed in many viral infections 
including Epstein-Barr virus, Herpes simplex virus (HSV), Human Immunodeficiency 
Virus (HIV) Retroviruses, Hepatitis B virus and poxviruses and Hepatitis C virus (HCV) 
(Meckes & Raab-Traub, 2011), but not in HRV16 infection to date. 
There are a vast amount of studies demonstrating EV discharge from viral infected cells 
harbour and distribute regulatory factors to recipient cells (Robbins & Morelli, 2014). 
These include viral RNA and proteins, viral and cellular miRNA, as well as host 
functional genetic elements to nearby cells. This leads to production of infections particles 
and modulating cellular responses including the spread or limitation of infection 
conditional on the type of pathogen and target cells. EV have been exploited as candidates 
for the development of antiviral or vaccine treatments (Chahar, et al., 2015), showing the 
potential of MV derived from viral infection. 
The study of MV secretion during viral infection is complex because of their similarity 
in size and the density of EV and infectious viral particles, making it a challenge to tell 
them apart. For example, HIV particles have biophysical properties indistinguishable to 
exosomes secreted from the same cells. Including size similarity because they are 
approximately 100 nm, have a buoyant density of 1.13 to 1.21 g/ L, and functional effects 
on immune cell activation (Wang, et al., 1999; Cantin, et al., 2008). HRV16 on the other 
hand is approximately 30 nm and much smaller than MV and has no lipid envelope 
(Tuthill, et al., 2010) like HIV, they may therefore be considered to be separated entities.  
MV have been found to be beneficial either to the host cell or to the infectious agent via 
the packaging and transfer of functional proteins, messenger RNA/miRNA, and other 
cytosolic components, (Manjunath, et al., 2009). Virally infected cells have been proven 
to be advantageous to exemplify the role of microvesiculation in intercellular 
communication (Wurdinger, et al., 2012). 
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All types of viruses retain individual properties that allow protection from immune attack. 
Wurdinger, et al., (2012), outlined the influential immune modulatory steps involved in 
virus-induced MV arrangement and release during different viral infections. According 
to their review report in accordance with other studies (De Gassart, et al., 2009; Klibi, et 
al., 2009), the conservancy of the virus relies on MV release of infected cells.  
MV released by infected cells consist of particular components of the cell and the virus, 
including some that may promote the capability of virions to remain in an unfavourable 
antiviral immune environment. Intercellular processes are well orchestrated and it 
depends on the virus type and their viral cycle to produce specific cellular and immune 
outcomes. These highlight some aspects of EV that are hijacked by viruses (enveloped) 
to assist in their spread or avoidance of the immune system (Wurdinger, et al., 2012).  
HSV for example, targets the MHCII molecule processing pathway by viral envelope 
glycoprotein (GP) B. The antigen-presenting cells consistently organise the MHCII 
surface receptor human leukocyte antigen to MHCII compartments for presenting peptide 
antigens to the immune system, to elicit or suppress T-helper cell reaction that encourages 
B-cell generation of antigen-specific antibodies (Temme, et al., 2010).  MV containing 
viral tegument proteins and GP’s, can prime nearby cells for beneficial infection and 
lessen immune recognition. This demonstrate their potential of evading the host immune 
system (Wurdinger, et al., 2012).  
In relation to HRV16 (enterovirus- non envelope), there may be numerous hypothesis 
(not the aim of this PhD study) including that it may use the viral RNA synthesis, protein 
translation, protein processing and the general intracellular localisation of viral proteins. 
This may be embedded in MV to disrupt host-cell functions including nucleo-cytoplasmic 
trafficking because this was demonstrated in HRV infected HeLa cells (Amineva, et al., 
2011). 
Furthermore, Walker, et al., (2016) suggested that the HRV16 genome encodes two 
proteases specifically, 2A and 3C as well as a precursor protease, 3CD. These proteases 
are necessary for adequate virus replication, for the precise localisation of proteins during 
infection and for the temporal regulation of 2A and 3CD/3C protease activities during 
HRV16 infection. Therefore, these proteases may be hypothesised to be embedded in MV  
because MV generally express some of the characteristics of their parent cell, suggesting 
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that MV derived from HRV16 infected cells could potentially be hijacked by the virus to 
spread infection.  
Indeed, EV derived from viral infection do not replicate as an independent entity. They 
can however facilitate the movement of infectious material through tissues and may be 
the cause of pathologies resulting from the infection (Lagana, et al., 2013; Schwab, et al., 
2015).   
Pegtel, et al, (2010) suggested that viral particles can enter monocyte-derived dendritic 
cells using EV to safely spread their miRNAs. This is because MV are undetected by the 
immune system, resulting in the undetected miRNAs of non-host origin facilitating the 
rapid spread of the virus, using the exosomes/MV to transport viral miRNAs. 
Additionally, MV and exosomes have been observed to be increased in HIV-1–infected 
Monocyte-derived macrophages, showing that EV derived from viral infection not only 
serves as a model for cell to cell communication but also serves as an inducer for 
microvesiculation (Kadiu, et al., 2012). 
1.4 Cellular mechanism processes involved in EV uptake 
A variety of mechanisms for EV uptake have been proposed during the past few decades 
including receptor-mediated endocytosis, phagocytosis, macropinocytosis, and plasma 
or endosomal membrane fusion. These mechanisms have been summarised by Mulcahy, 
et al., (2014) in their review article.  Endocytosis is the action of capturing a substance 
or particle from outside the cell by swallowing it up. This occurs when the membrane 
folds over the substance and it becomes utterly confined by the membrane and the 
membrane-bound sac (vesicles) compresses and the substance is then moved into the 
cytosol. The three main subtypes of endocytosis are summarised in Fig. 1.4.1. 
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There has been evidence suggesting that EV are consumed into endosomal 
compartments through endocytosis (Morelli, et al., 2004). Uptake of EV have been 
considered to be fast, being pinpointed inside cells from as soon as 15 minutes after 
initial admittance (Feng, et al., 2010). Several studies have demonstrated that when cells 
are incubated at 4°C, their potential to internalise EV is quantitatively reduced. Thus 
suggesting that the uptake is an energy-requiring process, that might be affected by the 
decreased fluidity of the lipid layer at lower temperatures, as the fatty acid tails of the 
phospholipids become more rigid at cold temperatures and that the process requires a 
functioning cytoskeleton, both of which are indicative of endocytic pathways 
(Escrevente, et al., 2011; Tian, et al., 2013). 
Fig. 1.4.1. The three main subtypes of endocytosis. Adopted from Zhenzhen & Roche (2015) and adapted by Roberta Freezor 
using online Pixlr photo editor. An example showing the three main types of endocytosis in dendritic cells. Where 
1.Phagocytosis represents cellular eating - plasma membrane engulfs the solid material and unambiguous association with the 
internalised material is not necessary, it comprises the internalisation of specific crude matter, such as bacteria and fragments of 
apoptotic cells. This is a receptor-mediated event that engages the progressive arrangement of invaginations nearby the 
molecules intended for internalisation, indepedently of the cooperation of enveloping membrane extensions (Doherty & 
McMahon, 2009). 2. Pinocytosis (engulfs vesicles) represents cellular drinking - membrane bend inward to design a channel 
granting dissolved substances entry to the cell. The disarranged extensions of the plasma membrane extend beyond cell surface 
and envelop an area of extracellular fluid, which is then internalised completely, due to the blending of the membrane projections 
amonsgt themselves or back with the plasma membrane (Swanson, 2008). And 3. Receptor-mediated endocytosis, where a 
particular receptor on the cell surface binds securely to the extracellular macromolecule (the ligand) - the plasma membrane 
domain accommodating the receptor-ligand complex then under goes endocytosis, becoming a transport vesicle. This process 
comprise the arrangement of particular membrane patches called pits, which are determined by the presence of the cytosolic 
protein clathrin (Alberts, et al., 2002). 
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It has been suggested that the fusion of the EV with the cell plasma membrane (lipid 
bilayers are carried into close concurrence and the outer-leaflets come into absolute 
association), leads to the creation of a hemi-fusion stalk with fused outer-leaflets. The 
stalk expansion creates the hemi-fusion diaphragm bilayer from which a fusion pore 
opens and as a result, the two hydrophobic cores mix, creating one steady structure with 
the collaboration of a variety of protein families including SNAREs, Rab proteins, and 
Sec1/Munc-18 related proteins (Valapala & Vishwanatha, 2011).  
Parolini, et al., (2009), demonstrated EV fusion by showing diffusion of lipids in the 
membrane of recipient cells, explaining how EV could release their internal content into 
the cytosol of recipient cells through lipid interaction (Kosaka, et al., 2010). It also 
revealed significant EV involvement in physiological processes such as 
immunomodulation, inflammation, coagulation, and intercellular communication (Distler, 
et al., 2005; Tissot, et al., 2010; Théry, 2011; Fleissner, et al., 2012).  
Each case presented above, indicates that bioactive ligands disclosed on the MV surface 
are believed to be answerable for a variety of regulatory processes that may change 
recipient cells random circulation of MV in tissue and body fluids, or even by directional 
uptake of MV based mechanisms. Nevertheless, further studies are necessary in order to 
fully understand these mechanisms, especially when considering EV heterogeneity. 
1.5 The potential biological interaction between MV and neighbouring cells  
MV have demonstrated characteristics of delivering molecular signals using lipids, 
proteins, nucleic acids, and/or functional transmembrane proteins that are the same as in 
the parent cell. This is through interaction with surrounding cells, mimicking the 
characteristics of a long-distance cell-cell communicator (Ardoin & Pisetsky, 2008; 
Bruno, et al., 2009).  
Generally, during cell communication, the signalling cell discharges a distinct signalling 
molecule that is then recognized by the target cell, which may lead to cleavage by receptor 
molecules, internalisation and cellular responses.  An example of the three general stages 
of cell signalling is summarised in Fig. 1.5.1. 
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A challenge for the EV field is understanding how EV may reinforce physiological and 
pathophysiological processes while being able to exhibit EV transferring material 
among cells. EV and cell interactions have been suggested as occurring locally, 
regionally or systemically via lymph and blood vessels (Cocucci, et al., 2009; Castellana, 
et al., 2010; Swartz & Lund, 2012; Lee, et al., 2011). They are often external by nature, 
as a result of straightforward surface-to-surface interaction and stimulation between the 
target cell and the EV surface. This lead to the assumption that EV may act via surface 
interactions with receptor molecules on target cells, or act as delivery vectors by directly 
transferring their contents, including RNA (Diehl, et al., 2012), bioactive lipids, and 
proteins into the recipient cell (Watanabe, et al., 2003; Cardo, et al., 2008). 
Fig.1.5.1. A representation of the three general stages of cell communication and signalling in Hairy cell leukaemia. 
Adopted from Sivina, et al., (2014) and adapted by Roberta Freezor using online Pixlr photo editor. Where (1) represents the 
target cell detecting a signalling molecule present in the exogenous environment (a signal molecule-ligand) which binds to a 
receptor protein (receptor), compelling it to change shape. (2) where the conversion of the signal to a configuration that can 
generate a particular cellular response (the cascades of molecular interactions broadcast signals from receptors target the 
molecules in the cell) and (3) where the particular cellular effect generated by the signalling molecule reacts and the cell 
signalling advances to the regulation of transcription or cytoplasmic activities including protein synthesis by switching particular 
genes on or off within the nucleus. 
 
 
25 
The cargo of MV have been demonstrated to be active in recipient cells, and are not just 
a means for the removal of cellular waste (Thebaud & Stewart, 2012), and can either be 
internalised or be cleaved at the cell surface where they remain (Robbins & Morelli, 2014). 
The protein architecture of EV may regulate their performance in different manners. 
Surface-exposed receptors and ligands are answerable for dissemination, for the cleavage 
of EV to target cells or to the extracellular matrix. This is where EV may invoke 
intracellular signalling pathways through a simple intercommunation with the surface 
receptors or ligands of target cells or by going through internalisation (Yáñez-Mó, et al., 
2015). 
EV interaction with target cells may be dependent on the recipient cells and its ability 
may be dependent on the phagocytic capabilities of the recipient cell in general (Feng, et 
al., 2010). Whereas with viral-EV in particular, ESCRT components have been observed 
as being recruited to the site of budding, leading to the development of the “Trojan 
exosome hypothesis”. This hypothesizes that retroviruses have adapted to use host 
exosome machinery for the arrangement and transfer of virions by a non-viral route, but 
retrovirus-directed transmission. This is with the particular lipid composition of retroviral 
particles, the host cell proteins existent in retroviral particles, the complex cell biology of 
retroviral discharge, and the skill of retroviruses to infect cells free of envelope protein–
receptor interactions (Gould, et al., 2003).  
1.6 EV in circulation 
Previous studies have shown that purified exogenous EV, artificially introduced into 
circulation, is rapid. For example, biotinylated rabbit EV demonstrated rapid clearance 
in rabbit circulation, in approximately 10 minutes (Rand, et al., 2006). Other examples 
were observed in EV from splenocyte supernatants (Saunderson, et al., 2014) eMV 
(Willekens, et al., 2005) and EV from B16 melanoma cells (Takahashi, et al., 2013) all 
of which showed a clearance of more than 90% after 30 minutes (Yáñez-Mó, et al., 
2015). But human platelet concentrate-derived EV persisted in the circulation for 5 ½ 
hours (Rank, et al., 2011).  
EV derived from human monocyte-derived dendritic cells and cells of B lymphocyte 
cells may be able to protect themselves from complement-mediated lysis because their 
express GPI-anchored CD55 and CD59. EV removal from circulation may be due to 
storage and apprehention in target organs (Clayton, et al., 2003). Indeed, a 
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biodistribution study with eMV showed an uptake by the liver (44.9%), bones (22.5%), 
skin (9.7%), muscles (5.8%), spleen (3.4%), kidneys (2.7%) and lungs (1.8%) 
(Willekens, et al., 2005).  
An extensive example of in EV in circulation was demonstrated by Lai, et al., (2014), 
in which Human embryonic kidney (HEK) 293T cells transduced with lentivirus vectors 
were investigated. Engineered EV displayed a supremely delicate and adaptable 
membrane system reporter named EV-GlucB (Gaussia luciferase- Gluc fused to a biotin 
acceptor domain, a metabolically biotinylated in mammalian cells in the existence of 
biotin ligase). Fluorescence-mediated tomography was used to identify and record the 
circulation of intravenously administered EV in vivo labelled with streptavidin-
Alexa680 conjugate, and EV-GlucB with Phosphate Buffered Saline (PBS; control) 
were injected into athymic nude mice. After 30 minutes of coelenterazine injection of 
EV-GlucB-injected, mice showed a significant amount of Gluc signal in the spleen and 
liver. No signal was observed in the control mice. EV signal depreciated by more than 
half from 30 to 60 minutes in the liver and the kidneys, while, the spleen and the lungs 
levels stayed relatively steady. Then at 360 minutes, the spleen and the heart showed the 
most EV signal (spleen 22.4 %; heart 9 % of initial levels), while the lungs showed 4 %, 
the liver 1.3 % and the kidneys showed 0.6 %. The brain indicated the least EV 
distribution, showing signal only at 120 minutes and the muscle retained a significant 
fraction of activity (9 %) out to 120 minutes. 
Even though a particular mechanism for EV distribution is not yet fully elucidated, the 
examples presented above, suggest that the bio distribution of EV may be dependent on 
the parent cell source, as well as the ability of different target cell types to internalise the 
circulating EV. To further support this statement, EV from distinct parent cells may 
show divergent innate homing capabilities in vivo. An observation of the bio distribution 
of EV derived from 3 different mouse cell sources, including a muscle cell line (C2C12), 
a melanoma cell line (B16F10), and primary immature bone marrow-derived DC was 
conducted to compare intrinsic tropisms (Wiklander, et al., 2015). Where, C2C12-
derived EV displayed 71% liver accumulation compared to B16F10-EVs (56%) and DC-
derived EVs (46%). The lung accumulation was 5% for C2C12-EVs, 13% B16F10-EV 
and 10% in DC-EV. In the gastrointestinal tract B16F10-EV accumulated 15%, C2C12-
EVs (8%) and DC-EVs (10%). Furthermore, DC-EV demonstrated elevated 
accumulation in the spleen (28%) in comparison to EV derived from C2C12-EVs and 
B16F10-EV, which displayed similar splenic distribution (both 12%).  
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Despite substantial progress in this field, the complexity and challenges associated with 
EV research remain considerable. EV released from different cell types and even from a 
single cell type are heterogeneous in size and composition. 
1.7 EV as delivery vehicles/vectors  
EV are potentially unique in terms of functioning as natural delivery vectors because they 
can be seen as free, membrane coated, relatively stable entities due to the lipid content of 
their membranes, specially exosomes (Record, et al., 2014) that may be involved in cell 
communication within the extracellular space through ligand-receptor interactions. EV 
surface molecules are of particular interest as biomarkers because surface molecules in 
general (cells) perform essential biological functions, including the mediation of cell 
communication and reply to external signals (see chapter 1.5).  
The cell “surfaceome” specifies phenotypic and practical diversity between cell types, 
and between normal and abnormal cells, such as cancer cells (Mirkowska, et al., 2013). 
There are three main classes of cell-surface receptors, that can transduce extracellular 
signals in different ways and this is summarised in Fig. 1.7.1.  
Target cells may use a range of intracellular mechanisms to react to an increasing 
concentration of an extracellular signal or to change a short-lasting signal into a long-
lasting reaction. They may often reversibly accommodate their sensitivity to a signal to 
allow the cells to react to changes in the concentration of a specific signal 
molecule, across a variety of concentrations (Alberts, et al., 2014).  
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Despite their seemingly homogeneous characteristics, EV surface composition carries 
various membrane lipids, such as the anionic phospholipid phosphatidylserine and altered 
membrane lipids besides transmembrane proteins (Wang, et al., 2014). MV surface also 
exhibits antigens that are particular for the membranous elements of the cell of origin 
(Liu, et al., 2016) making them heterogeneous. 
It has also been suggested that surface receptors can potentially alter the cell function 
that interact with the MV. For example, MV transfer using Glycosyl 
phosphatidylinositol (GPI)-anchored proteins (peripheral membrane proteins tethered to 
the cell through a lipid anchor- alpha subunits of heterotrimeric GTP binding proteins-G 
proteins) CD55 and CD59 to erythrocytes can correct paroxysmal nocturnal 
Fig. 1.7.1. The three main classes of cell surface receptors. Adopted from Alberts, et al., (2002) and slightly modified by 
Roberta Freezor using online Pixlr photo editor. Where (1), the Ion-channel-linked receptors are transmitter-gated ion channels 
that gives or block access briefly in return to the binding of a neurotransmitter; (2) G-protein-linked receptors discursively 
trigger or blocks plasma-membrane-bound enzymes or ion channels via trimeric GTP-binding proteins (G proteins); and (3) 
Enzyme-linked receptors can operate precisely as enzymes or are associated with enzymes. They are generally protein kinases 
that phosphorylate particular proteins in the target cell, and the functional signalling complexes are often assembled using  
modular binding domains (one or more domain binding to the same ligand) in the signalling proteins (Pawson, et al., 2002). 
These domains allow different protein assemblies to function in signalling networks (Alberts, et al., 2014). 
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haemoglobinuria by inhibiting complement-mediated erythrocytes (Sloand, et al., 
2004). Additionally, CD24 (GPI-linked protein) cell surface receptor has been shown 
to promote apoptosis in developing B cells and induces B cells to release MV 
(presenting CD24) (Ayre, et al., 2015).  
EV have been demonstrated as having important physiognomy for intracellular delivery 
(specificity and selectivity), and compelling characteristics for the systemic delivery of 
experimental agents. For example, Sun, et al., (2010) tested EV for the delivery of anti-
inflammatory agents including curcumin (a substance in turmeric) via the 
Lipopolysaccharide -induced septic shock model (mouse) into activated myeloid cells in 
vivo. This is where the target specificity was selected by exosomes, and the advancement 
of curcumin activity was accomplished by conducting curcumin to inflammatory cells 
affiliated with therapeutic, but not toxic effects.  
In addition to MV potential role in interacting with cell surface receptors and markers as 
well as, in directly stimulating target cells, their potential role in transferring bioactive 
molecules present inside MV (cargo) has been investigated intensively for the past decade. 
This is due to their possibly most important potential function, that is their biological 
effect on neighbouring cells (Collino, et al., 2010; Ratajczak & Ratajczak, 2016).  
It has become progressively clearer that a large class of small noncoding RNAs (ncRNAs) 
function as important regulators of a wide range of cellular processes, modulating gene 
expression (van Rooij, 2011). These classes include small interference RNAs (siRNAs), 
micro RNAs (miRNAs), repeat-associated siRNAs (rasiRNAs) and piwi (P-element 
induced wimpy testis) interacting RNAs (piRNAs). Small RNAs act as repressors of gene 
expression in plants, animals and many fungi (Finnegan & Matzke, 2003). Different 
sequence and/or structural elements in the precursor transcripts of small RNAs engage 
RNA-processing enzymes and proteins which are accountable for small RNA maturation, 
and for the subsequent congregation of these RNAs into effector complexes that reveal 
their function (Ruby, et al., 2007; Farazi, et al., 2008).  
Valadi, et al., (2007) demonstrated that EV contain and transfer genetic information, in 
the form of messenger RNAs (mRNAs) and non-coding RNAs (miRNAs), between mast 
cells regulating protein expression of recipient cells. EV transferrence of intact, functional 
mRNAs to recipient cells was also accomplished by studying the treatment of murine 
bone marrow mononuclear cells with embryonic stem cell-derived EV enriched in Oct4 
mRNA. This led to the enhancement of Oct4 protein expression in the bone marrow cells, 
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while pre-treating the EV with RNAse abrogated this effect (Ratajczak, et al., 2006). 
Endothelial progenitor cell-derived EV have also been demonstrated as transferring 
functional mRNAs to microvascular endothelial cells, thus triggering neoangiogenesis 
(Deregibus, et al., 2007). 
The remarkable stability of extracellular miRNAs is hypothesised by the formation of 
miRNA-vesicle package, MV directly packing miRNAs by forming a protrusion and then 
detaching from the cell surface (Muralidharan-Chari, et al., 2009). They can easily 
translocate across the cell membrane, which easily facilitates miRNA entry into recipient 
cells and mediates cell-to-cell communication (Hunter , et al., 2008). 
The understanding that EV might function as a vehicle/vector to transfer genetic 
information and are able to regulate gene expression in target cell opened up a completely 
new field of research regarding intercellular communication mechanisms. Currently, 
there is increasing evidence that the effect of EV on target cells is mainly dependent on 
their intravesicular miRNAs expression (Diehl, et al., 2012). The study conducted by 
Valadi, et al., (2007) demonstrates that by incubating human mast cells with mouse mast 
cell-derived EV, murine miRNAs can indeed be relocated to the recipient cells by EV 
where they were translated into murine proteins, but EV did not demonstrate functional 
machinery for the protein synthesis. 
It is important to be selective with EV parent cells (their properties) in order to produce 
uninduced and/or induced/engineered EV. This is because uninduced EV might transfer 
naturally occurring biological effects to the neighbouring cells, while induced/engineered 
EV samples may have greater potential as delivery vehicles because of their scalability 
and the possibility of overexpressing specific molecules (Lässer, et al., 2018). For exam-
ple, the photoreceptor cryptochrome (CRY) 2 has been observed to be expressed on the 
inside of EV, and this can help load proteins carrying the CRY-interacting basic-helix-
loop helix (CIB) 1 into the EV (Liu, et al., 2008). Yim & Choi (2016), made good use of 
this information and implemented this into their EV protein-loading system, named exo-
somes for protein loading via optically reversible protein–protein interactions (EX-
PLORs), where CIBN (a truncated version of CIB1), was fused with CD9 (usually en-
riched in EV), and CRY2 was fused with a cargo protein which was visualised being 
recruited to the plasma membrane. Eventually secreted as EV cargo, it successfully de-
livered several functional proteins such as Cre recombinase, a Type I topoisomerase from 
bacteriophage that catalyses the site-specific recombination of DNA between loxP sites, 
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into the target cells. It is also important because loading and injection of purified EV has 
been suggested by other research groups (Alvarez-Erviti, et al., 2011; Kooijmans, et al., 
2013). 
Therefore, there is supporting evidence that EV transfer biological functional molecules 
such as proteins and miRNAs to target cells, which shows their increasing potential as 
novel regulators in intercellular gene regulation (Pfeifer, et al., 2015). 
1.8 Aim of this PhD research project 
Increased levels of eMV have been observed during blood storage and have been 
associated with numerous diseases (see chapter 1.7.1). Therefore, it is important to 
acknowledge their biological role and cargo because they are free entities present in the 
bloodstream and may be able to deliver vital information to neighboring cells. The 
objective of this PhD research was to characterise eMV and analyse their cargo with a 
specific interest in cell communication helper molecules.  
The decision to study MV derived from a different source (Hela cells infected with 
HRV16) in parallel, is based on the rationale of being able to carry out a comparative 
study with a control sample to produce substantial parameters. Also, because the 
mechanisms by which viral infections induce the release of EV and because viral derived 
EV enter and communicate with neighbouring cells have been well studied and shown to 
be of use on this role for this study.  
This study proposes to answer: 
1. What are the size and concentration of eMV? Does it differ when erythrocytes 
are induced with CaCl2 and CaCl2 +NHS? 
2. Do eMV interact with neighbouring cells? What entry mechanism do they use?  
3. If they do interact with neighbouring cells, what is the overall message that eMV 
pass on once inside the cells? 
Chapter 3.1 investigates whether erythrocyte induced by exposure to different inducers 
(CaCl2 and with CaCl2 + NHS) yield a different amount and/or produced a greater number 
of detectable eMV in comparison to the uninduced sample. It compares instrument 
detection of eMV sizes using FC (sub-micron Particle size ranging between 0.5-2000 nm) 
and qNano (polystyrene calibration particles ranging between 115-1150 nm). This 
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chapter also investigates eMV extraction methods by comparing classic 
ultracentrifugation and Size Exclusion Chromatography approaches. 
Chapter 3.2 investigates and compares surface markers, total proteins and proteases using 
different immunoblotting techniques, to identify the potential presence of 
intracellular/extracellular molecules in uninduced and induced samples. This is because 
these proteins may enable eMV to communicate with neighbouring cells and may allow 
their survival in the extracellular environment.  
In results chapter 3.3, an investigation and comparison is conducted on the potential 
presence of an immunology panel composed of 68 miRNA in all samples (including 
parent cells), to understand whether eMV could affect recipient cells by down-regulation 
of gene expression.  
In results chapter 3.4, a variety of cell lines were used to observe whether eMV directly 
interacts with the cell membrane using fluorescence microscopy. If so, to observe the 
impact of eMV on the growth rate of the observed cell lines using FC Guava ViaCount 
software.  
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2. Materials and Methods 
 
 
2.1 Materials  
2.1.1 Chemicals and kits 
BD Vacutainer™ Safety-Lok™ Blood Collection Sets (Fisher Scientific REF 367286) 
BD Vacutainer Plastic K2EDTA Tube 10 mL with Lavender Hemogard Closure-10 mL 
(Fisher Scientific REF 367525) 
Bicinchoninic Acid Protein Assay Kit (Thermo scientific B2161296) 
Bovine Serum Albumin (Sigma-Aldrich) 
Calcium Chloride (Sigma-Aldrich) 
Claritytm western ECL substrate (BIO-RAD 170-5061) 
Crystal Violet Solution (Sigma-Life sciences V5265-250 mL) 
DL-Dithiothreitol Solution (Sigma-Aldrich 646563)  
Exosome-depleted FBS media supplement (SBI EXO-FBS-50A-1) 
Ficoll-PaqueTM Plus (GE healthcare 17-1440-02) 
Foetal Bovine Serum (Sigma-Aldrich) 
Flow cytometry Sub-micron Particle Size Reference Kit (Molecular probes-Life 
technologies F13839) 
GlutaMAXTM-I Dulbecco's Modification of Eagle's Medium (Gibco 31966-021) 
Herpes buffer solution (Sigma-Life sciences-83264-100 mL) 
Laemmli 2X sample buffer (Bio-Rad 161-0727) 
MegaCellTM RPMI 1640 medium (Sigma-Aldrich m3817-500 mL) 
Mini-PROTEAN TGX™ Stain-Free™ precast gels 4-20% (BIO-RAD 456-8093) 
mirVana™ miRNA isolation kit, with phenol (ThermoFisher scientific AM1560) 
Multiplex miRNA Assay Immunology Panel - Circulating (ab204064) 
Non-fat dried milk power (Marvel-original less than 1% fat) 
Penicillin-Streptomycin (Sigma-Aldrich)  
Pierce® reversible protein stain kit - for PVDF (Thermo scientific 24585) 
Precision Plus ProteinTM dual colour standards (BIO-RAD 161-0374) 
Phosphate Buffered Saline (PBS) (Sigma-Aldrich p4417-100TAB)  
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Protease Inhibitor Cocktail (Sigma-Aldrich P8340-5 mL/013M4034V) 
Proteome Profiler Human Protease Array Kit (R & D systems ARY021) 
Radio-Immunoprecipitation Assay (RIPA) (Sigma-Aldrich R 0278) 
Sodium Bicarbonate (Sigma-Aldrich) 
Sypro®ruby Protein Gel Stain (invitrogen tm s12000) 
Trans-Blot® Turbo™ Mini PVDF transfer packs (BIO-RAD 170-4156) 
Trans-Blot® Turbo™ Mini Nitrocellulose Transfer Packs (BIO-RAD 170-4158) 
Tris-Glycine-SDS buffer 10x (BIO-RAD 161-0732)  
Triton® X-100 (Sigma-Aldrich T8532-500L)  
ViaCount Reagent (Guava technologies) 
2.1.2 Technical devices 
Cell culture flask 100x20 mm with vent (Sigma-Aldrich) 
Dishes Nunclon™ Surface (Thermo scientific) 
FLUOstar omega plate reader (BMG labtech, UK) 
GelDoc-it imaging system (UVP systems, UK) 
Guava EasyCyte flow cytometry (MerckMillipore)  
LumaScope™ 500 Series (Etaluma) 
Mini-PROTEAN Tetra cell vertical electrophoresis system (BIO-RAD) 
NanoDrop® ND-1000 UV-Vis Spectrophotometer (ThermoFisher)  
Trans-Blot® Turbo™ Transfer System (BIO-RAD) 
qEV Size Exclusion Column (IZON science)  
qNano particle analyser (IZON science) 
UVP ChemiDoc-it system (UVP systems, UK) 
2.1.3 Antibodies 
2.1.3.1 ImmunoTools IT-Box-139.3 Roberta Freezor 2013 award (anti-human) Flow 
cytometry application includes: 
FITC: CD14 (18D11 antibody), CD36 (antibody TR9), CD46 (antibody MEM-258), 
CD54 (antibody 1H4), CD58 (antibody MEM-63), CD63 (antibody MEM-259), 
CD235ab (antibody HIR2), HLA-ABC (antibody W6/32), Control-IgG1 (clone PPV-06), 
and Annexin V (detection of Phosphatidylserine).  
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2.1.3.2 Western blotting application includes: 
Anti-CD47 AB mouse (ab3283)  
Active human CD47 protein fragment standard (ab174029) 
Monoclonal Anti- β -Actin, Clone AC-74 (Sigma-Aldrich A2228) 
Monoclonal Anti-Human Band 3, clone BIII-136 (Sigma-Aldrich B 9277) 
Monoclonal Anti-Protein Kinase C AB mouse (Sigma-Aldrich P 5704) 
Monoclonal Anti-Glycophorin (α) AB mouse (Sigma-Aldrich G 7900)  
Monoclonal Anti-spectrin (β), AB mouse (Sigma-Aldrich S 3396)  
HRP conjugated Goat anti-mouse Ig-polyclonal (BD PharmingenTM 554002)  
2.1.4 Buffers and solutions 
2.1.4.1 Complete Growth Medium (CGM)  
500 mL RPMI 1640 or DMEM  
50 mL Foetal bovine serum or exosome free serum 10% (v/v) 
5 mL Pen/strep 1% (v/v) 
2.1.4.2 Human Rhinovirus (HRV) medium 
500 mL DMEM  
5 mL Pen/strep 10% (v/v) 
10 mL Herpes 2% (v/v) 
5 mL Sodium Bicarbonate 1% (v/v) 
10 mL exosome free serum 2% (v/v) 
2.1.4.3 Cell freezing medium  
100 µL DMSO 10% (v/v) 
100 µL Foetal bovine serum or exosome free serum 10% (v/v) 
800 µL cell containing Complete Growth Medium 80% (v/v) 
2.1.4.4 Western blotting washing buffer (PBST-20)  
1 mL tween-20 in 999 mL PBS (v/v) 
2.1.4.5 Western blotting blocking buffer  
3 g BSA non-fat powdered milk in 100 mL PBS (w/v) 
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2.1.5 Cell lines  
HeLa Ohio cells, passage +6 (European collection of cell culture 2013) 
Jurkat cells, passage +8 (European collection of cell culture 2013) 
THP-1, passage +13 (European collection of cell culture 2013) 
PC-3, passage +6 (European collection of cell culture 2013) 
MCF-7, passage +9 (European collection of cell culture 2013) 
 
2.2 Methods 
2.2.1 Maintenance of cell lines  
The passage history for maintaining all cell lines was recorded throughout this PhD 
research and the following procedures were used consistently for the entire project. 
2.2.1.1 Non-adherent cell lines  
Non-adherent cell lines were maintained in the Roswell Park Memorial Institute 1640 
(RPMI) Complete Growth Medium (CGM), at 37°C in a 5% CO2 incubator. The cells 
were normally sub-cultured every three days. They were centrifuged at 160 g for 5 
minutes to remove depleted medium and the pellet was suspended with 5 mL of sterile 
Phosphate Buffered Saline (PBS), pH 7.4 and centrifuged at 160 g for a further 5 minutes 
3 times consecutively. The retained cells pellet was diluted in an appropriate volume of 
CGM according to cell number and prepared as required for further analysis.  
2.2.1.2 Adherent cell lines  
Depending on the cell line, adherent cell lines were maintained in either RPMI CGM, or 
Dulbecco's Modification of Eagle's Medium (DMEM) CGM. The cells were normally 
sub-cultured every three days by removing the depleted medium from the flask and 
rinsing once with 200 nm filtered PBS, pH 7.4. Subsequently, 5 mL trypsin was 
introduced to the flask, and the cells were incubated for approximately 5 minutes at 37°C 
in 5% CO2. The flask was tapped several times to detach any remaining cells and 1 mL 
of CGM was added to inactivate the trypsin. The cells were then centrifuged at 200 g for 
5 minutes, and the retained cell pellet was suspended with 5 mL of sterile PBS, pH 7.4, 
and centrifuged at 200 g for a further 5 minutes 3 times consecutively. The retained pellet 
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was diluted in an appropriate volume of CGM, according to cell number and prepared as 
necessary for further analyses.  
2.2.2 Isolation of erythrocytes  
Human venous blood was collected (0.75 in size needle used) into Ethylene Diamine 
Tetra-acetic Acid (EDTA)-containing tubes (10 mL) from a healthy donor. The same 
donor provided blood throughout this research and was screened regularly as a National 
Health Service Blood and Transplant, Tissue Service donor. This dononor was approved 
by the London Metropolitan University Ethics Committee.  
Blood cells were purified and isolated utilising the Ficoll-Paque PLUS method, according 
to the manufacturer protocol. The blood was diluted with 200 nm filtered PBS, pH 7.4 
(ratio 1:1) and carefully layered on top of the required volume of Ficoll-Paque PLUS, 
maintaining approximately the same height of the Ficoll-Paque PLUS 2.4 cm and of 
diluted blood sample 3 cm accordantly. Volumes of blood were adjusted and processed 
with the same efficiency of separation by increasing the diameter of the centrifuge tube, 
while maintaining approximately the same height of the Ficoll-Paque PLUS, and 
centrifuged at 4,000 g for 30 minutes at 18-20°C. 
Once the blood was separated into layers (erythrocytes at the bottom, followed by the 
Ficoll-Paque PLUS, the white cells, platelets and finally the diluted plasma at the top) 
they were transferred into separate tubes and suspended with 200 nm filtered PBS, pH 
7.4. The erythrocytes were centrifuged at 200 g for 10 minutes with 200 nm filtered PBS, 
pH 7.4 and the pellet was ready for further procedures. 
2.2.3 HRV16 preparation and infection 
Plaque-based assays are the standard method used to determine infective virus 
concentration in terms of viral infectious substances. The viral titre is a quantitate 
measurement of the biological activity of a virus and it can be determined by enumerating 
plaque forming units per volume (PFU/ mL), or alternatively multiple replicates of the 
virus dilution are made and the 50% Tissue Culture Infective Dose (TCID50) titre is 
calculated from the 50% endpoint of the inoculated culture medium.  
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2.2.3.1 HRV16 replication 
A stock of HRV16 was stored at -80°C in 5 mL aliquots (kindly supplied by Dr. McLean). 
The aliquot was thawed for 5 minutes in a water bath at 37°C and 7.5 mL of HRV medium 
was added. This was then added to a T175 fully confluent flask of HeLa cells and 
incubated for 1 hour at Room Temperature (RT) using a platform shaker. Subsequently, 
12.5 mL HRV medium was added to the flask and incubated at 37°C, 5% CO2 for 24 
hours. Cells were then lysed by two freeze thaw cycles (-80°C) and the medium was 
clarified by centrifugation at 4,000 g for 1 hour at 4°C. The resultant supernatant was 
centrifuged at 25,0000 g for 90 minutes (optimised step for this project), at 4°C. The 
supernatant stock was used immediately or stored at -80°C until further analysis.  
2.2.3.2 HRV16 quantification 
HRV16 stock was serially diluted ten-fold (10-1 to 10-9), 6 replicates per dilution. Then 
1.8 mL of HRV medium was added to 9 different dilution vials and 200 µL of the stock 
of virus was added to the 10-1 vial. Next, 200 µL of the 10-1 vial was serially diluted to 
10-9. In a 96 well plate, 50 µL of HRV medium was added into each control well (cells 
only) and 50 µl virus (relevant dilution) was added to each virus well. 150 µL of HeLa 
Ohio cells were added (cell number ~5x105/ mL and viability > 95% was recorded prior 
experiment), and incubated for 5 days at 37°C, 5% CO2. The cytopathic effect (CPE) was 
observed by microscopy (5 days) to identify the differences between virus dilutions and 
control wells. 
At day 5 (end of CPE observation) the HRV medium was gently removed from the 96 
well plate and 50 µL/well of crystal violet solution containing 0.1% in ddH2O (v/v) was 
added into each well and incubated for 10 minutes to stain adherent cells by binding to 
proteins and DNA. Then the cells were washed gently with ddH20 for 4-5 minutes and 
the 96 well plate was allowed to dry at RT for 1 hour. Subsequently, stained cells were 
dissolved in 30 µL  Sodium Dodecyl Sulphate (SDS) in a platform shaker for 1 hour at 
RT and the absorbance Optimal Density (OD) at 560 nm was recorded (Fig. 2.2.3) using 
the FLUOstar omega plate reader. 
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The optimal TCID50 of viral infection dose (concentration required to induce cell death 
and/or pathological changes in 50% of cultures inoculated), was determined by using the 
following formula utilising an excel spreadsheet based on the Reed & Muench (1938) 
method (Fig. 2.2.4) as follows:  
 Log of lowest dilution (L) -Difference of stepwise dilution (d) x (Sum of positive 
tests (S) - volume of the virus used) 
 
 
Fig. 2.2.4. TCID50 of HRV16 stock Excel spreadsheet. The TCID50 method is a statistical derivative of the PFU/ mL assay. Instead 
of counting individual plaques, multiple replicates of the virus dilution were prepared (Fig.2.2.3). The TCID50 titre is calculated from 
the 50% endpoint of the tissue culture (wells). The spreadsheet represents the TCID50/ mL obtained during an experiment.  
 
L d S ml
-1 1 5.33 50
 L=Log of lowest dilution
d=Difference of stepwise dilution
S=Sum of positive tests
(1) TCID 50=10E-5.83
TCID50 (1)
-5.83
TCID50/ml
1.35E+07
antilog 0.83 =
6.76
Fig. 2.2.3. Determination of infectious titre of HRV16 stock. A representation of the CPE in a quantifiable manner, to determine 
the infectious titre of the virus in the tissue culture. It is related to how the 50% Tissue Culture Infective Dose (TCID50) which is 
calculated by the sum of positive (plaques formation) and negative tests (absence of plaques) over the period of 5 days while cells in 
culture remain viable. Where 10-1 to 10-9 dilution was prepared at 6 replicates for each sample including infected and control (not 
infected cells) samples. Wells with destroyed cell monolayers were observed manually for 5 days (data not shown here) under an 
inverted microscope. Then, automatically using a viable colorimetric/cytotoxicity assay known as crystal violet assay. This assay 
quantifies the cytotoxic effect as a function of the number/viability of remaining cells after the infection. The assay was performed at 
day 5(graphed- as the dilution rate of HRV16 decreases cell viability increases). Graph Pad version 7.3 was used, where Group family 
XY was used connecting lines with error bars (the values represent mean ± SEM - 95% confidence interval of independent replicates). 
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The following formulae were then used to determine the titre in PFU/ mL and 
Multiplicity Of Infection (MOI) of the viral stock: 
 PFU/ mL= TCID50/ mL * 0.69 (Poisson distribution 1TCID50=0.69 PFU) 
Example: 1.35 x 107 * 0.69 = 9 x106 PFU/ mL  
 Total PFU needed = cell number * desired MOI   
Example: 8 x105 * 0.2 = 1.6 x105 PFU 
 Total amount of virus needed : PFU/ mL ÷ PFU  
Example:  9 x106 PFU/ mL ÷ 1.6 x105 PFU = 56.25 mL 
In µL= 1000 ÷ 56.25 mL = 17.78 µL in suspension  
 
2.2.3.3 HeLa cells HRV16 infection 
HeLa cells were maintained on 100x20mm culture dishes prior to and whilst performing 
the infection experiments. For the experimental work, 95% or greater confluent flasks 
containing HeLa cells were used and the CGM was gently removed. Subsequently, the 
dishes were rinsed twice with 200 nm filtered PBS, pH7.4 and then the flasks were treated 
with 5 mL of HRV16 containing medium (MOI 0.2) apart from the control. The control 
wells were treated with the same volume added for the HRV16 wells, but only HRV 
medium was added instead. All flasks were incubated at 37°C, 5% CO2 for 12 hours (~5 
x105/ mL). The supernatant of cultures were collected 24 hours after infection to extract 
derived MV. Cell number and cell viability was also recorded after the supernatant was 
removed.  
2.2.4 Isolation of MV 
In order to understand the properties present in MV, all MV samples used during this PhD 
project were produced and extracted using the same method for all experiments.  
2.2.4.1 Isolation of eMV 
The retained pellet (erythrocytes concentrate), which yields approximately 4.5 mL, was 
used for the extraction of eMV. The eMV were prepared in three different ways: 
 (i) Control - erythrocyte pellet with 10 mL 200 nm filtered PBS pH 7.4; 
 (ii) As in (i) with the addition of 20 µL of 2 mM of CaCl2; and 
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 (iii) As in (i) with the addition of  1 mL 20 nm filtered normal human serum 
(NHS) in 10 mL 200 nm filtered PBS pH 7.4 and 20 µL of 2 mM of CaCl2. 
All samples were incubated for 45minutes in a 37°C water bath, and placed on ice for 
approximately 5 minutes to stop the reaction, then centrifuged at 600 g for 5 minutes to 
pellet the cells and the supernatant was collected and centrifuged at 4,000 g for 60 minutes. 
The supernatant was collected once again and sonicated for 5 minutes to disperse 
aggregation and centrifuged at 25,000 g for 90 minutes at 4°C. The resultant pellet was 
suspended in 200 nm filtered PBS, pH 7.4 (or RPMI 1640 used if eMV were to be 
introduced to cell lines). They were used immediately, or frozen at -80°C to store until 
further analysis.  
2.2.4.2 Isolation of HeLaMVC and HRV16iHMV 
Conditioned medium was collected from cell cultures (infected and healthy cells) at 
specific times (depending on experiment demands) and centrifuged once at 200 g for 5 
minutes. Then the supernatant was collected and sonicated for 5 minutes, and centrifuged 
at 4,000 g for 60 minutes and subsequently centrifuged at 25,000 g for 90 minutes at 4°C. 
The resultant pellet was suspended in 200 nm filtered PBS, pH 7.4 (or DMEM used if 
MV were to be introduced to cell lines) and used immediately or frozen at -80°C to store 
until further analysis.  
2.2.4.3 An alternative method for EV extraction 
The preparation for the use of the Size Exclusion Chromatography (SEC) column was 
carried out according to the manufacturer’s instructions (IZON sciences). Briefly, the 
column was placed in a holder and levelled vertically, leaving the bottom Luer-slip cap 
in place, then the top-cap was removed. Subsequently, the column was equilibrated by 
removing the lower Luer-slip cap and removing the bed volume (10 mL) by rinsing the 
column with 10 mL 200 nm -filtered PBS buffer.  
With the bottom Luer-slip cap on, the PBS buffer above the top filter was removed, then 
the sample (prepared as in 2.2.4.1 and 2.2.4.2, after the 4000 g centrifugation step) was 
introduced. The bottom Luer-slip cap was removed and 0.5 mL fractions were collected 
immediately (the first six fractions were discarded because it is the void volume and does 
not contain MV). Then, 200 nm -filtered 10 mL PBS buffer was introduced to the column. 
Immediately after the void volume was discarded, a fraction of 1 mL of the sample was 
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collected. After the collection of the MV fractions, the column was rinsed with 10 mL of 
PBS buffer, the bed volume (10 mL) was reintroduced to the column and then stored at 
4°C until further use (reused for same sample type 3 times).  
The samples were then centrifuged at 25,000 g for 90 minutes at 4°C to concentrate MV. 
The resultant pellet was suspended in 200 nm filtered PBS, pH 7.4 and used immediately 
or frozen at -80°C to store until further analysis. 
2.2.5 Flow cytometry analyses 
The Guava flow cytometry (FC) EasyCyte HT system allows complex biological studies 
such as cell counting and viability testing, cytokine detection, cell activation marker 
analysis and discriminates events between different cells/particles based on their size, 
granularity and fluorescence staining. The Guava FC can be used to perform ten different 
assays, but, for this PhD study only two assays were utilised. These were the ViaCount 
assay (for counting cells and determining viability) and ExpressPlus assay (MV 
concentration, size and surface marker analyses).  
2.2.5.1 Cell number and viability 
The quantitative measure of cell number and percentage (%) viability was an important 
consideration for performing cell culture and/or cellular assays. This evaluation was 
fundamental for this research. 
For cell analysis, the ViaCount assay (FC) was used. After wash and suspension, the cells 
were seeded into 96 wells plate and stained with Guava ViaCount reagent (ratio 1:1). The 
cells were then analysed via Guava ViaCount software. Cell number/ mL and % viability 
was recorded using EasyFit. 
The remaining stock of the cells was transferred into a culture flask to allow growth, or 
was seeded into well plates at ~ 13 x105/ mL (only cells of 95% viability or greater were 
used for the experiments). 
2.2.5.2 MV enumeration and sizing 
The size range of bioparticles in the experimental sample was estimated by comparing 
the side scatter signals (SSC) with forward scatter signals (FSC) provided by the reference 
microspheres sizes (500 to 2000 nm), using the FC Sub-micron Particles size reference 
kit. 
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The ExpressPlus assay software was used to perform all measurements using the Guava 
FC EasyCyte HT system. The settings were adjusted by establishing the threshold value 
to less than or equal to 5000 events per sample (for very low flow) for accurate particle 
counting (particles/ mL). The voltages (using the SSC and FSC parameters) were adjusted 
by evenly distributing the particles between 100 and 108, allowing discrimination of sizes.   
The accepted background “noise” consisted of events per second when 200 nm filtered 
PBS, pH7.4 was used as a blank solution. Debris or other unwanted events were excluded 
(accepted that MV are larger than 100 nm) during analysis using the FCS Express FC De 
Novo Software (optimized for use with Guava instruments), which allowed gating of 
specific areas, discrimination of sizes and sample population. To obviate MV aggregates, 
samples were sonicated briefly before analysis and the total amount of MV samples were 
seeded into 96 wells plate to allow the MV to be counted singly.   
2.2.5.3 Fluorescence detection 
The size range and % fluorescence detection of MV was estimated by comparing the SSC 
with those of the reference microspheres sizes (500 to 2000 nm) as established in chapter 
2.2.5.2 but utilising the green scatter (GRN-Log) parameter instead of FSC-Log, using 
the ExpressPlus software. 
To determine the expression of surface markers (fluorescence), MV samples were 
labelled with a specific panel of cluster differentiation (CD) Fluorescein-Isothiocyanate 
(FITC)-Conjugated antibodies in PBS containing 1 % BSA and 0.09 % sodium azide -pH 
7.4. The antibodies were free of unconjugated FITC and adjusted for direct use, therefore, 
no reconstitution was necessary for the direct method of labelling.  
A percentage of total volume (up to x106 / mL), of each MV sample was diluted with 100 
µL binding buffer and incubated for 30 minutes at RT. The relevant CD was added (5 
µL-recommeded by manufacture) and incubated for 1 hour at RT. Subsequently, the MV 
samples were concentrated via ultracentrifugation at 25,000 g for 90 minutes at 4°C. The 
resultant pellet was then diluted with 200 nm filtered PBS, pH7.4 and washed through 
centrifugation at 25,000 g for 90 minutes at 4°C, and seeded into 96 wells plate. Samples 
were then analysed by FC Guava Express Plus software.  
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2.2.6 qNano standard operating protocol   
Nanopore (NP) size 300 (target size between 115-1150 nm- MV samples sizes 
expected to be 100- 1000 nm), was used along with the Polystyrene calibration 
particles (CP) CPC200 particles matching the expected size range of unknown 
particles, to accurately estimate the size of unknown particles/samples.  
The CP was vortexed rapidly to ensure homogeneity and sonicated briefly to remove 
aggregates. Then they were diluted in 200 nm -filtered PBS (as sample buffer), to the 
target desired concentration (1 x109/ mL). 
80 µL of 200 nm -filtered PBS was applied and removed from the lower fluid cell, to 
reduce the risk of air bubble formation under the nanopore when applying the 
electrolyte to the lower fluid cell. 
The nanopore was then placed onto the 4 arms of the instrument and the digital 
callipers were used to measure the distance between two opposite arms and enter the 
distance in mm into the stretch input field. Subsequently, the calibrate stretch option 
was  set to 47 mm and 80 µL of 200 nm -filtered PBS was introduced and removed 
from the lower fluid cell to allow more flexibility to the pore. 
Then, the upper fluid cell and shielding cage was placed on the nanopore, and 40 µL 
of diluted CPC200 was introduced in the upper fluid cell. The variable pressure module 
was used to apply ≥0.8 kPa positive pressure, and the stretch was reduced to 44 mm, 
whilst analysing the blockade events caused by the CPC200 and observed in the signal 
trace panel. The particle rate measurements were recorded until 500 particles were 
reached, which provided a stable baseline current for appropriate measurement of the 
samples. 
The CPC200 was then removed from the upper fluid cell, which was washed three 
times with 1000 µL 200 nm-filtered PBS to remove residual particles. Then the 
samples were introduced into the upper fluid cell with baseline current within 3% 
observed during measurement, showing particle rate plot display constant sample 
detection.  
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2.2.7 Western blotting analyses  
Western blotting is a widely used analytical technique used in molecular biology, 
immunogenic and other molecular biology disciplines to detect specific proteins in a 
sample of tissue homogenate or extract.  
2.2.7.1 Preparation of sample lysates 
After the removal of the final (wash) PBS buffer from the cells and MV, an appropriate 
volume of RIPA Buffer was added (1 mL for 0.5 to 5 x 107 cells) with protease inhibitor 
cocktail (1X). For MV samples the volume of RIPA was optimised to 200 µL to maximize 
concentration/dilution. Then the cells were incubated on ice for 5 minutes, and MV 
incubated for 1 hour on ice. Samples were rapidly vortexed and placed on ice for 5 
minutes, and the lysates were centrifuged at 8000 g for 10 minutes at 4 °C to pellet the 
debris. Then, the supernatant containing the soluble proteins from all samples were ready 
for analysis. 
2.2.7.2 Total protein concentration and SDS-PAGE sample preparation 
Following the manufacturer’s instructions, 200 µL of working reagent (WR) is required 
per sample (25 µL). The WR is made up using reagent A (sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and 
reagent B (4% cupric sulphate) at ratio 50:1 (v/v). In parallel, a dilution series of Bovine 
Serum Albumin (BSA) stock solution was prepared and used as a standard in the later 
evaluation of unknown concentrations. Applied concentrations of the standard ranged 
between 0- 2000 µg/ mL BSA. The preparation of the working reagent was determined 
by the following formula:  
 (No. of standards + No. of unknowns) x (No. of replicates) x (Vol. of working 
reagent per sample) total = Total volume required. 
Subsequently, the 96 well plate containing the standards and samples was incubated at 
37°C for 30 minutes. The plate was allowed to cool down at RT and the OD at 562 nm 
readings were recorded, using the FLUOstar Omega microplate reader. Protein 
concentrations of the unknown samples were determined by interpolation on the standard 
curve (Fig. 2.2.7). 
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Subsequently, 50 µg/ mL (total protein concentration) of the samples were diluted with 
(2X) Laemmli sample buffer and reducing agent Dithiothreitol (DTT-1M to 950 µL of 
ddH2O for 50 mM DDT solution). Finally, the samples were boiled for 5 minutes at 95°C 
to ensure denaturation/reduction. The samples were then allowed to cool before loading 
onto an SDS-PAGE gel.  
2.2.7.3 SDS-PAGE standard procedure 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 4-20% Mini-PROTEAN Tris-Glycine 
eXtended (TGX)™ Stain-Free™ precast gel (which retains Laemmli-like separation 
characteristics while using a standard Tris-glycine running buffer system) was placed into 
the electrode assembly device, inside a clamping frame in the tank of the Mini-
PROTEAN Tetra cell vertical electrophoresis system. Then the Tris-glycine-SDS buffer 
(1x) was added to the inner and outer chambers of the tank, and the plastic comb of the 
gel was carefully removed. The Precision plus proteinTM dual colour standards ranging 
between 250-10 kDa were applied by loading 10 µL into the gel. Subsequently, 
appropriate concentrations/volumes of samples were distributed along the wells. 
Electrophoresis separations were performed at 150V (constant voltage), until the SDS 
sample buffer reached the end of the gel. 
Fig. 2.2.7. BSA standard curve for protein concentration. Where 0- 2000  µg/ mL BSA dilution in triplicates are shown (blank 
corrected data). The response values (absorbance) were plotted against known concentrations and a best-fit line drawn through 
the points. The unknown protein concentration of samples was determined by reference to the standard curve. Graph Pad version 
7.3 was used, where Group family XY was used connecting lines with error bars (Mean and Error). 
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2.2.7.4 SYPRO® Ruby protein gel stain 
After electrophoresis, the gel was washed with ddH20 and placed in a clean container with 
100 mL of fix solution containing 50 mL of 99.8% pure methanol, 7 mL acetic acid and 
43 mL ddH20 (v/v), and agitated on a platform shaker for 30 minutes and fix solution was 
discarded. Then 60 mL of SYPRO® Ruby protein gel stain was added to the container 
and placed in the microwave (80-85°C) for 30 seconds, agitated for 3 seconds to distribute 
heat evenly, and microwaved for a further 30 seconds (80-85°C) and then agitated for 5 
minutes. The gel was reheated for 30 seconds and agitated for 23 minutes (30 minutes 
total staining time). Subsequently, the gel was transferred to a clean container with 100 
mL of wash solution containing 10 mL of 99.8% pure methanol, 7 mL acetic acid and 83 
mL ddH20 (v/v) for 30 minutes and briefly washed with ddH20 before protein bands 
visualization with GelDoc-it imaging system. 
2.2.7.5 Membrane transfer 
The Trans-blot Turbo blotting system was used throughout this research (semi-dry 
transfer). The gels (protein bands) were transferred to Trans-Blot® Turbo™ Mini 
Nitrocellulose (for western blotting procedure) and/or Polyvinylidene Difluoride (PVDF) 
(for visualisation of bands - to test successful band transfer) membrane Transfer Packs. 
The membrane packs allowed the gels to be sandwiched between sponge and paper and 
all are clamped tightly together, to ensure no air bubbles were formed. The sandwich was 
placed in the centre of the cassette bottom and the lid was placed on the top of the 
membrane, and the cassette was locked by turning the knob clockwise. When the cassette 
was inserted into the instrument, the BIO-RAD existent protocol for 3 minutes mini gel 
transfer was selected. The membrane was then ready for further analysis.  
2.2.7.6 MemCode reversible protein stain kit- PVDF membranes 
To verify successful protein transfers to the membrane (PVDF only), the membrane was 
manually rinsed with ddH20 three times and quickly decanted. MemCode
TM sensitizer 
was poured into the container, and agitated at RT for 2 minutes on a rotary platform shaker, 
at moderate speed, and the solution was decanted. Then MemCodeTM reversible stain was 
poured into the container and the membrane was agitated for 1 minute at RT, then the 
solution was decanted. Subsequently, the membrane was rinsed with the MemCode TM 
destain solution three times, quickly decanted and stained protein bands were visualised 
by eye.  
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The membrane was then submitted to the eraser/methanol solution, agitated for 20 
minutes at RT on a platform shaker and rinsed with ddH20. Western blotting was 
performed with PVDF membrane for trial purposes only (data not presented here).  
2.2.7.7 Western Blotting standard procedure 
The resultant nitrocellulose membrane was incubated for 1 hour at RT with western 
blotting blocking buffer. Following blocking, the membrane was washed 3 times for 10 
minutes in a platform shaker with PBST-20 and incubated with the relevant primary 
antibody in the desired dilution (diluted with Western blotting blocking buffer and 
according to the manufacturer’s instructions) for 2 hours at RT, or overnight at 4°C and 
washed with PBST-20 (3 times for 10 minutes in a platform shaker). Subsequently, the 
membrane was incubated with the relevant secondary antibody for 2 hours at RT, and 
washed 3 times for 10 minutes in a platform shaker with PBST-20. 
Visualization of positive protein bands detection was performed using the enhanced 
chemiluminescence reagent system (ECL), where reagent A and B (ratio 1:1) was added 
to the membrane and incubated for 5 minutes at RT under dark conditions. The images 
were visualised using the UVP ChemiDoc-it system. 
2.2.8 Proteases profiling 
2 mL of array buffer 6 (buffered protein based with preservatives serving as a blocking 
buffer) was added into each well of the 4-well multi-dish. Then each sample membrane 
(each containing 34 different capture antibodies printed in duplicates) was placed in the 
wells (4-well multi-dish: 4 samples: 4 membranes), and incubated for 1 hour on a rocking 
platform shaker.  
Sample preparation and total protein concentration procedures were carried out as in 
chapters 2.2.7.1 and 2.2.7.2. 
Cells and MV lysates were diluted and adjusted to a final volume of 1.5 mL (50 μg/ mL 
of protein) with array buffer 4 (buffered protein based with preservatives serving as 
diluent buffer) and 15 μL of reconstituted protease detection antibody cocktail (diluted in 
100 μL of DDH2O) and incubated at RT for 1 hour. Then the array buffer 6 was aspirated 
from the wells of the 4-well multi-dish containing the sample-membranes, and the 
prepared antibody mixtures, with the corresponding sample was introduced to the 
membranes and incubated overnight at 2-8°C on a rocking platform shaker. Each 
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membrane was removed and placed into individual plastic containers with 20 mL of 1X 
Wash Buffer and washed 3 times for 10 minutes.  
Then, 2 mL of 1X streptavidin-HRP was introduced into each well of the 4-well multi-
dish (the 4 samples-4 membranes) and incubated for 30 minutes at RT, on a rocking 
platform shaker. Each membrane was then washed 3 times with 20 mL of 1X Wash Buffer 
for 10 minutes. 1 mL of the prepared chemi Reagent Mix (1:1 ratio) was evenly 
introduced onto each membrane and incubated for 1 minute. The image/stained spots 
were detected using the UVP ChemiDoc-it system (UVP systems, UK). 
2.2.9 miRNA profiling  
miRNA profiling involves comparisons between two or more groups of different 
biological samples, to therefore calculate the differences of miRNA expression between 
groups and/or samples.  
2.2.9.1 miRNA extraction 
PBS was removed from all samples (N=3: erythrocytes, eMV control, eMV CaCl2, eMV 
CaCl2 + NHS, HeLa cells, HRV16iHc, HeLaMVC, and HRV16iHMV), and 300–600 μL 
Lysis/Binding Solution for 100-107/ mL cells was added. Approximately 300 μL for small 
numbers of samples (hundreds), and closer to 600 μL when isolating RNA from larger 
numbers of cells (thousands/millions).  
Then, 1/10 volume of miRNA homogenate additive was added to all samples, which was 
mixed well by vortexing and inverting the tube several times and incubated for 10 minutes 
on ice. A volume of Acid-Phenol Chloroform that was equal to the original lysate volume 
(before addition of the miRNA homogenate additive) was added. Samples were vortexed 
for 30–60 seconds and centrifuged for 5 minutes at 10000 g at RT to separate the aqueous 
and organic phases. The aqueous phase was recovered without disturbing the lower phase 
and transferred to a fresh tube.  
Subsequently, 1/3 volume of 100% ethanol was added to recovered the aqueous phase, 
and the samples were mixed thoroughly by vortexing. Samples were then, introduced into 
the filter cartridge (one per sample) which was supported by the collection tubes, and 
centrifuged for 15 seconds at 10000 g and the filtrate collected.  
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2/3 volume of 100% ethanol was added to the filtrates and mixed thoroughly. The mixture 
was introduced to a second filter cartridge, centrifuged for 15 seconds at 10000 g and the 
filtrate discarded. Then the filter was washed with 700μl miRNA wash solution by 
centrifuging all samples for 15 seconds at 10000 g.  Then, the filter was washed twice 
with 500 μl wash solution (centrifuged for 15 seconds at 10000 g). 
100 μl of pre-heated (95°C) elution solution was introduced to the centre of the filter and 
centrifuged 30 seconds at 10000 g. At the end of this procedure, the eluate was collected 
and samples were ready for analysis or stored at –80°C until further analysis. 
2.2.9.2 miRNA quantification  
The RNA concentration range was measured within manufacturer specifications for the 
NanoDrop® ND-1000 UV-Vis Spectrophotometer, and the ultraviolet (UV) absorbance 
measurements were acquired under the RNA-40 settings at RT.  
The concentration of the samples was assessed by pipetting 2μl of each sample directly 
onto one measurement pedestal, a measurement of the elution buffer was recorded and 
acted as a blank (background-subtracted). The ratio of A260 to A280 was used because 
it provides an indication of RNA purity. After this procedure samples were diluted with 
elution buffer to attain the required concentration (aiming at 10 ug/ mL). 
2.2.9.3 Firefly™ circulating miRNA profiling assay (immunology panel) 
Each sample prepared in 2.2.9.1 and quantified in 2.2.9.2 went through the procedure 
presented in Fig. 2.2.9. All samples (N=3: erythrocytes, eMV control, eMV CaCl2, eMV 
CaCl2 + NHS, HeLa cells, HRV16iHc, HeLaMVC, and HRV16iHMV) were sent to 
Abcam and scanned on an EMD Millipore Guava 8HT flow cytometry (technical 
replicates of each sample were independly analysed by Abcam), and the resultant data 
was analysed with the Firefly™ Analysis Workbench software.   
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2.2.10 MV labelling for fluorescence microscopy  
For MV-cell interactions, Annexin-V-FITC-Conjugated was used to label the MV 
samples, the purified antibody used here was conjugated with FITC- free of unconjugated 
FITC, under optimum conditions and adjusted for direct use, no reconstitution was 
necessary. A percentage of total volume of the MV samples were diluted (ratio 1:1 with 
cells) with binding buffer and incubated for 30 minutes. 5 µL of Annexin-V-FITC-
Fig. 2.2.9.3.1. Summary of the miRNA experimental procedure. The workflow diagram was built on information provided 
by Abcam (2015), and it represents the step by step experimental procedure used for the miRNA profiling. It permits profiling 
of up to 68 miRNAs across multiple samples, with readout on a standard flow cytometry. A detailed procedure is provided in 
Appendix I.  
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Conjugated was added to each MV sample and incubated for 1 hour at RT. Subsequently, 
the MV samples were concentrated/washed through centrifugation at 25,000 g for 90 
minutes at 4°C. The labelled MV were added to the 95% or greater viable cells, and MV 
to cell interaction was observed using time-lapses settings, utilising an automated system 
alternating between bright field and fluorescence using LumaScope™ 500 Series 
Fluorescence Microscope LED imaging analysis. Photographs of interactions and/or 
outcomes were recorded every two minutes for 15 minutes. 
2.2.11 The addition of eMV on the growth of different cell lines 
For the observation of the impact of eMV on the growth of cell lines, THP-1, Jurkat, PC-
3 and MCF-7 cells were used. The cells in the exponential phase were washed and 
quantified accordingly using the flow cytometry ViaCount assay as in 2.2.5.1. Cells 
(treated with exosome free serum CGM) were seeded into sterile 24 well plates at ~13 x 
105/ mL cell (only cultures with 95% viability or greater were used) in triplicate. Then 
RPMI 1640 diluted eMV control (quantified using FC Express Plus software as in 2.2.5.2) 
were added to each well (except controls- RPMI 1640 only) containing the different the 
cell lines, THP-1, Jurkat, PC-3 and MCF-7, at 1:1 ratio.  
Plates were incubated at 37°C in a 5% CO2 incubator and left untreated for the duration 
of the experiment (96 hours). Cell growth rate was analysed (concentration and viability 
determined) every 24hours against eMV treated cells.  
2.2.12 The addition of HeLaMVC and HRV16iHMV on the growth of HeLa cells  
To investigate the effect of HeLaMVC and HRV16iHMV on the growth rate of HeLa 
cells, HeLa cells in the exponential phase were washed as in chapter 2.2.1.2 and 
quantified accordingly as in chapter 2.2.5.1. Cells were seeded into 24 well plates at ~16 
x105/ mL cell (only cultures with 95% viability or greater were used) in triplicate.  
Quantified by FC and DMEM diluted HeLaMVC and HRV16iHMV (ratio 1:1) were 
added to each well (except controls) containing the HeLa cells treated with DMEM CGM 
(exosome free serum). The plates were then incubated at 37°C in a 5% CO2 incubator and 
left untreated for 24 hours. HeLa cells control samples were observed against MV-treated 
cells (1:1 ratio) and concentration/ mL and viability was determined every 4 hours after 
an initial incubation period of 12 hours to determine the effect of MV on the growth of 
the cell line before cells were apoptotic (MOI 0.2).  
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2.2.13 Statistical Data Analysis 
Statistical analysis for all data presented in this PhD thesis, unless noted otherwise in 
figure description, were performed by using multiple T test for comparison between 
groups (one unpaired t test per row- per period of time). The points and connecting line 
are shown as Mean and Error (XY graph family). The statistical significance between 
groups was determined correcting for multiple comparisons using the Holm-Sidak 
method, where alpha=0.05 with fewer assumptions. This analysed each row individually, 
not assuming consistent Standard deviation. P > 0.05 considered not significant (NS), and 
P < 0.05 (P < 0.05 *, P < 0.005**, P < 0.0005 *** and P < 0.00005****) were considered 
statistically significant utilising GraphPad Prism version 7.2 for Windows (GraphPad 
Software, USA). 
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3. Results 
 
 
3.1 Heterogeneity of MV samples: their concentration and size  
3.1.1 Introduction  
Due to the large number of publications in this field, EV may be referred to as entities 
that contain material which may mirror the content of the parent cell. Nevertheless, it is 
important to acknowledge that EV are heterogeneous in size, biogenesis, composition and 
can derive from diverse sets of biological/immunological processes which may be 
dependent on their parent cells, and their biology requires further elucidation.  
The physiological, pathophysiological processes and biological functions of EV are 
becoming increasingly characterised. Most, if not all cells secrete at least one type of EV, 
which comprise heterogeneous populations of vesicles of different compositions, 
physiochemical properties and sizes (Sadallah, et al., 2011; van der Pol, et al., 2012; 
Tissot, et al., 2013; Yáñez-Mó, et al., 2015). As previously mentioned (chapter 1.2.1-
pages 12-13), MV are considered to be a subtype of EV and are the focus of this PhD 
research.  
The concept of induced microvesiculation is not new and has been observed by a variety 
of study groups (chapter 1.2.2). For example, microvesiculation can be induced by a 
plethora of cellular events including cell death, hypoxia, stress,  expression of oncogenes, 
differentiation and infection by viruses (Inal & Jorfi , 2013).  
An early report by Liepins (1983), focused on cytoskeletal disruption as a mechanism for 
MV formation and reported that treatment of mouse mastocytoma P815 cells with 
colchicine (β- tubulin interactor), vinblastine (cell cycle regulation), and cold 
temperatures disrupts the microtubule cytoskeleton. These treatments appear to cause a 
localized rupture of the plasma membrane from the underlying cytoskeleton, as well as 
subsequent blebbing due to hydrostatic pressure differences (Jiang & Sun, 2013).  
Furthermore, it has been suggested that even a single cell may release more than one type 
of EV and that induced microvesiculation may lead to heterogeneous populations of EV 
(concentration and size). For instance, in platelets, where isolation protocol, the quantity 
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and protein content were compared in microvesiculation induced by thrombin, collagen, 
lipopolysaccharide and, Ca2+ ionophore generated different results (Aatonen, et al., 2014).  
In addition to sample stimulation, MV general sample preparation and extraction is yet to 
be standardised, despite there being many studies attempting to establish clinical stand-
ards (Bobrie, et al., 2012; Witwer, et al., 2013). There are numerous uncertainties over 
protocol standardisation and how to define the pre-analytical and analytical variables, 
which may influence the interpretation of the results (Mora, et al., 2016).  
Donor heterogeneity factors, such as diet and age should be considered in order to facili-
tate understanding of the analytical parameters/variables and to ensure that MV can be 
reliably quantified in patients and other clinical settings. Other factors including sample 
collection, sample handling, storage period, and isolation/extraction conditions can affect 
the results. Therefore, standardised protocols are essential because variation in the steps 
of the protocol used can lead to significant fluctuations in MV numbers and their purity, 
resulting in unreliable experimental results (Witwer, et al., 2013).  
Indeed, EV extraction and identification/characterisation technologies have been widely 
investigated, and this area of research has accumulated increasing interest and knowledge. 
Nevertheless, it is generaly accepted this is an area of research that is unprepared for 
clinical applications/practice. It may be suggested that this area of research is still early 
stage, particularly the ability to state that EV-data can unquestionably be used for clinical 
purposes. Considering their heterogeneity, more data is needed to positively reveal EV 
concentration, size and their biological role. 
In this results chapter, the investigations focus on the characterisation and comparison of 
eMV released from uninduced erythrocytes (control) with those induced with CaCl2 and 
CaCl2 +NHS (Hela cells derived MV were used for source differentiation purpose) 
considering:  
1. eMV size and concentration isolated from ultracentrifugation procedure using the 
FC Express Plus assay;  
2. eMV size distribution using the Tunable Resistive Pulse Sensing (TRPS) principle 
(qNano instrument); and  
3. eMV concentration isolated from ultracentrifugation compared to the Size 
Exclusion Chromatography (SEC) column approaches analysed using the FC 
Express Plus assay. 
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The primary functions of Flow Cytometry (FC) are to measure the scattering of light 
caused by a particle, hence the FC Sub-micron Particle Size Reference Kit. Forward 
scatter (FSC) is light from the illuminating laser beam that has been bent (refracted or 
otherwise deflected) at a small angle as it passes through a particle. The intensity of the 
FSC signal is proportional to the particle’s size (Tzur, et al., 2011). Therefore, it is 
possible to analyse the size of bioparticles using a standard FC by comparing their FSC 
signals with that of a population of microsphere standards that have known diameters. 
The Guava EasyCyteTM HT system FC Express Plus Software (used for this PhD 
research), allows analysis of large numbers of MV using very small volumes (5-200 μL). 
It is also used for performing one-, two-, and three-colour assays, and is designed for 
measuring intracellular or cell surface marker expression. It can also be adopted for a 
range of assays including accurate quantification and sizing of samples 
(MerckmilliporeGroup, 2015).  
Secondly, with the aim of understanding eMV size distribution, the qNano instrument 
was used. This is because it compares the resistive pulses caused by the unknown particles 
with the resistive pulses caused by calibration particles with a known diameter. This can 
be done because the concentration and rate of blockades are linearly proportional 
(Willmott, et al., 2010). Using a single calibration sample, together with particles of 
known concentration and particle size allows for the measurement of size distribution of 
an unknown sample (Maas, et al., 2014).  
Additionally, due to research technologies rapidly expanding in the field of the EV, a Size 
Exclusion Chromatography (SEC) was used as an alternative method to extract MV 
samples to test whether it provided a better MV isolation procedure compared to the 
classic ultracentrifugation method.  
3.1.2 Results  
Chapter 1.2.2 hypothesised how different cell inducers may stimulate the release of MV. 
Therefore, in an effort to increase the production yield of eMV, erythrocytes were induced 
with CaCl2 and CaCl2 + NHS and compared to uninduced erythrocytes (control eMV), 
(Hela cells were infected with HRV16 to act as a parallel sample) as described in chapter 
2.2.4. 
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The FC size analysis of MV is shown in Fig. 3.1.2.1, where the events were plotted using 
the side scatter (SSC-allows for particles/cellular differentiation within a heterogeneous 
population) against forward scatter (FSC - allows for discrimination of particle sizes) 
parameters. Both were set at the common logarithmic (Log) scale because data is 
condensed to a substantial degree at the high end in comparison to the low end (natural 
logarithm- In), which provides a more suitable view for data with very different medians 
(Bushnell, 2017).  
Fig. 3.1.2.1a represents the known populations of the size beads ranging between 500-
2000 nm and 200 nm-filtered PBS (blank buffer/noise) that were used to create the MV 
optimized gate. This was performed according to the predicted MV size ranging between 
100-1000 nm. The size beads were overlaid over each other and the MV gate was 
activated in order to investigate particles/MV sizes.  
The triggering threshold (minimum value) was set on forward scatter below the power of 
particles scattered light but above the systems background noise (PBS gate). The 
background noise subpopulations of particle events disappear after the gating system is 
activated (bottom left dots next to the Y axis). This is when the noise is subtracted from 
the event count (5000 maximum for all analysis), and the true centre of the gated 
population acts as a reference for all samples.  
eMV control (Fig. 3.1.2.1b), eMV CaCl2 (Fig. 3.1.2.1c), and eMV CaCl2 +NHS (Fig. 
3.1.2.1d)   samples (N=3) show similar characteristics in terms of sizing and FC position, 
with the majority of samples (dots) laying within the MV gate created. These samples 
appear to be smaller than 500 nm when observed against the size beads (reference), with 
a significant population positioned below the area established at 500 nm. The eMV 
control and eMV CaCl2 samples appear to be smaller than the eMV CaCl2 +NHS sample, 
as the dots shifted further right and upwards when observed against the created MV gate.  
HeLaMVC (Fig. 3.1.2.1e) and HRV16HiMV (Fig. 3.1.2.1f) were demonstrated as being 
larger than eMV samples in general. More particles/dots appeared outside the gate created 
and they presented similar characteristics to the eMV CaCl2 +NHS sample (dots shifting 
further right and upwards). 
Also, a small number of particles/dots were observed as present below the MV gate 
created, suggesting that smaller particles where present in the samples and showed more 
heterogeneity in terms of their sizes.   
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a) Known size beads 
  
Fig. 3.1.2.1. Dot-plot gating- FC analyses of MV sizing and counting strategy. Where a) represents the dot plots acquired from 
the size beads overlaid over each other and displayed as the SSC HLog vs. FSC-HLog separated by sizes (gated) and showing 
events which were used to create the MV gate and to establish appropriate instrument settings. Each dot represents a single particle, 
and the characteristic position of the different populations is determined by differences in particle sizing and granularity. The MV 
gate was defined as >100 nm and <1000 nm by verifying resolution capabilities of the FC against beads, which was also used to 
define the size distribution of all samples. The gate showing 500 nm paricles was purposely used for the MV sizing and counting 
and PBS was used as buffer control which was excluded from background when analysing MV numbers (Fig. 3.1.2.2).  Fig. 3.1.2.1 
b), c), d), e) and f) represent MV samples (N=3) as labelled above each diagram. FCS Express 6 FC and Image Cytometry Software 
was used for the analysis. 
b) eMV control  
 
c) eMV CaCl2 
 
d) eMV CaCl2 + NHS 
 
 
f) HRV16iHMV  
 
e) HeLaMVC  
Mean 2.92 × 105 
 
Mean 3.04 × 106 
 Mean 2.63 × 10
7 
 
Mean 2.57 × 106 
 
Mean 7.25 × 106 
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To compare the concentration of eMV population released in the presence of CaCl2 and 
CaCl2 + NHS, with the amount released from eMV control each condition was assessed 
in Fig. 3.1.2.1. This was achieved using parameters established in Fig. 3.1.2.1a, where 
the concentration of samples were analysed excluding particles/MV (dots) that did not fit 
within the parameters used for the MV gate. 
As shown in Fig, 3.1.2.2a, erythrocytes released higher levels of eMV in the presence of 
CaCl2 (N=3, mean 3.4x10
6/ mL) when compared with uninduced erythrocytes/eMV 
control (N=3, mean 4.5x104/ mL). The production of eMV was further increased when 
erythrocytes were induced with CaCl2 and NHS (N=3, mean 2.9 x 10
7/ mL), in 
comparison to eMV control. Furthermore, eMV CaCl2 +NHS yield a greater amount when 
compared to eMV CaCl2 suggesting that there is an additive effect as a result of NHS in 
eMV production. 
The data obtained (Fig 3.1.2.2) supports the assertion that it is possible to produce 
reproducible MV populations when using FC settings (gate created), because eMV CaCl2 
and eMV CaCl2 +NHS did not show significant inaccuracy for the amount released within 
the same group (N=3, Mean and Error). However, eMV control samples did show a small 
variation between samples (Mean and Error). eMV CaCl2  and eMV CaCl2 +NHS samples 
showed an increased trend in their amount of release (statistical significance) when 
compared to uninduced samples (eMV control).  
To relate the amount of eMV produced with the number of erythrocytes, it can be 
suggested that all eMV samples show less than a 1:1 ratio production in comparison with 
the original erythrocyte numbers (~5.9 x109/mL) used for the experiment.  
In addition, to further compare the amount of MV released from erythrocytes, MV from 
HeLa cells (HeLaMVC) and HeLa cells infected with HRV16 (HRV16iHMV) were used. 
HeLaMVC (N=3, mean 2.4 x 106 / mL) and HRV16iHMV (N=3, mean 7.5 x 106/ mL) 
also produced a greater amount of MV when HeLa cells were infected with HRV16. 
However, it did not show inaccuracy between MV types for the amount released within 
the same group (N=3, Mean and Error). In relation to the number of cells used (2.5 x107 
HeLa cells/mL) it also suggests that HeLa cells produce less than 1 MV per parent cell.  
 
 
 
 
60 
 
 
 
a) 
b) 
Fig. 3.1.2.2. The measurement of MV numbers- assessment by FC analyses. Comparison of the total concentration of the MV 
samples. Where Fig a) represents triplicates of each sample (Mean and Error) estimated per ~5.9x109/ mL erythrocytes where 
statistical analysis was performed between groups (eMV control vs eMV CaCl2 P<0.001, eMV control vs eMV CaCl2+NHS 
P<0.0001, and eMVCaCl2 vs eMV CaCl2+NHS P< 0.0001) and Fig b) represents triplicates for HeLaMVC and HRV16iHMV 
estimated per ~2.5 x107/ mL (N=3, Mean and Error) showing statistical significance between HeLaMVC vs HRV16iHMV 
(P<0.00004). The strategy used here allows the total concentration of the samples to be estimated by activating the gate created 
using the size beads, where only particles/MV lying within the MV gate created in Fig. 3.1.2.1a were considered for the 
concentration analysis.  
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To further analyse/characterise and confirm the size range of MV samples against FC 
analyses the qNano (TRPS technology) was used. The measurement of MV sizing was 
obtained using the reference beads within expected samples sizes being 100- 900 nm and 
the polystyrene CP200 that complements the nanopore (NP300 115 - 1150 nm).  
Fig. 3.1.2.3 demonstrates that eMV size is dependent on the stimulation used. The size 
dispersal can be practical in terms of noticing the intervals between spikes that may be 
notably plentiful (visible as peaks). An increase in concentration distribution of eMV 
samples was observed to be greater (size spectrum ranging 100nm to 800nm) for induced 
samples. In Fig. 3.1.2.3a (N=3, eMV control) peaks are more concentrated between 170 
nm to 220 nm (size ranging between 100 nm to 370 nm). Whereas in Fig. 3.1.2.3b (eMV 
CaCl2), a greater concentration distribution (peaks) is shown between 150 nm to 250 nm 
(size ranging between 100 nm to 600 nm). In Fig. 3.1.2.3c (eMV CaCl2 +NHS) an 
increased concentration distribution is shown between 120 nm to 350 nm (size ranging 
between 100 nm to 750 nm).  
HeLaMVC samples (N=3) show greater concentration distribution between 120 nm to 
250 nm (size ranging between 100 nm to 600 nm) and HRV16iHMV (N=3) appears larger, 
with the concentration distributed between 120 nm to 370 nm (size ranging between 100 
nm to 600 nm).  
Notably, overall qNano data indicated that the concentration of small MV (< 400 nm) is 
greater than the larger MV (>500 nm- which can be due to MV aggregation, variation of 
the pore dimension, and electronic noise) at all of the testing points. The peaks 
demonstrate that concentration distribution varies between each MV sample. It also 
shows that the majority of MV analysed here stand between 100 nm and 800 nm, which 
confirms the MV gate used the FC analyses (Fig. 3.1.2.1) gated system (<1000 nm), but 
it contradicts that HeLaMVC and HRV16IHMV are larger (in comparison to eMV 
samples analysed with FC).  
Despite the fact that the qNano analysis provided a more accurate manner to understand 
the size range of MV samples, the FC analysis is the method of choice for further 
experiments during this PhD research. This is because it proved to be an accurate and 
valuable tool for the concentration measurement of MV, which were the measurements 
required for further experiments (following results chapters).  
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Fig. 3.1.2.3. MV sizing- assessment by qNano analyses. Size comparison of the MV group population (obtained by differential 
sample preparation). Where the size distribution of MV was plotted against CPC200.  Fig a) to e) represents an overlay of each MV 
sample (N=3) as labelled on the right hand corner of each diagram. The size distribution profile for a single sample shows a fairly 
monodisperse profile allowing the estimation of sizes, which suggests that all MV analysed here are >100 nm and <800 nm. The 
Izon Control Suite software was used for the analysis of all platforms for both data acquisition and particle analysis. 
  
a) 
b) e) 
c) 
d) 
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To compare MV isolation methods, two approaches were employed and tested. Samples 
were divided as follow: 
1. In approach one, samples were prepared using the classic ultracentrifugation 
method as in 2.2.4.1 and 2.2.4.2; and 
2. In approach two, samples were submitted to the Izon qEV SEC as prepared in 
2.2.4.3. 
Both approaches were centrifuged at 4,000 g for 60 minutes and MV concentrated at 
25,000 g. In approach two, samples were passed through the column, MV samples were 
loaded on the SEC and fractions were collected and gathered for concentration. All 
samples were analysed by FC using the protocol described in chapter 2.2.5.2 and settings 
in Fig. 3.1.2.1a. 
The SEC method using qEV columns provided a poor MV recovery rate in terms of 
concentration when compared to the classic ultracentrifugation method. As Fig.3.1.2.4 
shows eMV Control recovery decreased from 2.7 x 105/ mL ( ultracentrifugation)  to 1.3 
x 105/ mL (column) , eMV CaCl2 from 2.1 x 10
6 / mL to 1.8 x 105/ mL  and  eMV CaCl2 
+ NHS from 5.8 x 107/ mL to 1.9 x 107/ mL. Similarly, HeLaMVC recovery decreased 
from 3.1 x 105/ mL (ultracentrifugation) to 1.2 x 105/ mL (column) and HRV16iHMV 
from 2.2 x 106 / mL to 2.1 x 105/ mL. The decrease may be due to the loss of particles 
associated with density gradient purification but, no significant differences (N=3, Mean 
and Error) in MV amount of release within the same method were observed. 
The results presented here show that EV isolation methodologies differently affect the 
MV preparation/extraction and alter the quantification of total MV release. In this line, 
although new technology tools could represent a quick and easy method suitable for 
implementation, the results here (Fig.3.1.2.4) suggest otherwise. The influence of the 
isolation methods may lead to a different yield of MV in general and therefore, the 
ultracentrifugation method was used for further experiments (following results 
chapters).  
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Fig. 3.1.2.4. Effect of qEV purification on MV amount of release - assessment by FC analyses. Comparison between 
ultracentrifugation and qEV SEC extraction methods of each MV type (N=3). Profile shows that the qEV SEC purification 
causes a statistically significant decrease in concentration of the samples submitted to the qEV SEC. The Mean and Error was 
calculated according to the variability of samples within the same group/MV type, which suggests accuracy, but statistical 
significance was observed whilst comparing groups of MV samples (ultracentrifugation method against column), showing P 
value of 0.0007 for eMV control, 0.005 for eMV CaCl2, 0.01 for eMV CaCl2 + NHS, 0.0032 for HeLaMVC, and 0.005 for 
HRV16IHMV samples.   
. 
 
a) 
b) 
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3.1.3 Discussion  
In this research, induced microvesiculation mechanisms, CaCl2, CaCl2 + NHS and 
HRV16, were used and the data obtained (Fig. 3.1.2.2) suggests that membrane 
perturbation can lead to a loss of phospholipid asymmetry and MV release which is in 
accordance with previous studies (chapter 1.2.2). The MV samples obtained in this study 
imply that CaCl2, CaCl2 + NHS, and HRV16 can induce cells to release an increased 
number (amount) of MV.  
FC data also suggests that induced eMV samples do not significantly differ in sizes, with 
eMV control, eMV CaCl2, and eMV CaCl2 and NHS fitting in with the created MV gate  
(>100 nm and <1000 nm). However, HeLaMVC and HRV16iHMV demonstrated more 
heterogeneity in size (larger), with a small percentage of total amount of samples 
observed as being present outside the gate created (<1000 nm).  
However, induced samples do show statistical significance for the amount released, in 
comparison with the control samples. The size and concentration of a particular type of 
EV may be relevant to the sample quality. For example, Ferreira, et al., (2013) indicated 
that the size of EV (the larger) secreted by human embryos could be associated with de-
creasing embryo quality. Their data suggested that average EV size could potentially be 
used to predict embryo aspects and improve the assessment of slow developing embryos. 
Likewise, the concentration and diameter of EV secreted by embryos derived from in 
vitro fertilisation differed from those secreted by parthenogenetic activation embryos, 
demonstrating that the characteristics of the population of EV vary depending on embryo 
competence (Mellisho, et al., 2017).  
FC is the widely used method of choice for MV phenotyping (Pospichalova, et al., 2015; 
Pockley, et al., 2015). The primary concern over FC analyses is the ability to reliably 
distinguish between EV that carry specific protein markers, and to accurately measure 
EV proportion and the use of proper controls that robustly validate the test and establish 
background levels, which are still unavailable (Hulspas, et al., 2009). Nevertheless, in 
order to relate the measured light scattering to a particle size the FC can be calibrated by 
using beads that refer to the Mie theory (Hergert & Wriedt, 2012), assuming spherical 
particles of known refractive index. As beads meet these criteria, Mie theory can be used 
to determine particle-size distribution, resulting in dedicated FC being the most accurate 
in sizing particles with the hypothesis that MV are spheres with a refractive index (van 
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der Pol, et al., 2014), which was previously estimated (Konokhova, et al., 2012) and 
compatible to the refractive index of cells (van Manen, et al., 2008). Here, the beads 
proved to be useful not only for the measurement of MV sizes, but also for the 
concentration as MV samples fitted with the created gate. An advantage of general FC is 
the knowledge of the analysed sample volume, such that the particle concentration can 
also be determined without calibration with beads (van der Pol, et al., 2014). 
In relation to MV concentration distribution, according to their sizes, the qNano proved 
to be a helpful apparatus by accurately distributing the concentration of MV according to 
their size spectrum. The qNano analyses demonstrated that MV are <800 nm.  
Size profiling of different types of EV has also been suggested to be successfully 
measurable by Tunable Resistive Pulse Sensing (TRPS) (Harry, et al., 2013). Using the 
IZON qNano, the movement of particles through the nanopore (NP100 target size range 
40 - 320 nm, NP200 target size range 80 - 640 nm, and NP300 target size range 115 - 
1150 nm) is determined by electro-kinetic (electrophoretic and electro-osmotic) and 
fluidic forces (Vogel, et al., 2012). However, even when applying significant pressure 
(which is necessary sometimes), the electro-kinetic forces can, depending on particle 
surface charge, remain non-negligible (Kozak, et al., 2012).  
The accurate sizing of EV by TRPS requires that the electrical conductivity of a particle 
is negligible, in comparison with the conductivity of the electrolyte. Both polystyrene 
beads and MV meet this requirement (van der Pol, et al., 2014). Nevertheless, the 
measurement restrictions made the TRPS measurements impractical for use in this study 
and when working with EV, operating the instrument was challenging and this may be 
due to particle aggregation. These challenges consisted mainly of a high rate of nanopore 
blocking (sudden drop in baseline current). The inability to recover baseline currents 
within 3% of calibration measurement, or to identify significant differences in particle 
rates between identical samples is another down side to this technology. Resulting in a 
measurement time of several hours, and losing the total concentration of samples.  
Additionally, electron microscopy (EM) and Cryo-electron microscopy (cryo-EM) has 
considerably helped EV studies. Nevertheless, the nanometre-scale proposing strength of 
transmission electron microscopes also has pitfalls including elongated sample 
preparation time, deficiency of multi-parametric phenotyping, and low throughput 
capacity (Trajkovic, et al., 2008; Conde-Vancells, et al., 2010; Yuana, et al., 2013). 
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Nanoparticle Tracking Analysis is another popular method for EV characterisation 
(Gardiner, et al., 2016). This is a technique that uses laser light scattering and the 
Brownian motion of particles (Frisken, 2001) to calculate concentration and size 
distribution. It recognises the particles’ speed in a medium of noted temperature and 
viscosity which may allow the calculation of its hydrodynamic diameter as well as 
providing specific results for labelled EV in fluorescent mode (Dragovic, et al., 2011). 
However, it should be noted that it depends upon a variety of optimization steps by an 
experienced operator in order to identify convenient settings for the video capture and 
analysis. The high error bars in the results are regularly generated by the diversity of 
particle counts between each measurement (vary between samples), and this variation in 
the number of particles encountered is directly linked to the imprecision of the particle 
concentration provided by this technique (Filipe, et al., 2010).   
To avoid contamination of other peripheral cells Ficoll-Paque™ PLUS was used to isolate 
the erythrocytes pellet. This is a sterile, ready to use density gradient medium for 
purifying blood cells in high yield from small or large volumes of blood, and it uses a fast 
centrifugation procedure based on the method developed by Bøyum (1968) so that purity 
can be obtained (Amersham Biosciences, 2002). This is because when erythrocytes are 
aggregated, lymphocytes may be trapped in clumps and precipitate erythrocytes which is 
avoided by diluting the blood with PBS because it reduces the size of the red cell clumps. 
Also, erythrocyte aggregation may occur because of higher temperatures (37°C), and at 
lower temperatures (>20°C) the rate of aggregation is decreased (Neumann, et al., 1987).  
Ultracentrifugation is a common and well reported method, but similar to other methods 
variation in protocols (rotors speed and time) may also modify the final concentration of 
EV samples (Cvjetkovic, et al., 2014; Lobb, et al., 2015).  Linares, et al., (2015) reported 
that ultracentrifugation induces the formation of EV aggregates composed of a mixture 
of EV of various phenotypes and morphologies. This may cause incorrect interpretation 
with respect to the existence of EV bearing surface antigens from divergent cells. 
Throughout this PhD research, samples were sonicated briefly before FC analyses, to 
allow the MV to be counted as single events and avoid aggregation. Also, there are other 
extraction methods that may be helpful in this case, density gradient centrifugation for 
example, may also be used as an alternative because it enables the greater purification of 
EV and the potential separation of distinct subpopulations by size (Heijnen, et al., 1999; 
Théry, et al., 2001). 
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The SEC did not show advantages in this research. As shown in Fig. 3.1.2.4, this process 
loses a large number of MV compared to FC analysis and just adds an extra step to the 
classic ultracentrifugation method. Supporting the assertion that the classic 
ultracentrifugation method is still a valuable procedure to reveal the actual amount of MV 
that have been released under different conditions. Nevertheless, according to IZON the 
SEC purification of vesicles is able to remove >99% of contaminating free proteins and 
provides 95% removal of contaminating high-density lipoproteins from EV samples. 
Therefore, it might be beneficial for biological samples including urine, plasma, serum 
and/or ascites fluid for further characterisation/proteomic analysis.  
The technical approach of the combination of SEC, also known as qEV Size Exclusion 
Column separation and TRPS analysis of EV are supposed to provide valuable results for 
EV analysis. Maas, et al., (2014) demonstrated that it is possible to accurately measure 
the size of MV in general. However, distinguishing between MV aggregates can also be 
problematic, but for this research, samples were sonicated briefly before analysis, to allow 
the MV to be counted as single events.  
Isolation of MV is a time-consuming process that increases the difficulty of large-scale 
sample preparation and detection. As a result it may be more practical and convenient if 
MV could be obtained in a shorter time, hence the alternative method. The results 
obtained by this PhD research using the ultracentrifugation method may meet the up to 
date requirement for sample collection, thus assisting in the batch processing of samples 
and promoting the development of MV detection. An excessive centrifugation speed 
might lead to fragment contamination of the MV pellet, and appropriate speed is critical 
for intact MV isolation. The data obtained during this research indicates that the classical 
ultracentrifugation (alone) at 25,000 g for 90 minutes is sufficient to achieve the 
requirements of MV sample isolation acquired for this research, and therefore this is the 
method of choice for subsequent analysis. Nevertheless, there are other extraction tools 
available today, that may be useful and can be used individually or combined for the 
isolation of EV including density-gradient separation, polymer-based precipitation, 
immune selection, microfluidic, and Tim4-based isolation methods. It is important to note 
that each of these methods, whilst they have been acceptable, also have their limitations 
(Greening, et al., 2015; Furi, et al., 2017). 
EV/MV surfaceome and profiling (explored in the following chapters 3.2 and 3.3) in 
general is important in general in order to adopt the concepts mentioned above. This is 
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because of their heterogeneity and they may express different characteristics between 
induced and not induced samples. Utilising purer isolates consisting of a single 
subpopulation of EV, and using the knowledge regarding influence and advantage of 
unalike subpopulations of EV, it can become  possible to judge whether subpopulations 
display therapeutic potential and indeed activity as mentioned by Tkach, et al., (2017) in 
their opinion article.  
A combination of the different approaches described here may be able to provide useful 
information on the amount of MV released from inducements. These methods should be 
further assessed and validated by comparing measurement results, so that precise, reliable, 
and fast extraction methods and measurements analysis can eventually be translatable 
from the bench to the clinic, in which are being addressed by researchers (yearly ISEV 
meetings/workshops). Indeed, this field of research is rapidly developing and extraction 
methodologies/tools are advancing, but reliable studies on EV profile and content in 
general are needed for a better understanding of their role and for a possible use in clinical 
settings, for example, the use of MV in tissue regeneration (Panagiotou, et al., 2016). 
These may include combining complementary characterisation approaches, which are 
investigated during this research (following results chapters 3.2 and 3.3). 
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3.2 An investigation into key biomolecules required for MV 
communication and survival   
The communication network between the cell microhabitat and the cell centre is vital to 
understand their potential behaviour, and the Extracellular Matrix (ECM) components 
perform a significant role in signalling network transduction. This is because of their 
capacity to travel to the nucleus upon attachment to the cell’s interior mediated by 
adhesion molecules (Lelièvre & Bissell, 1998). Important information may be transduced 
from the membrane to the nucleus of cells, and the potential function of MV in 
communication and intercellular signalling is dependent on their cargo (as it is for cells), 
including different biomolecules particularly when taking into account their biogenesis 
(Valadi, et al., 2007; Subra, et al., 2010).  
As a result of standing-in as inducers and coordinators of biochemical cascades, these 
biomolecules including proteins, can promote the chemical and mechanical mechanisms 
of intracellular signalling (Lelièvre & Bissell, 1998). Therefore, this chapter intends to 
identify the biomolecules present in MV samples acquired during this PhD research that 
may be involved in the communication network, and how MV can potentially survive in 
the microhabitat.   
3.2.1 Surface markers identification in MV samples 
3.2.1.1 Introduction  
MV composition (especially their membrane) contains general characteristics inherited 
from their parent cell making them naturally non-immunogenic, which may allow them 
to communicate and to resist fast clearance from circulation and thereby increase delivery 
efficiency to target tissues (Johnsen, et al., 2014; Wiklander, et al., 2015). 
Identifying/profiling EV “surfaceome” might not only lead to the identification and 
development of new diagnostic markers and therapeutic targets, but it could also provide 
insight into the biology of unknown substances, including environmental interactions and 
the identification of important cellular subtypes and signalling pathways (Gedye, et al., 
2014). This includes possible ways to communicate with neighbouring cells (see chapter 
1.5).  
Cluster of Differentiation (CD) antigens can act as ligands and receptors, and can control 
cell adhesion, cell signalling and even adaptive immunity. The concept of the receptor-
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ligand interaction is an important component to the activity of biological systems (Engin, 
et al., 2017), and it may allow MV/cells to transmit a message to one another. A MV/cell 
might present a receptor in its membrane and when it binds to a complementary ligand 
on a nearby MV/cell, may allow the receptor to operate its function.  
An example of this receptor-ligand interaction is CD58 (widely expressed in erythrocytes 
and tested for in this chapter), a Lymphocyte Function-associated Antigen 3 (LFA-3) 
interaction with CD2 (for example). CD2 is a transmembrane glycoprotein commonly 
expressed on virtually all T cells and functions in both T cell adhesion and activation 
processes (Tibaldi, et al., 2002). CD2 is known to bind to the CD58 through counter-
receptor interaction, which empowers the opening stages of T cell connection with the 
antigen presenting cells (APCs) (Meuer, et al., 1984). The adherence of domains between 
CD58 and CD2 allows the antigen recognition activity by supporting cell-cell contact 
(Tibaldi, et al., 2002).  
Bierer, et al., (1998) demonstrated that LFA-3+ L cells  (can be found in the ileum, large 
intestine-colon, duodenum and jejunum), together with anti-CD3 (a T cell co-receptor 
allows the activation of the cytotoxic T cell, CD8+ naive T cells, as well as T helper cells, 
CD4+ naive T cells monoclonal antibody) or with doses of Phytohaemagglutinin (PHA) 
(a mitogenic agent used as a red-cell agglutinating agent that promotes proliferation of 
human peripheral blood T cells) promotes proliferation of human peripheral blood T cells. 
Moreover, proliferation was inhibited by monoclonal antibodies directed against either 
CD2 or LFA-3 and resulted in the increased expression of key molecules including the 
interleukin-2 receptor (IL-2R). Their data supports the fact that LFA-3 plays a role in 
CD2-dependent T cell activation.  
Given the importance of surface markers to a wide range of biological processes and their 
broad utility as research and clinical tools for identifying specific characteristics of 
biological samples, this PhD research studied a panel of surface markers to test the 
hypothesis that markers signify MV differentiation, identification and potential role 
including:  
1. Annexin V binds specifically to phosphatidylserine (PS), a phospholipid 
component of the cell membrane, acting as important activators in cell cycle 
signalling, specifically in relation to apoptosis (Lizarbe, et al., 2013). FITC-
conjugated Annexin V can be used as a fluorescent probe to label the 
phosphatidylserine of the plasma membrane from the inside surface to the 
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outside surface. The exposure of PS on the cell membrane of cells draws a signal 
for recognition and engulfment by phagocytic cells (Vance & Tasseva, 2013). 
Annexin V is extensively used in this research area and it is categorised as a 
marker for MV in general due to the exposure of PS (Chandler, 2016; Kong, et 
al., 2015). 
2. CD235ab (antibody HIR2) recognises N-terminal of glycophorin (GYP) A and 
faded signal of GYP (B) and are the major transmembrane sialoglycoproteins. 
These are a combination of sialic acid and glycoprotein/GYP, itself sugar and 
protein expressed on erythrocytes and their precursors. They supply the cells 
with a substantive amount of mucin-like surface, minimising aggregation 
between erythrocytes in the circulation. GYPA is the carrier of blood group M 
and N specificities, while GYPB accounts for S, s and U specificities (Poole, 
2000).  
3. CD54 is a transmembrane glycoprotein (GP) expressed on many cells including 
T lymphocytes, B lymphocytes, monocytes, macrophages, granulocytes, 
activated endothelial cells, epithelial cells, and dendritic cells. The expression of 
CD54 is upregulated by activation. It binds to Intercellular Adhesion Molecule 
1 (ICAM-1) and mediates cell adhesion by binding to integrins CD11/CD18. 
The interaction of CD54 with Lymphocyte function-associated antigen-1 
enhances antigen-specific T-cell activation (Roebuck & Finnegan, 1999). CD54 
has been reported being a cell surface entry receptor for HRV (Shukla, et al., 
2017). 
4. CD46 (antibody MEM-258) is a type I membrane protein that identify an 
epitope on SCR4 (the membrane-proximal SCR) domain. CD46 is expressed on 
platelets, granulocytes, monocytes, T and B lymphocytes, fibroblast, epithelial 
and endothelial cells. It is negative on erythrocytes under normal circumstances. 
CD46 in its monomeric form is an important governor of the complement 
activation cascades (classical and alternative), by preventing amplification of 
the activities on CD46 presenting cells by factor I to the proteolysis of 
deposited C3b and C4b. Thus, protecting the host cell from damage by 
complement activity (Liszewski & Atkinson, 2015). CD46 also serves as a 
receptor for several human pathogens (both bacteria and viruses). When CD46 
is expressed on T lymphocyte its ligation alters the polarization toward antigen-
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presenting cells or target cells, inhibiting lymphocyte function (Barilla-LaBarca, 
et al., 2002; Persson, et al., 2010). 
5. CD14 (18D11 antibody) is a lipopolysaccharide (LPS) receptor. It is a 55 kDa 
Glycosylphosphatidylinositol (GPI)-anchored GP, constitutively expressed on 
the surface of mature monocytes, macrophages, and neutrophils. CD14 serves as 
a multifunctional LPS receptor. It is also released to the serum as a secreted and 
in an enzymatically cleaved GPI-anchored form. CD14 binds to the 
lipopolysaccharide molecule in a reaction catalysed by lipopolysaccharide-
binding protein (an acute phase serum protein). CD14 affects allergic, 
inflammatory and infectious processes and it is a specific marker for 
monocytes/macrophages (Pugin, et al., 1998; Ziegler-Heitbrock & Ulevitch, 
1993). 
6. CD36, antibody TR9 reacts with glycoprotein integrin beta 3 subunit –GPIIIb, a 
fatty acid translocase (FAT) - beta subunit of the platelet membrane adhesive 
protein receptor complex. It is a ditopic glycosylated protein that belongs to the 
class B family of scavenger receptors, and is widely expressed. It operates in 
affinity with tissue uptake of long chain fatty acids, and helps lower excessive 
fat supply to lipid assembly and metabolic impairment. CD36 can bind to 
multiple ligands with its alliance with other transmembrane proteins, supplying 
to the diversity of its signal transduction. The ligands can diversely control CD36 
signalling and downstream protein-protein interactions within metabolic protein 
clusters (Pepino, et al., 2014; He, et al., 2011). 
7. CD58, is widely expressed by both haematopoietic and non-hematopoietic cells, 
often on antigen presenting cells. CD58, antibody MEM-63 reacts with the 
Lymphocyte Function-associated Antigen (LFA)-3, an immunoglobulin family 
adhesion molecule. As previously mentioned in this chapter, it serves as a ligand 
of CD2, an interaction that is essential for T cell-mediated immunity. In its 
transmembrane form, CD58 activate kinase activity and its GPI-anchored form 
interactions are associated with protein kinases  (Li, et al., 2009; Itzhaky, et al., 
1998).  
8. CD63, is a 40-60 kDa tetraspanin GP expressed by platelets, 
monocytes/macrophages, granulocytes, endothelial and T cells. CD63 antibody 
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MEM-259 reacts with lysosome-associated membrane protein LAMP-3. 
Cellular surface exposition of CD63 is usually activation-dependent. CD63, the 
LAMP-3 is a GP of tetraspanin family, and is present in lysosomes, late 
endosomes, and secretory vesicles from a variety of cell types. CD63 also serves 
as a T-cell co-stimulatory molecule (Pols & Klumperman, 2009). 
9. Human Leukocyte Antigen (HLA)-ABC monoclonal antibody recognises an 
epitope common among 43 kDa chains of the HLA-ABC antigens. HLA-ABC 
are detectable on virtually every human nucleated cell. HLA-ABC  antigens 
reacts the human Major Histocompatibility Complex (MHC) class I. HLA-A, B, 
and C, and the frequency of this antibody makes it a very good condidate for a 
positive control for HLA tissue typing and cross matching. MHC class I antigens 
associated with β 2-microglobulin are expressed by all human nucleated cells 
and are central in cell-mediated immune response and tumour surveillance 
(Giacomini, et al., 1997). 
As previously described (see chapter 3.1.1) FC is a higher-throughput technique, 
allowing rapid analysis of significant numbers of MV in liquid suspension.  Nevertheless, 
a persistent concern in FC analyses is the inability to reliably distinguish between the 
positive and negative population of samples and to accurately measure the positivity of 
labelling without appropriate control. This is useful to describe quantitatively, and 
qualitatively the degree of separation between the populations that may be present in the 
same sample. A prerequisite for exploiting these tools is the proper use of control 
samples to confirm that the test sample was prepared correctly and to establish the level 
of machinery background (noise) (Hulspas, et al., 2009).  
This chapter aims to identify EV surface markers, and direct labelling was used because 
it can provide reliable information about their expression, as well providing an insight 
into their distribution in heterogeneous samples. FC utilise chemically or fluorescently 
tagged antibodies to detect surface markers. The assay is specific, sensitive and 
reproducible, and can provide information at the level of individual MV (Gedye, et al., 
2014).  
3.2.1.2 Results  
In this result chapter, the investigation focused on the percentage (%) fluorescence signal 
of surface markers of labelled eMV control, eMV CaCl2, and eMV CaCl2 +NHS 
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(HeLaMVC and HRV16iHMV as parallels) samples. This was performed by using 
fluorescence FC Sub-micron Particle Size Reference, to act as a reference for the MV 
samples fluorescence intensity/expression utilising the FC Express Plus assay.  
The FC Sub-micron Particle Size Reference Kit provides a set of green fluorescent 
microsphere suspensions to serve as reliable size references for FC users. All the 
microspheres are green (excitation and emission maxima at 505 nm and 515 nm), and the 
beads show excitation and emission profile similar FITC (excitation and emission 
maxima at 490 nm and 525 nm) stained samples. This is ideal for the Guava EasyCyte 
HT system  because the green fluorescent dye molecules are localised within the bead 
polymeric matrix, which makes the beads brighter and photo stable and therefore, selected 
for use in this work.  
The Dot plots in Fig. 3.2.1.1a represent the levels of fluorescence versus reduced wide-
angle SSC-log. The analysis was conducted by raising the fluorescence threshold, and 
noise events could also be eliminated, and then 500 nm and 2000 nm-sized fluorescent 
beads where subjected to FC measurements set at SSC-Log. These allow for 
particles/cellular differentiation within a heterogeneous population against Green 
fluorescence-Log (GRN-Log), differing from those applied in chapter 3.2.1, Fig 3.1.2.1a, 
where SSC-Log against FSC-Log was used. The beads were overlaid over each other and 
the MV gate was created, discriminating vesicles that did not fit within the parameters 
created according to the fluorescence size beads and fluorescence scale. 
The green fluorescence-based thresholding was used to analyse the fluorescence intensity 
of the beads and the events are shown in Fig. 3.2.1.1b against PBS buffer (left hand side 
of the histogram). This demonstrated a low fluorescence signal against high fluorescence 
provided by the size beads (right) threshold, where the amount of fluorescent signal 
obtained is equivalent to the number of fluorochrome molecules on the particles. The 
histogram peaks allow the intensity of the fluorescence to discriminate positively or 
negatively labelled samples and to assess the percentage fluorescence in the sample. As 
the sample penetrates the laser beam spot, it precipitates scattered light and fluorescence 
signals that display in a stream of electrons (current) from the anode of the photo-
multiplier tube (PMT). The extent of the current is equivalent to the number of photons 
that touch the photo cathode, which is also equivalent to the intensity of the scatter or 
fluorescence signal created by the sample. While the sample joins the laser beam spot, 
the production of the PMT increases, achieving peak volume and where the particle is 
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fully illuminated, reaching the greatest total of optical signal. This production of a pulse 
is considered the “event”, where height signifies the maximum amount of current output 
by the PMT, area signifies the integral of the pulse, and width signifies the time interval 
in the course of pulse occurrence (BIO-RAD laboratories, 2014). 
The fluorescence expression of the size beads acted as a reference for fluorescence 
intensity for the MV samples. This is shown in red representing the positive (+VE for >50% 
stained) labelled samples. Grey represents the negative (-VE for <50% stained) labelled 
samples. Additionally, the background fluorescence and background noise were excluded 
in Fig. 3.2.1.1a positioned in the left hand side of the dot plot diagram along with the 
fluorescence signal of the size beads (500 nm-2000 nm), shown in Fig. 3.2.1.1b.  
Generally, any cell membrane disruption/remodelling can cause non-specific binding of 
Annexin-V to PS from the inner face of the plasma membrane to the cell surface. FC 
analysis revealed that samples obtained here reacted with Annexin V, suggesting PS 
exposure on their surface, where all MV samples were positively (fluorescence signal) 
labelled with PS/Annexin V, representing a non-specific marker. This can be observed in 
Fig. 3.2.1.2 using the parameters established in Fig. 3.2.1.1. Annexin V stained MV 
samples (red histograms) were plotted against unstained MV samples (black histograms), 
Fig. 3.2.1.1. Fluorescence intensity measurements – assessment by FC analyses. Where a) represents the dot plots acquired 
with the fluorescence size beads, which were used to create the MV gate and to establish appropriate instrument settings against 
buffer/noise (left hand corner of the diagram). The MV gate was defined as>100 nm and <1000 nm, by verifying the resolution 
capabilities of the FC against beads, which was also used to define the size distribution of all samples according to the fluorescence 
intensity. The dot plot cluster of the 500 nm was purposely used to create the MV gate. In  b) the % intensity of each sample (size 
beads) is shown.On the left hand side (grey), samples/events represent negative staining and low fluorescence intensity, whereas 
the events (fluorescence size beads) shown on the right (red), represent positive fluorescence intensity. The parameters 
(histogram) were plotted as channel vs. number of events and FCS Express 6 FC and Image Cytometry Software was used for 
the analyses. 
  
a) b) 
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and the majority of the peaks show the highest intensity to be between 101 and 102 against 
unstained samples (<101). eMV control displayed a different profile (less concentrated) 
due to the length of time in the laser beam spot.  It is important to note that because Log 
scales cannot exhibit samples with zero or negative values, these particles are compressed 
on the Y axis in the Log displays (black histograms) present. 
 
 
To observe the general changes (switches) between samples showing positive 
fluorescence intensity and those showing unlabelled features, the parameters established 
in Fig. 3.2.1.1 were used. Each and all MV samples were tested for non-specific IgG1-
negative isotype control and the same IgG1-negative isotype stained sample was used for 
its type of MV. For example, one IgG1-negative isotype eMV control was used for all 
CD tested here for eMV control samples. The black histograms (IgG1-negative isotype 
stained samples) may appear differently in different plots, and this is due to the number 
of events occurring within labelled samples (more events), when overlaid over positively 
stained samples. 
eMV control  eMV CaCl2  eMV CaCl2 + NHS  
HeLaMVC  HRV16iHMV  
Fig. 3.2.1.2. Fluorescence gating - Annexin V (non-specific marker) labelled MV.  Represents % fluorescence gated 
according to the parameters established in Fig. 3.2.1.1. The MV gate was defined as <1000 nm by verifying resolution capabilities 
of the FC against beads, which was also used to define the size distribution of all samples displayed as the SSC HLog vs. FSC-
HLog. The positive fluorescence intensity of all MV samples (as titled) was established according to the settings in Fig. 3.2.1.1b.  
Unlabelled MV samples (different for each MV type) were overlaid over Annexin V labelled samples to provide differentiation 
between % fluorescence signals. FCS Express 6 FC and Image Cytometry Software was used for this analyses.  
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The IgG1-negative isotype control labelled samples displayed similar characteristics to 
the unstained MV samples (Fig. 3.2.1.2). This is showing particles being compressed on 
the Y axis in the Log displays (black histograms) particularly for eMV control and 
HeLaMVC. Whereas the other MV samples displayed a slight switch to the left side of 
the histogram, displaying a small amount of positive staining (<50% is considered to be 
the negative threshold).  
The expression of several CD’s used here, have been reported showing specific 
expression on the MV cell of origin (source - generally accepted surface profile). This 
was investigated and the results are set out in MV samples prepared here (Fig. 3.2.1.4). 
The results revealed that the MV originated from and were positively stained for the 
surface markers present in their source of origin (erythrocytes and HeLa cells) in 
accordance with their basic characteristics. For instance, the erythrocyte marker CD235ab, 
showed positive fluorescent signal on all eMV samples with >92% expression, and it was 
negative for HeLaMVC and HRV16iHMV (Fig. 3.2.1.4a) showing >93% positive stain 
for the negative marker (fluorescence intensity). Another example that justifies sample 
purity (source/parent cell) is set out in Fig. 3.2.1.4b, where all MV samples were tested 
for CD54, and showed >72% fluorescence intensity (positive marker) for HeLaMVC 
and >96% for HRV16iHMV (typically expressed on endothelial cells and a positive 
marker for ICAM1-receptor for HRV16), but >83% for the negative marker for all eMV 
samples. 
CD46 (Fig. 3.2.1.4c), the preventer of complement cascade amplification displayed >69% 
for the negative marker in eMV samples, and >84% positive staining in HelaMVC and 
HRV16iHMV samples.  
MV samples did not bind to CD14 (Fig. 3.2.1.4d), confirming that samples obtained here 
were derived from the expected sources (erythrocytes and HeLa cells), whereas CD58 
(Fig. 3.2.1.4e) and CD36 (Fig. 3.2.1.4f) were positive in all samples. In contrast, CD63 
(Fig. 3.2.1.4g), was not observed in the eMV control, but was slightly expressed in the 
other samples (>60%). HLA-ABC (Fig. 3.2.1.4h) was negative in all eMV samples, but 
present in HeLaMVC and HRV16iHMV samples (>90% positive).  
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Fig. 3.2.1.3. CD percentage fluorescence intensity in all MV samples. Fluorochrome-conjugated Mouse IgG1 (negative isotype 
control- black overlaid line) was plotted against events (counts) of positive (red) and negative (grey) markers established in Fig. 
3.2.1.1. This was used to discriminate/divide between positive and negative events according to the parameters established using 
the fluorescence size beads.  Each MV sample was tested for Mouse IgG1 (negative isotype staining control) and used against all 
CD’s markers for each sample (overlaid over positively or negatively stained samples). These events are drawn to include the % 
of staining as seen in the events created with the MV gate (fluorescence size beads). FCS Express 6 FC and Image Cytometry 
Software was used for this analyses.  
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The selected panel of surface expression is shown in summary in Fig. 3.2.1.4, where MV 
samples were labelled with different CD’s, including (-VE) and (+VE) labels, and 
analysed via Guava Express Plus software (Fig. 3.2.1.3). Not all MV samples were 
positive or negative for the same label, which simultaneously highlights their differences 
and their similarities, which may be dependent on the stimuli used (or control) and/or 
differentially regulated biological processes between them. The triplicates of each MV 
sample did not demonstrate a significance (Mean and Error) between expression within 
themselves (same type of MV), apart from eMV CaCl2 +NHS labelled with CD46 and 
CD63, which showed expression between the (-VE) and (+VE) markers (established in 
Fig.3.2.1.1b).  
 
3.2.1.3 Discussion   
Accurate and specific phenotyping analysis of EV is important due the implementation 
of biomarker profiling and its use in the clinical setting, but the issues are well understood 
and this is mainly due to their heterogeneity. The Journal of Extracellular Vesicles 
(official journal of ISEV) and ISEV members have released a variety of position 
statements and articles outlining experimental requirements, and suggestions for EV 
characterisation including Lötvall, et al., (2014) and Van der Pol, et al., (2016). Despite, 
providing valuable information, this field still requires further development.  
Fig. 3.2.1.4. Fluorescence intensity (in percentage) summary for positive markers.  Represents the Mean Fluorescence 
Intensity (MFI) in % of all three repeats of each MV sample against each label  and according to parameters established in Fig. 
3.2.1.1b. This compared to the appropriate controls (unlabelled and IgG negative control MV samples- N=3) which provides 
differentiation between % fluorescence signals. The increase in percentage indicates the increase in marker/antibody binding 
FCS Express 6 FC and Image Cytometry Software was used for the percentage analyses and GraphPad Prism was used to plot 
the XY graph (Mean and Error).  
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It is a widely accepted that Annexin V, a specific ligand to phosphatidylserine (PS) 
exposure on the cell surface is a common feature of MV release (György, et al., 2011) 
because this phenomenon has been observed in MV derived from different cell types. For 
instance, platelets and erythrocytes (Jayachandran, et al., 2012). PS exposure on the 
surface is considered a specific characteristic in apoptosis and it is due to the affluence of 
phospholipid in membranes, its negative charge and its talent to exchange interactions 
with other lipids priming the disruption of lipid rafts (Balasubramanian & Schroit , 2003; 
Demchenko, 2013). 
Nevertheless, PS exposure is not only conditional for apoptosis and may indicate different 
pathological conditions. For instance, it has been reported that the occurrence of PS 
expression on the surface of endothelial cells of tumour vasculature and stressed tumour 
cells, and has demonstrated its potential as a biomarker for non-invasive imaging and 
drug targeting (Stafford & Thorpe, 2011). The exposure has also been observed on 
platelet activation, being a part of the blood clotting process (Heemskerk , et al., 2002).  
The surface marker profile of MV samples observed here correlates with those from their 
parent cells when specific markers were used. CD235 is a specific marker for erythrocytes 
(Grisendi, et al., 2015), and CD54 is a specific marker for ICAM-1 (HRV16 receptor) 
(Shukla, et al., 2017). Therefore, there was an expectation of a positive result for their 
derived MV also providing evidence of a strategy for determining sample quality of their 
original source (parent cells). 
CD46 expression was observed on HeLaMVC and HRV16iHMV during this study. It is 
well understood that this encoded protein can act as a receptor for a variety of viruses 
including the Edmonston strain of measles virus, human herpesvirus-6, and type IV pili 
of pathogenic Neisseria (Plant & Jonsson, 2006). It is also known to be conversed in 
Adenovirus (Gaggar, et al., 2005). The binding to HRV16iHMV samples may be because 
HRV expresses a cytosolic 3C protease that has been hypothesised to mediate antagonism, 
which was predicted to cleave complement C3 (Tam, et al., 2014). It is also known that 
CD46 is expressed by all nucleated human cells (Joubert, 2014), which may provide an 
explanation of why it was weakly (negative) bounded to eMV CaCl2 +NHS, and negative 
for eMV control and eMV CaCl2 (erythrocytes do not have nucleus).  Moreover, the role 
of this membrane cofactor protein in regulation of C4b and C3b deposited on cells, is interesting 
because this expressed complement regulatory protein saveguard host cells from  
complement activity. This type-I membrane GP serves as a cofactor for the serine 
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protease factor I, to mediate inactivation of C3b and C4b deposited on host cells 
(Liszewski & Atkinson, 2015).  
It is notable that erythrocytes have previously been considered negative for CD36, 
whereas in this research there was a slight expression in eMV samples. The results 
obtained here are consistent with an early study by Van Schravendijk, et al., (1992), 
detecting CD36 on the majority of normal adult erythrocytes. Particularly, when 
comparing with staining for GYPA, LFA-3, and CR1, the level of expression of CD36 
was low, but nonetheless present. However, FC technology has advanced since then. 
Nevertheless, normal erythrocytes can adhere to plastic coated with anti-CD36 
monoclonal antibodies, suggesting that the level of expression of CD36 on normal 
erythrocytes is sufficient to be important in cell adherence. This may suggest that eMV 
could inherit this molecule during microvesiculation.  
Additionally, CD36 is a membrane GP present on platelets, mononuclear phagocytes, 
adipocytes, hepatocytes, myocytes, and some epithelia. Moreover, CD36 in a variety of 
cells is localised in specialised cholesterol-rich membrane microdomains and may 
interact with other membrane receptors, including tetraspanins and integrins. 
Recognisation of CD36 signalling pathways in specific cells evoked in response to 
specific ligands may result in novel targets for drug development (Silverstein & Febbraio, 
2009).  
The process of erythrocytes accumulation under low flow conditions by the capture and 
adhesion of normal erythrocytes to surface-adherent neutrophils and platelets observed, 
is distinct from the process of passive entrapment within fibrin fibres  (Goel & Diamond, 
2002). Goel & Diamond hypothesised that under venous flow conditions erythrocytes via 
receptor-mediated adhesion could attach to activated neutrophils, activated platelets, and 
surface-deposited fibrin. Their research implicate inflammatory responses causing 
neutrophil or platelet arrest and activation on activated endothelium, with subsequent 
receptor-mediated capture of erythrocytes under low flow conditions in the development 
of deep vein thrombosis. Erythrocytes attach to a thrombospondin-coated purified fibrin 
surface, but do not adhere to purified fibrin. Goel & Diamond visualised short-lived 
adhesion events (< 5 seconds) between erythrocytes and platelets, neutrophils, or fibrin 
as well as firm adherence of erythrocytes.  All interactions were assisted by erythrocyte 
membrane deformation and membrane tethering upon binding. 
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Likewise, CD58 is not a traditional erythrocyte marker. The influence of the age of the 
erythrocytes within its lifecycle at the time of blood donation on the erythrocytes storage 
lesion is still not well understood (Bicalho, et al., 2013). Nevertheless, the expression of 
cell adhesion molecules including CD58, GYPA and PS on young and old erythrocytes 
density separated prior to storage was determined by FC (Sparrow, et al., 2006). 
According to their results, older erythrocytes showed significantly reduced expression of 
GYPA throughout storage. Storage in the presence of leukocytes caused a significant 
decline in the expression of CD58 and GYPA, whereas erythrocytes that were pre-storage 
leukocyte depleted, maintained a relatively consistent level of expression throughout 
storage. Increased levels of Annexin V were detected in the supernatant of erythrocytes 
stored in the presence of leukocytes, with significantly greater supernatant levels found 
in older erythrocytes when compared to young erythrocytes. These findings provided an 
insight into the erythrocytes storage lesion and indicated that erythrocyte age at the time 
of donation may impact upon the quality of stored erythrocyte concentrates. This was 
acknowledged during this PhD research (storage time), and erythrocytes were 
immediately used after separation from other blood cells. However, these processes were 
not tested during this research project.  
Among tetraspanins CD63 has a broad tissue distribution, while others are restricted to 
specific cells. For example, CD37 and CD53 in haematopoietic cell and microscopy 
studies have shown that tetraspanins are abundant on various types of endocytic 
membranes and have been widely used as exosomal markers (Andreu & Yáñez-Mó, 
2014). However, since tetraspanins are ubiquitous in the plasma membrane, they may be 
present in the wider subpopulations of EV, and in some cases, do not permit successful 
discrimination of exosomes from other EV because all EV subtypes originate through 
budding from the plasma membrane and could not be distinguished from exosomes only 
by CD63.  
eMV did not show a positive signal for HLA-ABC. This is because their parent cells 
(erythrocytes) do not generally have HLA molecules (De Villartay, et al., 1985), in 
contrast to HeLa and HRV16 MV samples. Likewise, CD14 was negative for all MV 
samples in this research. It is a known specific marker for peripheral monocytes, and it 
was used here as a negative antibody control in order to enhance the hypothesis that the 
samples collected here only derived from the original source of choice. Nevertheless, this 
assumption could not be proven because erythrocytes probably picked up other cell 
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markers in circulation (CD36, CD58 and CD63), which were then assumed to be passed 
on to eMV or eMV adhering to these molecules whilst in the microenvironment. 
Byron, et al., (2010), explained the manner that adhesion receptors may be used to 
regulate chemical signalling by controlling the spatial-temporal congregation of enzymes 
and adaptors. This is demonstrated evidence that cell and ECM interactions also perform 
as sites of mechanotransduction, transferring short-range elastic force beyond the plasma 
membrane and understanding long-range alterations in tissue. Important information was 
acquired into the duty of integrins as mechanosensitive receptors that present catch-bond 
characteristics.  
The interaction network for the surface markers observed here (eMV samples) is 
extensive and their ligand-receptor arrangement potential is shown in Fig. 3.2.1.3.1. This 
is where the receptors-ligand may reveal a surprising quantitative and qualitative 
variation in receptor binding strengths providing a substantial source of novel recognition 
pathways and biological support, revealing the likely communication paths further 
motivating the need to understand the challenges and opportunities in pursuing selected 
target molecules. Each and every one of these proteins proposes different ways to 
communicate/signal with nearby cells. However, the communication network will also 
depend on the surface markers (receptor/ligands) present in the neighbouring cells for the 
MV-cell communication to occur successfully, according to the principles of cellular 
communication introduced in chapter 1.5.  
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Fig. 3.2.1.3.1. Protein interaction network for surface markers present in eMV. String database- CONSORTIUM 2017 
(Szklarczyk, et al., 2015). The analysis provides a system-wide understanding of all functional interactions between the surface 
markers present in eMV. The data is collected from a variety of sources and aims to integrate the information in a single diagram, 
by consolidating known and predicted protein–protein association data.The associations in this database include direct (physical) 
interactions, as well as indirect (functional) interactions, as long as both are specific and biologically meaningful to the protein 
(name) provided.  
   
 
 
86 
3.2.2 Total protein identification in MV samples 
3.2.2.1 Introduction 
A large proportion of cell surface receptors respond to the specialised actions of 
transmitters including hydrophobic signal molecules such as steroid and thyroid 
hormones that can diffuse across the plasma membrane of the target cell, and activate 
intracellular receptor proteins that directly regulate the transcription of specific genes 
(Cooper, 2000), and/or by triggering heterotrimeric guanine nucleotide binding proteins 
(G proteins). The binding of a G protein is consummate by the dissociation of their 
subunits which in turn modulate target effectors (Robillard, et al., 2000). They commonly 
operate as molecular triggers in the intracellular environment because they transmit 
signals from various biological processes from the external to the internal environment. 
A large number of G-protein-coupled receptors have been demonstrated to induce 
multiple signalling pathways when expressed in a variety of cells (Hutchings, et al., 2010), 
because they act as signal transducers (see chapter 1.5), converting the extracellular 
binding event into intracellular signals that alter the behaviour of the target cell (Alberts, 
et al., 2014). 
When MV are released into the extracellular space they can bind to neighbouring cells by 
acting locally or by travelling passively through the bloodstream for a more paracrine 
destination, or they can even be directed by marginal zone phagocytes in the spleen and 
liver (Robbins & Morelli, 2014). Therefore, once released by a variety of cell types, MV 
may have several fates themselves as well as being able to transfer molecules/messages 
to neighbouring cells and changing their fate, all of which dictate their potential function 
and survival depending on their cargo.  
This chapter aims to identify a number of proteins to test the hypothesis that their 
characteristics, signify MV differentiation and identification as well as, their potential 
survival in the extracellular space including: 
1. CD47 (integrin-associated protein) is a ubiquitously expressed cell surface 
transmembrane glycoprotein (GP). CD47 interacts with several integrins that 
attach the cytoskeleton to the extracellular matrix, and biochemically, by sensing 
whether adhesion has occurred and regulating their functions. Through soluble 
ligands or counter-receptors, CD47 modulates various signalling pathways 
including the activation of heterotrimeric G-proteins. CD172a (signal regulatory 
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protein α, SIRPα), an immune inhibitory receptor on macrophages ligates with 
CD47 resulting in CD47-positive cells that can avoid phagocytosis (Oldenborg, 
2013).  
CD47 has displayed the capability to have an impact on a variety of additional 
biological processes through interaction with different receptors, or because of 
the signalling within its intracellular cytoplasmic domain. For example, 
cooperation of CD47 with thrombospondin-1 (TSP-1) or vascular endothelial 
growth factor receptor 2 (VEGFR2) retarding angiogenesis and restraining 
tumour development (Kaur, et al., 2014; Bazzazi, et al., 2017).  
2. Protein Kinase C (PKC) are a large family of protein kinases. There are 
fifteen isozymes, which are divided into three subfamilies (Webb, et al., 2000): 
a. Conventional (or classical) isoforms α, βI, βII, and γ, require 
Ca2+, diglyceride, and a phospholipid such as phosphatidylserine for 
activation;  
b. Novel, include the δ, ε, η, and θ isoforms, and require diglyceride. They 
do not require Ca2+ for activation; and 
c. Atypical, include the Mζ and ι / λ isoforms.The do not require either 
Ca2+ or diacylglycerol for activation.  
PKC’s regulate the activity of proteins by phosphorylating the hydroxyl groups of their 
threonine and serine residues. Recurring themes are that PKC is involved in receptor 
desensitisation, modulation of membrane structure events, regulation of transcription, 
mediation of immune responses, regulation of cell growth, cell learning and memory, cell 
shape and regulation of cell-cell contact (Newton, 1995). 
3. Spectrins were originally discovered in erythrocytes by Marchesi, et al., (1968). 
Now spectrins are recognised as a large class of proteins found in all vertebrate, 
and invertebrate cells that are differentially expressed during development 
(Chorzalska, et al., 2010). The antibody used here localizes the 220 kDa (β) and 
240 kDa (α) bands of human erythrocyte spectrin staining. A large number of 
spectrin-like molecules have been found in non-erythroid cells. β Spectrin for 
instance, includes mammalian erythrocytic β-spectrin, non-erythroid β-
spectrin/fodrin (β -G, the general form of β-spectrin is expressed in multiple 
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tissues), a novel β -G spectrin (ELF1-4- protein coding gene) that lacks the C-
terminal pleckstrin homology domain, the brain-specific SPTBN2 (gene), and β-
V spectrin (SPTBN5 gene). They help to support of membrane integrity, 
stabilisation of cell-cell interactions, axonal growth, normal functioning of the 
Golgi complex and organisation of synaptic vesicles (Gallagher & Forget, 1996) 
4. Glycophorin A (GYPA) is one of the major intrinsic membrane protein of the 
erythrocyte. The external membrane N-terminal glycosylated segment bears the 
classification of human blood, the MNSs blood group system, which required 
two genes, GYPA and GYPB on chromosome 4 for expression. They are major 
sialoglycoproteins, a combination of sialic acid and GP’s. GYPA is important 
for the function of SLC4A1, a gene that provides instructions for making a 
protein known as anion exchanger 1. GYPA is needed for high activity of 
SLC4A1 and it might have an involvement in the translocation of SLC4A1 to 
the plasma membrane. It also appears to have a role in facilitating the movement 
of band 3 to the cell surface during biosynthesis (Tanner, 1993).  
5. Band 3 is a transmembrane protein responsible for the anion channel across the 
erythrocyte plasma membrane, and a cytoplasmic domain (large amino terminal 
segment exposed) displaying modular functions. This interaction is electrostatic 
and it is influenced by oxygenation (Galtieri, et al., 2002). Band 3 protein is the 
major integral membrane protein of erythrocytes and consists of 911 amino acids. 
The NH2-terminal 360 amino acid residues form a water soluble, with long 
domain that act as an attachment site for the binding of the membrane skeleton 
and other cytoplasmic proteins. The abundance of Band 3 has made it a useful 
model for the study of structure/function relationship in the transport protein. 
Band 3 protein assumes two conformational states during the exchange process, 
the inward facing form which can bind an anion from the intracellular surface 
and the outward facing form which can bind an anion from the extracellular 
surface (Passow, 1986; Hamasaki, 1999).  
3.2.2.2 Results  
In this result chapter, the investigation focused on the expression of different proteins that 
were present in the lysate of MV samples compared with their parent cells. This was 
assessed by Western blotting analyses to further investigate the hypothesis that MV 
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express the same characteristics as their original sources (parent cells). And are therefore, 
able to identify molecules that may enable MV to communicate with nearby cells and 
their potential ability to survive in the extracellular environment. 
Erythrocytes, eMV, eMV control, eMV CaCl2, eMV CaCl2 + NHS,  HeLa cells, 
HeLaMVC, and HRV16iHMV samples were subjected to SDS-PAGE SYPRO® Ruby 
protein gel staining (Fig. 3.2.2.1) following procedures set out in chapters 2.2.7.1-2.2.7.4. 
This was performed to identify potential proteins by their size position ranging between 
250-10 kDa, where the migration distance depends on the protein charge, its size, and the 
pore size of the gel which could be further investigated using Western blotting analyses. 
In Fig. 3.2.2.1a erythrocytes visually presented stronger intensity bands compared to 
eMV samples, despite the amount of total protein being the same for all samples (50 µg/ 
mL). The same bands appear to be present in all samples but were expressed at different 
levels (lower intensity) for eMV samples, in particular for eMV control.  
In Fig. 3.2.2.1b HeLa cells and their derived MV presented more bands at different 
intensities. Particularly, HeLaMVC which demonstrated to be less concentrated despite 
the same amount of total protein concentration being loaded (50 µg/ mL). 
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To identify the bands present in Fig. 3.2.2.1, the Western Blotting immunoassay test was 
performed (Fig. 3.2.2.2).  The presence of β Spectrin, PKC, CD47, and β actin was 
confirmed in all samples. Whereas Band 3 and GYPA was only present in erythrocytes 
and their derived MV, suggesting that each MV population did not differ in total protein 
presence when compared to their cell source.  
The exploration and confirmation that the chosen proteins were in fact present in the 
samples, was performed using β actin which acted as a "housekeeping protein", to correct 
for protein loading and transfer efficiency (present in all samples). This technique is 
commonly used and provides a useful reference in protein expression studies (Ferguson, 
et al., 2005). 
Also, in order to validate the assay and the true binding of the antibodies a gold protein 
standard was used (CD47 standard -Protein fragment), labelled as “CD47 standard”. This 
is where only the protein fragment was loaded into the gel well (no MV sample), along 
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Fig. 3.2.2.1. SDS-PAGE SYPRO® Ruby stain protein gels.  Representation of different proteins bands being separated by size. 
The molecular masses are indicated in kDa. All samples consisted of 50 µg/ mL (volume varied for each sample, therefore diluted 
with PBS buffer to make up for 25 µl per well) determined by BSA assay interpolation of standard curve (Fig. 2.2.7) Precision 
plus proteinTM dual colour standards ranging between 250-10 kDa and 10 µL were loaded into gel and it acted as a size guide for 
stained bands.  
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with samples tested against CD47 itself. This protein fragment acted as a separate entity- 
sample (standard) for the measurement of its binding ability in a functional antibody assay. 
 
 
The band intensity reflects specific antibody binding and to demonstrate that band 
intensity correlates with a specific antibody. Here reference samples (parent cells) and 
PBS negative binding control (blank spot) were used as a reference for intensity 
brightness subtraction, a parameter used for every test measurement in Fig. 3.2.2.3a. This 
was performed to compare band intensity across all samples. As shown in Fig. 3.2.2.3b 
(erythrocytes and their derived eMV) and Fig. 3.2.2.3c, all proteins were expressed at 
different levels which differ according to each sample.  
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Fig. 3.2.2.2. Western blotting analyses. A representation of six different experiments performed for erythrocytes and eMV 
samples (as labelled) and four experiments performed for HeLa cells and their derived MV (as labelled). Note, each of the samples 
consisted of the same amount of total protein (50 µg/ mL), determined by BSA assay interpolation of standard curve when loaded 
into the gel. Therefore representing different levels of antibody expression is a result of the content of each sample (total protein), 
indicating the approximate size (kDa) for each of the monoclonal antibodies tested here. 
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3.2.2.3 Discussion  
It is important to acknowledge that the data obtained with a Western Blot is typically 
semi-quantitative, only proving a relative comparison of protein levels, and not an 
Fig. 3.2.2.3. Western blotting band intensity analyses. The measurement of each band for each sample and each antibody 
binding is shown in a) representing the histograms, indicating the intensity of each of the bands (the larger the histogram peak, 
the brighter the band, the more protein binding). This was subtracted against PBS binding control samples clear spot (band). The 
summary of all samples and all antibodies tested here (in triplicates) is shown in b) erythrocytes and their derived eMV and c) 
HeLa and their derived MV, which represents the intensity of each band per sample as a numerical value (in pixels).  The brighter 
the band, the higher the number. The analyses was performed using the Image J software and GraphPad Prism was used to 
generate the XY graphs (Mean and Error). 
a) 
b) 
c) 
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absolute measure of quantity. The factors influencing this are due to variations in sample 
loading and transfer rates between the samples in separate lanes, which are different on 
separate blots. For a more precise comparison to be made, processing needs to be 
standardized and the signal generated by detection needs to be linear across the 
concentration range of samples. A nonlinear signal was produced, and therefore, should 
not be used to model the total concentration in each sample (Mahmood & Yang, 2012). 
There are additional complementary techniques that supplements and may support 
Western Blotting analyses which could be employed in future work.  
The Enzyme-Linked Immunosorbent Assay (ELISA) for example, can be used to assess 
the affluence of a target protein providing strong sensitivity, protein concentration 
(standards) and reduce experiment timing (less than 4 hours). However, it can be 
expensive due to the cost of readily available kits and the expensive machinery required 
to conduct the analysis (Haab, et al., 2013). 
Another technique commonly employed is the Liquid Chromatography Mass 
Spectrometry (LC/MS) for the analysis and detailed assessment of proteins. It can provide 
distinguishable benefits over ELISA as well as Western Blotting techniques, because the 
distinctions between different proteins as well as their isoforms is achievable with a 
greater degree of sensitivity and over a broad dynamic scope. But again, it requires highly 
specialised, expensive equipment and also technical expertise (Bass, et al., 2017). 
Notably, CD47, PKC and β-spectrin showed expression in all samples. This was expected 
because these proteins are not tissue/sample specific. But yet, it proves that the MV 
samples obtained here express similar characteristics to those of their original source 
(parent cells).  
CD47 serves as the ligand of SIRPα, which is expressed on phagocytic cells and, when 
activated, initiates a signal transduction cascade resulting in the inhibition of phagocytosis 
(Barclay & Brown, 2006). A number of studies suggest that blocking CD47 efficiently 
enhances macrophage phagocytosis in both physiological and pathological conditions in-
cluding human myeloma cells (Kim, et al., 2012) and MKN45 and MKN74 gastric cancer 
cells (Yoshida, et al., 2015). Thus, suggesting that CD47 positive MV have a greater 
chance of survival in the extracellular environment because they will not be depleted by 
phagocytic cells due to the “do not eat me signal” that they produce.  
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Nevertheless, Burger, et al., (2012) noticed that aged erythrocytes attach to SIRP using 
CD47 because it undergoes a conformational alteration during aging stimulated by oxi-
dative stress which allows erythrocytes to be recognised after the binding of thrombos-
pondin-1, 28, and 29, and therefore to be phagocytosed. This finding supports the state-
ment provided in chapter 3.1.3 (page 65) by Ferreira, et al., (2013) that sample quality 
may affect the enumeration of eMV samples, because in this case, if eMV present char-
acteristics similar to their parent cells it will also present the “eat me” signal. It also sug-
gests that eMV derived from younger erythrocytes may have a higher change of survival 
in the microenvironment, because this is before they undergo the conformational altera-
tion.   
A study by Alkan, et al., (2005) has suggested that PKC activation plays an important 
role in the survival of chronic lymphocytic leukaemia. They investigated the expression 
pattern of PKC isoforms, which this PhD research did not addressed. Nevertheless, their 
findings suggest that PKC activation overall, is important for chronic lymphocytic 
leukaemia cell survival and that inhibitors of PKC may have a role in the treatment of 
patients with chronic lymphocytic leukaemia. Moreover, it appears that the function of 
PKC is dependent on the different isoforms present, for instance PKC 𝛿 acts as a pro-
survival factor in human breast tumour cells in vitro (McCracken, et al., 2003). The 
activation of PKCε may improve retention, survival, and differentiation of transplanted 
primary mesenchymal stem cells in myocardia (He, et al., 2016).  
Therefore, PKC may also play a role in MV survival in the extracellular environment and 
may be involved in the MV role of cell growth regulation on neighbouring cells, as 
influential cell cycle-specific impacts of PKC signalling that can either favourably or 
adversely affect the proliferation of cells (Black & Black, 2012; Redig & Platanias, 2008).  
Integrin proteins may link specific integrins to PKC (Zhang, et al., 2001), the family of 
phospholipid-dependent serine and threonine kinases that is understood to partake in a 
vast range of biological activities (see Appendix II, table 5 and 6). The activation of 
cytosolic PKC by phorbol ester or diacylglycerol occurs in parallel with PKC 
translocation to cellular membranes. Membrane association has also been suggested to 
specific PKC interactions with phosphatidylserine (Jaken & Parker, 2000; Igumenova, 
2015) which is present in MV samples (Fig. 3.2.1.2). 
Spectrins are a critical component of the cell membrane skeleton, maintaining cell shape 
by conferring strength and elasticity as they associate with the plasma membrane through 
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protein–protein and protein–lipid interactions. Ankyrin is a key component in this 
network, because it binds both to spectrin and transmembrane proteins, thus linking 
spectrin to the plasma membrane (Clarkson, et al., 2014). In non-erythroid cells, spectrins 
form an extended protein network just below the plasma membrane bilayer by linking 
various actin fibres and many integral membrane proteins. They are also present in the 
cytosol, and can bind other proteins via numerous interaction motifs, such as the SRC 
Homology 3 Domain (proto-oncogene) (Chorzalska, et al., 2010). Therefore, the presence 
of spectrin in the eMV samples can only highlight their strength and ability to maintain 
MV shape intact.  
More specifically, Band 3 and GYPA are the two most abundant integral proteins of the 
erythrocyte membrane and were detected in eMV samples acquired here, probably due to 
their biogenesis (erythrocytes). The main functions of Band 3 are for membrane anion 
transport and the maintenance of erythrocyte membrane stability, through interaction with 
the cytoskeleton. Whereas, GYPA plays an important role in the prevention of erythrocyte 
aggregation in the circulation and contribution to the glycocalyx (Poole, 2000). 
GYPA has been well characterised in erythrocytes. This is a protein with abundant 
glycosylation, and studies have suggested that resistance of target cells to natural killing 
may be correlated with the level of GYPA expression (Ouagari, et al., 1995). In their 
native state GYPA do not seem to control membrane material properties and/or cell shape. 
Instead the binding of ligands may lead to a rise in membrane rigidity and a reduction in 
the lateral mobility of these molecules, which may have resulted from increased 
association of the cytoplasmic domain of GYPA with the skeletal network. This may be 
adjusted by the modifications on the exoplasmic domain (where the binding of ligand 
occurs), and can be considered a form of signal transduction in which ligand induce 
changes in cellular behaviour. This was described in granulocytes and platelets (Chasis 
& Mohandas, 1992).  
The presence of the proteins observed in this chapter, also suggests that the eMV cargo 
is likely to depend on the parent cell (same characteristics - similar to chapter 3.2.1) and 
that MV function and survival chances may be dependent on the molecules that they may 
express, combined with the proteins observed in this chapter (see Fig. 3.2.2.3.1 for protein 
interaction network). The availability of different target cell types to internalise the 
circulating MV is broad and provides a variety of possible mechanisms in which MV may 
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be able to process. The targeting by specific adhesion molecules may play a role in 
determining EV bio distribution (Yáñez-Mó, et al., 2015).  
Fig. 3.2.2.3.1. Protein interaction network for total proteins observed in eMV. String database- CONSORTIUM 2017 
(Szklarczyk, et al., 2015). Also see Fig. 3.2.1.3.1. The contact of these molecules with each other may induce a variety of 
interactions and associations among other proteins. Predicting the protein functionality is one of the main objectives of the 
network, which can be based on their contrasting structural and functional characteristics, in which each may have different 
biological effect outcomes. 
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3.2.3 Proteases identification in MV samples 
3.2.3.1 Introduction 
Proteases, are recognised as peptide hydrolases that have been observed in a variety of 
biological processes, in distinction to protein degradation in lysosomes to cell division. 
They are enzymes that perform proteolysis, which is the beginning of protein catabolism 
by hydrolysis of the peptide bonds that link amino acids together in a polypeptide chain 
(Castro, et al., 2011). Proteases represent 1- 4% of the genes per genome that have been 
sequenced and have been observed to be present in various species from viruses to mam-
malia. The human genome exhibits more than 670 proteases, of which approximately 
31% are serine proteases, 25% cysteine proteases, 33% metalloproteases, and 4% are as-
partic proteases (Bromme, et al., 2011). 
Proteases can be considered molecular scissors that engage a significant role in the intra-
cellular environment during regulatory processes consuming little energy. Therefore it is 
important to understand its specificity, considering that it determines the selection of its 
interactions in the protein-protein interface of cleavage-substrates (Fuchs, et al., 2013). 
The requirements to substrate specificity of regulatory proteases, participating in limited 
proteolysis of inactive precursors of enzymes and (or) hormones is even greater, particu-
larly in physiological conditions, where the proteolytic reaction is irreversible, represent-
ing the main difference of proteolysis from a set of ad hoc regulatory mechanisms 
(Rodriguez, et al., 2010; Berg, et al., 2002). 
In organisms of a higher organisation level, the domain composition of proteins is more 
complex and combinations of domains are more diverse (Chothia, et al., 2003). During 
the acquisition of new domains, several unique proteases with various catalytic or 
inhibiting domains encoded by the same gene were formed, and it is believed that the key 
mechanisms for the appearance of new proteins are gene duplications (Zhang, 2003).  
The high biological significance of proteolysis explains the origin of multiple, highly 
diverse types and familial proteases (Rao, et al., 1998). The diversity of proteolytic 
enzymes is resultant to a certain degree because of distinctions in the conditions of their 
functioning in various cellular structures  incuding organisms from different ecological 
niches, the pH, the temperature, the redox potential of the medium, and hydrophilic and 
hydrophobic surroundings (Nemova & Lysenko, 2013). Thus, they play a key role in 
various physiological processes, including division, differentiation, migration, aging, 
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cellular apoptosis, thermal shock, morphogenesis, reorganisation of tissues, angiogenesis, 
immunity, haemostasis, wound healing, ovulation and fertilisation (Nemova & Lysenko, 
2013; Shah, et al., 2012). Therefore a panel of different protease families was studied 
during this research including:  
1. ADAMs is a disintegrin and metalloproteinase family of multidomain 
transmembrane proteins belonging to the zinc protease superfamily 
(characterised by their manifestation of metalloprotease and integrin receptor-
binding activities). The ADAMs family has forty gene members currently 
identified of which 21 are functional in humans. Human ADAM’s include 
precursor forms of growth factors, cytokines, growth factor receptors, cytokine 
receptors, and several different types of adhesion molecules (Duffy, et al., 2011). 
The cytoplasmic domain, observed in many family members specify binding 
sites for various signal-transducing proteins (Seals & Courtneidge, 2003). 
Murphy’s work (2008), suggested ADAMs to be involved in the control of 
membrane fusion, cell migration, cytokine and growth factor shedding, 
fertilisation, muscle development, cell fate determination, involvement cell-cell 
and cell-matrix interactions.  
2. ADAMTS is also a disintegrin and metalloprotease family of proteases with 
thrombospondin motifs; a novel family of extracellular proteases. ADAMTS are 
distinguished from the ADAMs family members based on the multiple copies of 
thrombospondin 1-like repeats. The ADAMTS family members are spectulated 
by their structural domains to be Extracellular Matrix (ECM) proteins, with an 
extensive range of activities and functions including, growth factors and 
adhesion receptors (Kelwick, et al., 2015; Seals & Courtneidge, 2003) 
3. Cathepsins (CTS) are cysteine proteases that constitute one of the five catalytic 
types of proteases. The common feature is their catalytic mechanism, the 
increase in the rate of a chemical reaction by the active site of a protein. All 
cysteine proteases utilise a Cys residue as a nucleophile and a His residue as a 
general base for proton shuttling (Berg, et al., 2011). Based on sequence 
homology and three-dimensional structure similarity, they have been divided 
into clans, each consisting of one or more families. The most intensively studied 
cysteine proteases are papain and its relatives, including the lysosomal cysteine 
CTS in clan CA which comprises family C1 (Berdowska, 2004). The activity of 
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lysosomal cysteine CTS can be regulated in several ways, the most important 
being zymogen activation and inhibition by endogenous protein inhibitors (Turk, 
et al., 2001). The N-terminal pro-regions of the lysosomal cysteine CTS, which 
are removed during maturation, act as potent reversible inhibitors of the mature 
enzymes, preventing inappropriate activation of the protease zymogens. CTS 
have long been believed to be responsible for intracellular protein degradation 
(Mohamed & Sloane, 2006). Overall, CTS’s catalyse the hydrolysis of a variety 
of protein substrates with different specificities and are involved in a wide range 
of biological processes including, tumour metastasis, muscular dystrophy, 
emphysema and arthritis (Agarwal, 1990; Jedeszko & Sloane, 2004).  
4. Kallikreins (KLKs) are serine proteases present in diverse tissues and biological 
fluids. The KLKs enzymes have been split into two major groups, the Plasma 
KLKs and the Tissue KLKs. These differ notably in their molecular weight, 
substrate specificity, immunological characteristics, gene structure, and type of 
kinin (structurally related polypeptides) released (Yousef & Diamandis, 2001).  
 
The Plasma KLKs are encoded by a single gene located on human chromosome 
4q35 (Yu, et al., 1998) and their function is to participate in the process of blood 
clotting and fibrinolysis and, in the regulation of vascular tone and inflammatory 
reactions (Bhoola, et al., 1992; Yousef & Diamandis, 2001). Whereas, tissue KLK 
have diverse expression patterns and physiological roles, including cell growth 
regulation, invasion, angiogenesis, and metastasis in cancer. Tissue KLKs are part 
of a large multigene family, with similarities in the tertiary structure as well as at 
the gene and protein level. This has been demostrated in numerous studies 
(Riegman, et al., 1991; Murtha, et al., 1993; Nelson, et al., 1999; Yousef, et al., 
1999; Yousef, et al., 2000; Koumandou & Scorilas , 2013).  
 
Matrix Metalloproteinases (MMPs) are the family of calcium-dependent zinc-
containing endopeptidases associated with tissue remodelling and degradation, 
and the removal of the ECM from the tissue; including collagens, elastins, gelatin, 
matrix GP’s, and proteoglycan (Yadav, et al., 2011). Nevertheless, it has been 
suggested that the breakdown of ECM molecules or cell surface molecules 
changes cell-matrix and cell-cell interactions, and the release of growth factors 
that are bound to the ECM that model them for cell receptors. MMPs 
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are generally expressed in normal physiological conditions providing homeostatic 
maintenance (Loffek, et al., 2011).  
 
MMPs are derived from a number of connective tissue and pro-inflammatory cells 
such as fibroblasts, osteoblasts, endothelial cells, macrophages, neutrophils and 
lymphocytes. MMPs are expressed as zymogens, the active form result from 
processing by other proteolytic enzymes including, serine proteases, furin, 
plasmin, and others that leads the active forms. Under normal physiological 
conditions, the proteolytic activity of the MMPs is controlled at any of the 
following identified stages: 
  
1. Activation of the zymogens;  
2. Transcription; and 
3. Inhibition of the active forms by various TIMPs (Verma & 
Hansch, 2007). 
 
MMPs are regulated by hormones, growth factors, and cytokines, and are 
involved in ovarian functions (Verma & Hansch, 2007). These highly active 
proteases require tight physiological control via endogenous MMP inhibitors 
(MMPIs) and Tissue Inhibitors of MMPs (TIMPs) that if overexpressed can result 
in a variety of pathological disorders (Liu, et al., 2006). In addition, a number of 
non-ECM molecules are also potential substrates of MMPs (Nagase, et al., 2006).  
In relation to MV, EV proteomic analysis has suggested that metalloproteinases including 
the cell surface-anchored sheddases and metalloproteinases, and cell surface-bound and 
soluble MMPs are involved in EV activity from a variety of sources. Metalloproteinases, 
have been shown to impact not only ECM remodelling, but also cellular interactions. In 
particular, some of the metalloproteinases in EV have been shown to be proteolytically 
active, proposing that they may change the contents of EV by proteolytic processing and 
assist in EV-mediated cell–cell communication (Shimoda & Khokha, 2013). In addition, 
the release of metalloproteases from tumour cell derived MV has been observed to 
promote tumour invasion and metastases (Dolo, et al., 1999). 
The expression profile of proteases is fundamental for understanding their roles in normal 
cellular function, their dysregulation in diseases such as cancer, and their therapeutic 
applications (Craik, et al., 2011). Therefore, this chapter aims to identify 
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proteases/families present in MV samples using The Human Protease Array Kit (R & D 
systems) which is a rapid, sensitive, and economical tool to simultaneously detect 
protease and the relative expression differences between samples.  
3.2.3.2 Results 
In this results chapter, the investigation focused on the expression of different proteases 
that were present on the lysate of MV samples and their parent cells. These were assessed 
by selected capture antibodies (in duplicates) on nitrocellulose membranes, where the 
signal is produced in proportion to the amount of protein bound. Chemiluminescence was 
detected in the same manner as Western blotting analyses (results chapter 3.2.2.2).  
Erythrocytes were isolated from fresh venous blood utilising the Ficoll-PaqueTM Plus 
method. eMV control was extracted by incubating the erythrocyte pellet as in chapter 
2.2.4. HRV16iHMV were extracted from conditioned medium (exosome free serum), 
after 24 hours infection/incubation period. These MV samples were isolated following 
various steps of centrifugation: 200 g for 5 minutes; 4,000 g for 60 minutes; and 25,000 
g for 90 minutes. Subsequently, these MV samples and their parent cell were lysed with 
RIPA buffer and protease inhibitors (see chapter 2.2.7.1).  
Total protein concentration was determined with BCA assay and 50 µg/ mL of each 
sample was used for this experiment. All experimental design was followed according to 
the manufacturer instructions (Proteome Profiler Human Protease Array Kit, R & D 
systems (see chapter 2.2.8). 
Parent cells (erythrocytes and HeLa cells) were used to overcome substantial limitation, 
such as a relative protein recovery from a limited volume of eMV control and 
HRV16iHMV samples. The same amount of total protein (50 ug/ mL) was used for each 
sample, which was created to normalise the relative quantitative changing of the proteases 
array, and negate the lack of a housekeeping protein.  
Fig. 3.2.3.1 displays the membrane images acquired during the analysis, where the spots 
positioned at A1 and A2, A19 and A20, and E1 and E2 represent the positive controls. 
The absence of spots in positions E9 and E10 signifies the negative control, indicating 
the specificity of the antibody cocktail. The complete list of analyte names and 
position/mapping is available in Fig. 3.2.3.1a. This is where the position of each 
coordinate is shown in column 1 and the analyte ID is shown in column 2. All positions 
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can be identified/mapped in each membrane by placing the transparency overlay template 
(Fig. 3.2.3.1b). The signals for each array membrane (the samples) are displayed in Fig. 
3.2.3.1 c, d, e, and f which were quickly identified by placing the transparency overlay 
template onto the array image and aligning it with the pairs of reference spots in the three 
corners of each membrane. 
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Coordinate Analyte/control ID 
A1, A2 Reference/+ 
A3, A4 ADAM8 
A5, A6 ADAM9 
A7, A8 ADAMTS1 
A9, A10 ADAMTS13 
A11, A12 Cathepsin A 
A13, A14 Cathepsin B 
A15, A16 Cathepsin C 
A17, A18 Cathepsin D 
A19, A20 Reference/+ 
B3, B4 Cathepsin E 
B5, B6 Cathepsin L 
B7, B8 Cathepsin S 
B9, B10 Cathepsin V 
B11, B12 Cathepsin X/Z/P 
B13, B14 DPPIV/CD26 
B15, B16 Kallikrein 3 
B17, B18 Kallikrein 5 
C3, C4 Kallikrein 6 
C5, C6 Kallikrein 7 
C7, C8 Kallikrein 10 
C9, C10 Kallikrein 11 
C11, C12 Kallikrein 13 
C13, C14 MMP-1 
C15, C16 MMP-2 
C17, C18 MMP-3 
D3, D4 MMP-7 
D5, D6 MMP-8 
D7, D8 MMP-9 
D9, D10 MMP-10 
D11, D12 MMP-12 
D13, D14 MMP-13 
D15, D16 Neprilysin/CD10 
D17, D18 Presenilin 
E1, E2 Reference/+ 
E3, E4 
Proprotein 
Convertase 9 
E5, E6 Proteinase 3 
E7, E8 uPA/Urokinase 
E9, E10 Negative Control 
a) 
Fig. 3.2.3.1. Location of coordinates and the presence of different proteases in each array membrane. The positive signals 
seen in each membrane were identified using Fig. a) which provides the coordinate and ID of each spot, b) represents the overlay 
template and c), d), e) and f) representing the samples used as labelled.   
 
b) Overlay 
c) Erythrocytes  
d) eMV control 
e) HeLa cells 
f) HRV16iHMV 
a) ID 
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For the following sets of comparison graphs (Fig. 3.2.3.2- Fig. 3.2.3.4), Image J software 
was used to calculate the mean pixel densities of each analyte. This was performed by 
creating a template to analyse pixel density in each spot of each membrane, then the 
average signal (pixel density) was calculated using the pair of duplicate spots representing 
each analyte. This was determined by subtracting an averaged background signal from 
each spot, against the negative control spots as a background value. The signals on 
different membranes were used to determine the relative change in analyte level between 
samples (established as 535x210 pixels; 8-bit; 110k for all membranes), using the Red 
Green Blue (RGB) images and the results were calculated using brightness values. RGB 
pixels are converted to brightness values using the formula V=(R+G+B)/3, or 
V=0.299R+0.587G+0.114B if "Weighted RGB Conversions" were checked. For these 
analyses the following parameters were recorded: length, angle (straight lines only), mean, 
standard deviation, mode, min, max, and bounding rectangle.  
Fig. 3.2.3.2 show changes between positive and negative detection of the proteases in MV 
samples with respect to their parent cells (erythrocytes). Considerably, 34 relatively 
positive signals were observed in the erythrocytes membrane (that is 34 out of 35 tested 
proteases, some at very low level, but expression is observed), showing that the proteases 
analysed here may attach to erythrocytes in circulation (RIPA buffer lysed samples/total 
proteins analysis was obtained here). In comparison, 21 proteases (positive signal) were 
detected out of 34 for the eMV sample, showing that eMV inherit some but not all of the 
proteases present in their parent cells.  
Both, erythrocytes and eMV samples appear to be enriched with CTS D and V, KLK 7 
and 10, MMPs 3, 8 and 9, and PC9 (more than 2 x102/ mean pixels), whereas eMV 
demonstrated a higher concentration/expression of CTS D, E and V, DPPIV, KLK 10 and 
PC9 than erythrocytes (more than 3 x102/ mean pixels) and with a significant expression 
of MMP9 of more than 5.5x102/ mean pixels.  
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In contrast, much lower positive/binding signal was observed in HeLa cells, with 17 
proteases against 11 detected proteases in HRV16iHMV (Fig. 3.2.3.3), when compared 
to Fig. 3.2.3.2. Nevertheless, similarly the majority of proteases present in MV cell shows 
expression in parent cells, apart from MMP10 which was not present in HeLa cells.  PC9, 
Presenilin, MM9, KLK7 and CTS L, C and S was not present in HRV16iHMV. CTSC 
appears to be present only in the HeLa, which shows a significant change for both sets of 
parent cells (erythrocytes and HeLa), demonstrating a trend of assay validation.  
Neprilysin showed strong expression in HeLa and HRV16iHMV (more than 4.0x102/ 
mean pixels). It was also present in erythrocyte, but absent in eMV. Additionally, 
ADAM9, ADAMTS1, and MMP10 were expressed strongly on HRV16iHMV. CTS D 
and V, KLK 7 and 10, MMPs 3, 8 and 9 did not show presence in HeLa and HRV16iHMV 
samples (not present in the graph), in contrast to erythrocytes and eMV. 
 
 
 
Fig. 3.2.3.2. The comparison of the relative expression of proteases present in erythrocytes and eMV. The graph shows the 
identified positive expressions/signals highlighting the differences between the samples, where MV shows less proteases binding, 
but demonstrates higher concentration/intensity for the proteases present.  
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All the samples expressed a significant level of some CTS’s and ADAM’s family (Fig. 
3.2.3.4), where a set of proteases appear to progressively increase in terms of positive 
signal/binding. Especially for the CTS family with a progressive trend of A, B, D, V and 
Z showing more than 3.0x102/ mean pixels. MMP8 and MMP13 is also present in 
abundance in all samples when all samples are compared.  
 
Fig. 3.2.3.4. The comparison of  proteases present in all samples. The graph identifies positive and negative expression/signals 
highlighting the differences between the samples, where MV shows less proteases binding than their parent cells. It also shows 
the proteases that were not present in all samples (at the botton of  the Y-axis and at numeric value of 0 mean pixels in the X-
axis).  
 
Fig. 3.2.3.3. The comparison of the relative expression of proteases present in HeLa cells and HRV16iHMV. The graph 
shows the identified positive expressions/signals highlighting the differences between the samples, where MV shows less 
proteases binding signal, but demonstrates higher concentration/intensity for the proteases present.  
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3.2.3.3 Discussion  
CTS’s and MMP’s demonstrate substantive expression in this study. This is important 
because they are responsible for a variety of cellular photolytic (chemical compound is 
broken down by photons) mechanisms. Involved in the maturation of protein in the 
immune system, hormone generation and signalling transition on mammalian, which play 
a general role as intracellular acidic proteases in endolysosomal compartments (Stoka, et 
al., 2016). Therefore, they are able to control pH level and therefore catalyse key proteins.  
CTS’s of the A, B, D, V, and XZP classes were found to be markedly abundant in all 
samples, showing more than 3.0x102/ mean pixels. Interestingly, CTS’s are lysosomal 
proteases, which can exert their proteolytic activity in the extracellular space in ECM 
remodelling (Fonović & Turk, 2014), leading to the assumption that MV analysed here 
may play a role in membrane remodelling, and therefore can act as an effective 
mechanism whereby diverse cellular behaviours can be regulated. This concept is 
particularly important when considering processes and cell behaviours that need to be 
deployed promptly, transiently, and wherein cell–cell and cell–matrix interactions are 
constantly changing (Daley, et al., 2008).  
An example found to be present in all the samples is CTSX. This protease is capable of 
cleaving regulatory motifs at C-terminus, which affects the function of targeted molecules. 
Through the activation of β2 integrin receptor Mac-1, active CTSX increases adhesion of 
monocytes/macrophages to fibrinogen and regulates the phagocytosis (Kos, et al., 2009). 
By activation of Mac-1 receptor (CD11c/CD18), CTSX also dominates adhesion of 
monocytes, macrophages and dendritic cells (Sándor, et al., 2016), that is necessary in 
the comencement of adaptive immunity and also through the other β2 integrin receptor, 
Lymphocyte Function-associated Antigen 1 (LFA-1) which is involved in the 
proliferation of T lymphocytes. By modulating the activity of LFA-1, CTSX generates 
cytoskeletal rearrangements and morphological arrangements of T lymphocytes. This 
promotes ameboid-like migration in 2-D and 3-D barriers and enhacing homotypic 
aggregation. C-terminal amino acids of α and γ enolase cleavage by CTSX terminates 
their neurotrophic activity distressing neuronal cell survival and neuritogenesis (Kos, et 
al., 2009), which clearly contributes to the survival and function of MV expressing this 
protease.   
 
 
108 
The presence of MMP8 and MMP13 in all samples is a further highlighting expression 
that was observed in this study. These are collagenases (able to cleave the collagen triple 
helix into characteristic 3/4 and 1/4 fragments). In addition, collagenases can perform 
proteolytical processess in other ECM proteins, as well as a number of bioactive 
molecules such as IL-8, protease-activated receptor-1, MMP-8 targets type I collagen and 
MMP-13 preferentially cleaves type II collagen (Fanjul-Fernández, et al., 2010). 
Therefore implying that MV may reflect local changes in the extracellular 
microenvironment. 
KLK’s family did not in general demonstrate presence in the samples used here. However, 
KLK7 was present in HeLa, erythrocyte, and eMV samples. KLK10 demonstrated 
enrichment in erythrocyte and eMV samples only. It is widely accepted that KLK’s 
possess potential membrane-active properties as a fundamental component in their mode 
of action (Epand & Vogel, 1999). It is interesting that the effects of KLK on various 
biological membrane model systems has been demonstrated and KLKs have shown 
involvement in a broad range of normal physiologic processes, from the regulation of cell 
growth to tissue remodelling (Emamia & Diamandis, 2007).  
Aichinger et al., (2008) demonstrated that KLK avidly interacts with membrane vesicles 
without perforating the membranes. Their hypothesis is that lipid rafts of  DC cells, are 
preferential targets of KLK and via its binding and integration KLK might facilitate the 
uptake and intracellular distribution of ODN1a ( a synthetic oligodeoxynucleotide, that is 
a Toll-like receptor 9 agonist lacking containing cytosine phosphate guanine motifs) and 
antigens, thus stimulating downstream immunomostimulatory functions of the antigen-
presenting cell. Suggesting that the samples analysed here could trigger the immune 
response and decays ECM, showing an ability to avoid recognition as non-self-substances 
and it contributes towards MV entrance to neighbouring cells. 
Neprilysin, a cell surface metallopeptidase, cleaves and inactivates pro-inflammatory and 
vasoactive peptides, and predisposes the lung vasculature to exaggerated remodelling in 
response to hypoxia. It showed strong expression in HeLa and HRV16iHMV (more than 
4.0x102 mean pixels), but not in erythrocyte and eMV samples. In addition to its peptidase 
activity, basic amino acid residues in the tail of Neprilysin contribute to protein–protein 
interactions, resulting in modulation of signalling factors. This has been demonstrated in 
prostate cancer cell lines (Sumitomo, et al., 2005) and it could contribute towards the 
mechanism of HRV16iHMV interaction with neighbouring cells.  
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DPPIV, which is a prolyl peptidase that attaches proteins and peptides after a proline 
amino acid residue, was highly expressed in erythrocytes and eMV, but not in 
HRV16iHMV.  DPP IV is also the CD26 T-cell activating antigen found in almost all 
human organs and tissues (Misumi & Ikehara, 2013). It is attached to the plasma 
membrane of endothelia and is also found solubilised in body fluids such as blood plasma. 
The broad distribution of DPP IV allows access to endocrine peptides, neuropeptides and 
a broad range of paracrine and autocrine peptides and polypeptides (Green, et al., 2006). 
High levels of plasma DPPIV are positively correlated with type II diabetes (Müller, 
2012), suggesting that its  presence in eMV may be an indication of donor characteristics, 
but this needs to be further assessed to corfirm the condition. DPP-IV degrades the active 
form of the incretin, glucagon-like peptide-1, which is liberated from intestinal L-cells 
after meal intake and enhances insulin secretion in a glucose-dependent manner, 
suggesting that MV could have a role in metabolic processes. 
The expression of the proteases observed in this chapter, suggests that the MV cargo and 
function depends on the characteristics present in parent cells (similarly to chapters 3.2.2 
and 3.2.3), because MV expressed the similar characteristics (not all) to their sources. 
The protein interaction network (see Fig.3.2.3.1) show the possible interaction network 
of the proteases present in eMV. This is because they can potentially change the kinetic 
properties of enzymes, can pose as a common mechanism to permit for substrate 
channelling, can create an alternative binding site for small effector molecules, can 
immobilise or repress a specific protein, can modify the specificity of a protein for its 
substrate during interaction with alternative binding sites, and act in a regulatory role in 
either the upstream or downstream level (Phizicky & Fields, 1995). Once more, 
demonstrating the qualitative and broad potential of MV.  
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Fig. 3.2.3.3.1. Protein interaction network of proteases observed in MV. String database- 
CONSORTIUM 2017 (Szklarczyk, et al., 2015). Similarly to Fig. 3.2.1.3.1 and Fig. 3.2.2.3.1 
the network presented here instigated the possible mechanisms which MV may be involved in 
and be able to process. Protease families may appear to interact with a similar network of 
proteins, but all and each of them express their expertise and uniqueness.  
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3.2.4 In silico analyses of biomolecules identified in eMV samples 
The current pace of genome-wide sequence analyses programs, coupled with functional 
genomic screenings has produced a perplexing array of sequence and biological data to 
be developed (Michalovich, et al., 2002). The identification of proteins and/or genes of 
interest in present biological studies requires the application of bioinformatics tools to 
process a vast number of datasets and access their significance. The enrichment analyses 
have played an important role in this regard, contributing to the detection of relevant 
genes amongst a significant amount of listed candidate genes in various high-throughput 
biological studies (Huang, et al., 2009). 
Evaluating the functional properties of protein/gene sets is a routine step in 
understanding high-throughput biological data and is commonly used to verify their 
implication in biological pathways, assess whether they are functionally relevant, and 
to discover unexpected shared functions between the entities of interest. Gene 
Ontology (GO) analysis is therefore, widely used to generate functional  enrichments 
between candidates genes, due to the use of comprehensive reference information and 
unified annotations of underlying functions to describe common features including 
biological processes, molecular functions and cellular components of the biology of the 
gene products to classify them (Glass & Girvan, 2014; Consortium, 2015).   
From a protein function standpoint, the change of annotation from known proteins to a 
novel target is a useful and practical manner to turn vast quantities of “data” into 
meaningful information. The importance of these analyses in the medical field/research 
is increasing due to the possibility of narrowing the search by modelling and discovering 
new biological properties in a systematic fashion that elucidate key functions of complex 
networks of bio-interactions (Bayat, 2002).  
In this PhD research, the primary focus on GO enrichments was associated with human 
proteins/genes only. After assessing the patterns of protein present in eMV samples, a 
list containing proteins conversion to gene names was generated using the String and 
UniProt database (Appendix III- Table 1). 
To systematically detect the functional enrichments among the multiple proteins detected 
in eMV samples, a comprehensive reference information list including gene and 
phenotype ontologies, description, alternative names, chromosomal and map location 
(full list is provided in Appendix III- Table 2) was produced. This list was the raw data 
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used to explore the connections between the query protein/genes and to detect statistically 
significant common features among them. With this strategy it was possible to uncover 
enrichment of cellular component (Fig. 3.2.4.1), molecular function (Fig. 3.2.4.2), 
biological processes (Fig. 3.2.4.3), and specific biological pathways involved (Fig. 
3.2.4.4). This list was created using the FunRich functional enrichment analysis tool 
(Pathan, et al., 2015) , which performs functional enrichment analysis on background 
databases that are integrated from heterogeneous genomic and proteomic resources.  
Appendix III, table 3 provides the list of the genes mapped for the data input in detail. 
HRV16iHMV GO annotations and analyses is presented in Appendix IV. 
The statistical significance of enriched and depleted terms was checked using hypergeo-
metric distribution testing. Additional, the Bonferroni and Benjamini-Hochberg (BH) 
(also known as False Discovery Rate-FDR) method was applied to correct for multiple 
testing, each associated with a P-value (P <0.05). This is where GO analyses were aligned 
to the P value (red bar), P value lower than 0.05 (yellow bar) was also considered signif-
icant, and the blue bar indicated the percentage of genes classified in clusters (not mutu-
ally exclusive) in a whole analysis. The reason for this is that the product of a single gene 
could have one or more molecular functions, be associated with different cellular compo-
nents, and be involved in several biological processes.  
In Fig. 3.2.4.1, the first cluster of the cellular components enrichments includes the genes 
that presented frequencies between 50-75%. This means that ~15 genes of the list (out of 
27) were involved in 2 different processes related to plasma membrane and extracellular 
activities. The following group with a frequency of 25-50% was made by ~10 genes of 
the list. They were related to regulatory processes of extracellular space, integral to 
plasma membrane, exosome and lysosome. The cluster of 0-25% frequency was formed 
by 15 miscellaneous processes with an average of ~2 genes in each of the following 
categories: membrane fraction, cell surface, Golgi apparatus and endoplasmic reticulum.  
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In Fig. 3.2.4.2 the enrichment showed a prevalence of genes (~8) regulating processes 
that modulate metallopeptidase activity (frequency, rate, extent), which refers to the 
catalysis of the hydrolysis of peptide bonds using water as a nucleophile (Nagase, 2001). 
The remaining genes were distributed in 10 miscellaneous processes with an average of 
~1 gene per function including receptor activity, transport protein activity, cytoskeletal 
protein binding, and serine/cysteine peptidase activity. 
 
 
 
Fig. 3.2.4.1. Cellular component enrichment of biomolecules observed in eMV. Frequency of proteins/genes that shared the 
same characteristics in relation to its location, at the levels of subcellular structures and macromolecular complexes.  
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In Fig. 3.2.4.3, the enrichment of biological processes showed a considerable amount of 
genes (~17) regulating protein metabolism. The rest of the genes were distributed in 6 
miscellaneous processes with an average of ~1 gene per process, including immune 
response, cell communication, signal transduction and others. 
Fig. 3.2.4.2. Molecular function enrichment of biomolecules observed in eMV. The graph shows the frequency of 
proteins/genes according to their molecular role.  
Fig. 3.2.4.3. Biological processes enrichment of biomecules observed in eMV samples. The figure represents a complex of 
potential changes on the level of granularity of eMV that is mediated by one or more gene products at the cellular or organisational 
level. It shows the frequency of proteins/genes grouped according to their involvement in biological processes. 
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In Fig. 3.2.4.4, the biological pathways showed an enrichment of cell surface interaction 
by integrin-family with ~15 genes. Within the same cluster of 50-75% frequencies, there 
was a large number of pathways controlling vital process related to cell growth, apoptosis 
and metabolism such as the mTOR, IGF, and insulin pathways, showing the same set of 
~14 genes involved in that network. The following cluster of 25-50% was made by ~10 
genes only related to haemostasis, the physiological process that stops bleeding at the site 
of an injury while maintaining normal blood flow elsewhere in the circulation (Gale, 
2011). The last cluster of 0-25% showed 13 miscellaneous biological pathways with an 
average of ~4 genes each, including posttranslational regulation, cell signalling events, 
and cell surface interactions among others. 
Fig. 3.2.4.4. Biological pathway enrichment of biomolecules observed in eMV. Frequency of proteins/genes grouped 
according to their biological pathways.  
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The GO enrichments performed here provided further clarification of the functional roles 
described for the gene products detected in eMV in this PhD research. Being useful to 
understand from a system biology perspective the complexity of the network triggered 
and affected by the bio-information transported in the isolated eMV.  
Overall, the highest scores revealed that the cellular locations of the majority of the 
proteins from the list are in the plasma membrane carrying out extracellular activities. 
Their molecular function showed a significant representation of processes related to 
protein metabolism mainly metallopeptidase activity. In terms of biological pathways 
regulated by this group of proteins, the GO enrichment was consistent with the hypothesis 
presented in chapter 3.2.1, indicating a prevalence of cell surface interactions in the first 
place. This is combined with several pathways that control the fate of the cell such as 
growth, apoptosis and metabolism among others. This brings clarity to the functional role 
of the eMV characterised in this research, determined by the proteomic information 
embedded in them.  
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3.3 Identifying immune related miRNAs: properties that may allow 
MV to affect the target cell 
3.3.1 Introduction 
Small RNAs distinguish themselves by their peak length, which varies from 21 to 30 
nucleotides and by the mechanisms of biogenesis. The presence of a 5'-uridine, 
phosphorylation at the 5' end and 2'-O-methylation at the 3' end of the RNA molecule 
regulate the loading of small RNAs onto effector ribonucleoprotein complexes. 
MicroRNAs (miRNAs) concern the uttermost rich class of small RNAs in animals 
(Felekkis, et al., 2010). 
miRNAs, are small non-coding RNAs (ncRNAs) of approximately 20 nucleotides in 
length, that favour Messenger RNA (mRNA) for down-regulation by affiliation with a 
broad, multi-protein complex known as the RNA Induced Silencing Complex (RISC). 
RISC assortment depends upon the existence of sequences in each of the target mRNA 
which are defectively correlated to the miRNA sequence (see Appendix V for miRNA 
synthesis). The miRNA binding sites usually arise within the 3'-Untranslated Region 
(UTR) of the mRNA, however, functional miRNA binding sites can also arise within the 
5'UTR (Lytle, et al., 2007) or coding region (Forman, et al., 2008). Therefore, it regulates 
gene expression post transcriptionally by adhering to 3′UTR, coding sequences or 5′UTR 
of target mRNAs, and resulting in retardation of translation or mRNA degradation.  
It is predicted that miRNAs administer approximately 30% of the human protein-coding 
genome and rule the expression of genes associated with a variety of biological processes, 
including apoptosis, proliferation, differentiation, and metastasis (Ambros, 2004; Bartel, 
2004; Filipowicz, et al., 2008; Almeida, et al., 2011). 
miRNAs are assigned sequential numerical identifiers and databases such as miRBase, 
utilise shorten 3 or 4 letter prefixes to appoint the species, generating unique identifiers, 
for example hsa-miR-101 (hsa as in Homo sapiens). ‘miR’is used to label ‘mature’ 
sequences , whereas‘mir’denotes the precursor hairpins. The gene identifications are 
designed to transmit controlled details regarding the functional association among mature 
miRNAs, such as hsa-miR-101 in human and mmu-miR-101 in mouse are orthologous 
(Griffiths-Jones, et al., 2006).  
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Lettered suffixes are given to paralogous sequences by which mature miRNAs different at 
only one or two positions, for example mmu-miR-10aand mmu-miR-10b in mouse. Num-
bered suffixes are applied where well-defined hairpin loci cause indistinguishable mature 
miRNAs, for example dme-miR-281-1 and dme-miR-281-2 in Drosophila melanogaster 
(Griffiths-Jones, et al., 2008; Griffiths-Jones, et al., 2006).  
Over time, nomenclature may be subtly and progressively readdressed, as knowledge 
developes sequences may change for practical redundancy. Current research proposes 
that only the 5′ so-called seed region of the sequence design a compact duplex with the 
target mRNA and affiliated hairpin precursor sequences may promote mature sequences 
with only slight resemblance and divergent miRNA numbers. Where two different mature 
miRNA sequences present to be removed from opposite arms of the same hairpin 
precursor, for example miR-17-5p (5′ arm) and miR-17-3p (3′ arm) (Desvignes, et al., 
2015).  
It is inadvisable to depend on capitalisation to grant details, such as the mir/miR 
precursor/mature convention. let-7 and lin-4 pronounced deviation to the numbering 
scheme because they are preserved for historical reasons (Ambros, et al., 2003; Griffiths-
Jones, et al., 2006).  
The discovery of miRNAs adds a new aspect to the interpretation of complex gene 
regulatory networks (He & Hannon, 2004) and up to now, the possibility of EV as miRNA 
transporters have been the subject of research in the EV research field (Xu, et al., 2013). 
This is because miRNAs are understood to regulate the expression of a number of target 
mRNAs, by modulating a large number of biological processes. They could contribute 
towards an insight into the molecular changes in the cells that they are extracted/derived 
from as well as producing diagnostic information and tools (Redis, et al., 2012).  
miRNA expression profiles of circulating MV is not a new concept, having been studied 
in patients with parental hepatocellular carcinoma cells (Xiong, et al., 2013), coronary 
artery disease (Jansen, et al., 2014), in bone marrow mesenchymal stem (Wang, et al., 
2015) and many more. Up to now, they have not been extensively reported in eMV, and 
none in HeLaMVC or HRV16iHMV. Therefore, this chapter studies a panel of 68 
miRNAs for their expression in erythrocytes, eMV, HeLa cells, HRV16iHc, HeLaMVC, 
and HRV16iHMV.  
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The immunological panel was selected because it features general markers for multiple 
immunology-related diseases. Markers specific to certain autoimmune diseases and 
blood-based cancers which can provide insightful details of parent donor cells and 
therefore, MV cargo similarities and differences between samples. Also, MV are 
generally considered heterogeneous naturally and depending on the donor, it can even 
present more molecules/characteristics in relation of their potential effect on recipient 
cells.  
MV may be able to transfer miRNAs to the neighbouring cells (Zhang, et al., 2015), 
therefore,  it is important to acknowledge its possible targets. For example, during cardiac 
hypertrophy miR-23a, miR-23b, miR-24, miR-195, miR-199a, and miR-214 were 
upregulated, and this caused an induction of hypertrophic growth in cardiomyocytes in 
vitro. Similarly, miR-24, miR-125b, miR-195, miR-199a, and miR-214 were upregulated 
in the tissue of patients with end-stage failing human hearts (Zhang, 2008; Ardekani & 
Naeini, 2010; Thum, et al., 2008). 
The Firefly particle (technology used in this research) structure consists of three distinct 
regions (see Fig. 3.3.1.1), the capture target miRNAs and the encode particles. The 
particle presence is triggered in the green channel (FC analysis) and the events from all 
three regions are detected to evidence the bearing of a particle. The fluorescence intensity 
in the central region determines miRNA quantity and the FC recognises a fluorescent 
signal in the red channel from the centre of the particle. This arises from the captured and 
labelled target miRNA and is equivalent to the amount of miRNA recognised in the 
sample, and the fluorescent code to differentiate distinct miRNAs. By carrying two end 
regions of assorted fluorescence intensity, a particle code is triggered in the yellow 
channel, and up to 70 codes are achievable. In all panels each miRNA is independently 
assigned one of those codes so that data from a blend of particles can be assigned to 
distinct target miRNAs. Finally, after acquisition, the Firefly Analysis Workbench 
software processes events from the three regions of the particles and gather them into a 
single event, providing the affluence data for each target miRNA. 
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3.3.2 Results 
Erythrocytes, eMV control, eMV CaCl2, eMV CaCl2 + NHS, HeLa cells, HRV16iHc, 
HeLaMVC, and HRV16iHMV samples were prepared as set out in chapters 2.2.1.2, 2.2.2, 
and 2.2.4. The mirVana™ miRNA Isolation Kit was used for this procedure and the 
experimental design was followed in accordance with the manufacturer’s protocol 
(chapters 2.2.9.1 and 2.2.9.2). The samples were then submitted to Abcam for profiling 
(chapter 2.2.9.3), and data analysis was performed using Firefly Analysis Workbench 
software. 
In order to verify the assay performance, Abcam uses two measures in every well: (1) 
RNA spike-in controls; and (2) particles with no miRNA probe (blank) that defines the 
background fluorescence. The geNorm-like algorithm was used to regulate the stability 
reference of housekeeping-genes from a set of examined candidate reference genes in a 
stated panel. In consequence, a gene expression normalisation factor can be tallied for 
each sample hinged on the geometric mean of a user-defined number of reference genes, 
and can be applied to the data in order to select the three most appropriate miRNAs to use 
for normalisation. To improve the likelihood of identifying three appropriate 
normalisation candidates, several miRNA targets identified by previous researchers (Qi, 
et al., 2012; Chen, et al., 2013),  and by Abcam in an independent analysis were 
Fig. 3.3.1.1. Firefly particle structure. Adopted from Abcam discover more (2017) and then merged and modified by Roberta 
Freezor using online Pixlr photo editor. Three distinct regions apprehend target miRNAs and encoded particles are shown. The 
end regions (top and bottom) encode particles and hold dissimilar fluorescence intensities to promote a fluorescent barcode and 
in a known panel, all particles that capture a specific miRNA display the same code. Whereas the central analyte quantification 
region (middle) holds probes to capture an individual target miRNA. When particles are passed through a FC, they act as a series 
of three cells. By disconnecting the target quantification region from the particle encoding data, the communication between 
channels and banish the necessity for compensation. 
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automatically included in the fixed panels (in this case the immunology panel) signifying 
that those miRNA that were recognised as most stable across the samples.   
The normalised data used for this study consisted of background-subtraction, using the 
three most appropriate normalisers hsa-let-7i-5p, hsa-miR-20a-5p and hsa-miR-93-5p 
(green boxes), and negative miRNA controls hsa-miR-494-3p and hsa-miR-885-5p (blue 
boxes), in Fig. 3.3.2.1. These parameters were used to generate all the figures in this 
chapter, which may include signals at or below the detection threshold. The statistical 
confidence using multiple measurements of the non-normalised data was used to ascertain 
the average signal (in arbitrary units) for each miRNA target, as measured in every sample. 
Averages were calculated across multiple target-specific particles mixed with a sample.  
The Multiplex Circulating miRNA assay detects the same miRNA multiple times for 
every sample, in order to provide the statistical confidence in the results. The Mean 
fluorescence intensity (MFI) signal is provided with less background, showing a 95% 
confidence interval between particle methods. The limit of the detection of a probe is 
calculated from the negative samples, using a combination of two factors: Sww (1) the 
well-to-well standard deviation of the mean signals; and Spp (2) the mean of the particle-
particle standard errors. Then the limit of detection is calculated as [(3𝑆𝑤𝑤) 
2+(4𝑆𝑝𝑝)2]12. To determine whether a particular miRNA signal is detected, the assay 
background was subtracted from the miRNA signal measured in the samples and the 
result was compared to a target-specific detection threshold. This is performed when a 
probe is detected in a particular sample, and if the statistical distribution of the probe's 
particles in that sample were significantly higher than the distribution of that probe's 
particles in the negative samples. The limit of detection of a probe is an estimate of the 
positive fluorescence a probe would have, in order to be determined as significant in a 
given sample. 
Abcam has determined by comparison to dilution series on large numbers of probes, that 
give a conservative estimate of the limit of detection. If no negative samples are defined, 
no limit of detection is available. Although most miRNAs exhibit low background signal 
in negative control wells, there are exceptions where the miRNA probe sequence is 
complementarity to the amplification primers and a higher background signal is measured 
in negative control wells. The subtraction of the assay background resolves this and there 
is no effect on the assay, except to slightly decrease the dynamic range of detection of the 
chosen miRNAs. 
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Fig. 3.3.2.1. The average signal in RNA spike-in controls and miRNAs selected for data normalisation. RNA’s control and 
samples were labelled with the immunology panel (68 miRNAs) and analysed with the EMD Millipore Guava 8HT flow 
cytometry. Due to their stability in signal expression in all samples, hsa-let-7i-5p, hsa-miR-20a-5p and hsa-miR-93-5p were 
selected to act as normalisers, and hsa-miR-885-5p along with hsa-miR-494-3p were selected to act as negatives.  The graph 
shows Y axis representing the probes including blank and x-control used here, against the X axis representing the MFI of the 
signal detected with the FireFly particles.  
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Additionally, a third quality control measure employed by Abcam is to process a positive 
control well in parallel with the submitted samples. The positive control well is either 
pooled human sera or Firefly Control RNA that has been previously characterised by the 
Multiplex Circulating miRNA Assay. The positive control signals from this study are 
compared to historical values in Fig. 3.3.2.2. 
The heat map (Fig. 3.3.2.3) is a grid of normalised miRNA signal intensities indicated by 
colour, where orange represents highly expressed miRNA and blue represents lowly 
expressed miRNA. The miRNA targets with background-subtracted signal show the 
detection threshold in one or more samples. The white miRNA targets have background-
subtracted signals and show the detection threshold across all samples. The signal in low-
expressing targets (white) is often masked by sources of noise such as non-specific 
binding and FC noise. Therefore, it is considered not to meet the chosen threshold of 
detection and removed from further analyses. 
The geNorm-like algorithm, a popular method to assess the substantial reference 
housekeeping-genes against a set of tested candidate reference genes in a given sample 
panel, was used for normalisation in circulating miRNA detection. Henceforth, a gene 
expression normalisation factor can be computed for each sample positioned on the 
geometric mean of a user-defined number of reference genes. It can be applied to the data 
Fig. 3.3.2.2. Comparison of positive RNA spike-in controls to historical values. The graph shows the Y axis representing 
LOG signal for the immunology panel used for this experiment on the date of the experiment, against the X axis representing 
the LOG benchmark signal for the immunology panel, providing a presented trend line showing a visual confirmation of the 
positive correlation.   
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in order to select the three most appropriate miRNAs to be used for normalisation in this 
data set. To improve the likelihood of identifying three appropriate normalisation 
candidates (hsa-let-7i-5p, hsa-miR-20a-5p, and hsa-miR-93-5p), several miRNA targets 
identified by previous researchers (Chen, et al., 2013) were considered and utilised.  
According to Pritchard, et al., (2012), hsa-miR-451, 486-5p, 92a and 16 are significantly 
increased in haemolysed samples of human plasma and serum, and are highlighted as 
markers of such which explain why manufacturers include haemolysis markers in fixed 
panels. Here, only hsa-miR-451 and 486-5p were used as haemolysis markers and were 
excluded from erythrocytes and eMV data only. This is because hsa-miR-92a and hsa-
miR-16 were also present in all HeLa cells and their derived MV and expressed at 
different levels.  
hsa-let-7b-5p, 7d-5p, 7e-5p and 7g-5p were present in all samples analysed in this study. 
And it may be because these miRNAs members, belonging to the same family have 
identical seed sequence, a highly-conserved region of nucleotides 2 to 8, which is 
important for target recognition. This also suggests that the let-7 family members share 
at least some targets and functions (Su, et al., 2012). lin-4 and let-7 were the first two 
miRNAs identified, and it was discovered in the nematode Caenorhabditis elegans. They 
regulate the schedule of stem-cell division and differentiation. let-7 and its relatives are 
vastly preserved over species in sequence and function. Mis-regulation of let-7 generates 
a less differentiated cellular state and the development of cell-based diseases such as 
cancer (Roush & Slack, 2008).  
Since not all of the miRNAs were relevant to this study, those miRNAs showing low 
signal intensity (hsa-miR-16-2-3p, 33a-5p, 125a-5p, 129-5p, 140-3p, 142-3p, 154-5p, 
155-5p, 200a-3p, 205-5p, 339-5p, 375, 376b-3p, 429, 431-3p and 523-5p), were excluded 
from analysis, although, hsa-miR-122-5p remains in the heat map as an representative 
example of low signal detection. This was in order to ensure focus on the miRNAs of 
interest, in order to build a specific miRNA detection profile to gain further insight into 
the samples submitted for profiling. This can be observed in Fig. 3.3.2.3, where the 
heatmap is showing merged of each sample (N=3) and excluding triplicates of assay 
negative, blank and x-control, all normalisers and negatives. 
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Fig. 3.3.2.3. Expression profile comparison of all samples from merged triplicates. The Heatmap shows the major 
differences of the submitted samples, highlighting the increased and decreased expression of miRNAs. It also compares 
MV samples (N=3) derived from different sources showing the major differences of the samples derived from different 
sources comparing different detected miRNA’s.  The expression of shared and specific miRNAs for each sample group 
is shown in different colours, blue for low expression and orange for strong expression. 
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The potential plasma biomarker that may indicate progression of Gastric Cancer (Zhang, 
et al., 2015)  hsa-miR-16-5p, was highly expressed in all samples used for this study. It 
has been recommended that the candidate reference miRNAs should concern a distinct 
functional classes, which would fundamentally lessen the likelihood of contradict co-
regulation (Mestdagh, et al., 2009). Conversely, the same expression levels of reference 
miRNAs should be noticeable in all samples, and show low dispersion and no affiliation 
with a disease (Zampetaki & Mayr, 2012). This was not the case in this study, having 
been detected at different levels and therefore not used as a normaliser reference. Also, it 
has been noted that the expression level of miR-16-5p could exhibit individual variances 
(Konishi, et al., 2012) because miR-16-5p is a contaminant in haemolysed blood samples, 
and is not adequate as an optimal internal control. A vast spectrum of miRNAs associated 
with physiologic and pathologic events can be carefully loaded into the MV, increasing 
the complexity of the relationship of the miRNA levels between the tissues and 
circulatory system (Reid, et al., 2011).  
hsa-miR-92a-3p was also highly expressed in all samples, and it has also been suggested 
as a potential reference miRNA (Bignotti, et al., 2016). A search of hsa-miR-92a-3p in 
the miRBase database (Kozomara & Griffiths-Jones, 2014 ; Griffiths-Jones, et al., 2008) 
has identified gene targets including those involved in cell cycle regulation and cell 
signalling. It has also proven vital during all stages of mammalian development and 
necessary for the proliferation of cells, because it is readily available in healthy 
individuals’ serum. However, levels are irregular and seem to alter in response to the 
onset of certain cancers. As a result of its differing levels of expression observed in all 
the samples studied here, it could not be used as a normaliser in this study. 
Notably, 25 out of 68 miRNA were identified in all samples (apart from normalisers, 
negatives and haemolysis markers) in Fig. 3.3.2.4. The summary level of expression of 
the 25 miRNA identified (N=3) can be observed by comparing the Mean Fluorescence 
intensity (MFI).  
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In addition to the exclusion of low signal detection of miRNAs in the samples, major 
differences in miRNA expression between samples were observed. For example, 
miRNAs hsa-miR-10a, 23a-3p, 24-3p, 30a-5p, 34a-5p, 132-3p, 196a-5p, 203a-3p, 210-
3p, 422a, 181b-5p and 744-5p showed stronger expression in HeLa and their derived MV 
samples. However, hsa-miR-23a-3p was not expressed in erythrocytes, but slightly 
expressed in eMV samples (Fig. 3.3.2.5).  
 
Fig. 3.3.2.4. Summary of miRNAs present in all samples. The graph shows the major differences in expression of the submitted 
samples, highlighting the increased and decreased expression of miRNAs in each sample (N=3). It also compares MV samples 
derived from different sources. The analysis was obtained using the GraphPad Prism software version 7.2, where data was 
arranged in groups and error bars were obtained with the Mean and Error.  
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In contrast, hsa-miR-223-3p was not detected in HeLa or their derived MV samples, but 
strongly expressed in erythrocytes and eMV samples. Additionally, hsa-miR-146a-5p and 
150-5p were not expressed in erythrocytes, HeLa cells, HRV16iHC and their derived MV, 
but were expressed in eMV. (Fig. 3.3.2.6). 
Fig. 3.3.2.5. Summary of miRNAs demonstrating high expression in HeLa cells and their derived MV.  The graph compares 
HeLa cells and their derived MV samples with erythrocytes and eMV samples and demonstrates the major differences of the 
submitted samples. This is highlighting the increased and decreased expression of a number of miRNAs with higher expression 
in Hela and their derived MV. The conclusions were drawn from Fig. 3.3.2.3.   
 
Fig. 3.3.2.6. Summary of miRNAs demonstrating high expression in erythrocytes and their derived eMV. The graph 
compares the differences between all submitted samples, highlighting the increased and decreased expression of miRNAs in all 
erythrocytes and eMV, in comparison with HeLa cells and their derived MV.  
 
 
129 
3.3.3 Discussion  
Due to the common assumption that erythrocytes do not express RNA content, one can 
be confused to find that erythrocytes contain significant amounts of miRNAs (observed 
in results chapter 3.3.2). This is not only because of their presence, but also, owning to 
the reasons for miRNA to be present in cells to regulate gene expression by effecting 
mRNA translation which was believed to be non-existent in erythrocytes (Hamilton, 
2010). Nevertheless, the presence of miRNAs in erythrocytes has been reported in 
Malaria (Rathjen, et al., 2006),  and sickle cell disease because of the disease pathogenesis 
which is dramatically altered in homozygous sickle cell disease erythrocytes and their 
defect in terminal differentiation (Chen, et al., 2008). 
It is understood that erythroid cells misplace their nuclei and active transcription in the 
course of the reticulocyte stages (see Fig. 1.2.1). miRNAs are credible to participate in a 
regulatory role in post-transcriptional regulation in erythroid cells, but there is a lack of 
information explaining the reasons for this, as well as for the presence of miRNAs in 
erythrocytes. Felli, et al., (2005) reported the role of miRNAs that have been implicated 
in the process of erythropoiesis, and miRNA expression have been reported in in vitro 
erythroid differentiation also (Choong, et al., 2007), but no reasons were discussed. 
Therefore, the genomic study of miRNAs in erythrocytes may provide an individual 
opening to begin to build the understanding of miRNA regulatory roles in erythroid cells 
(Sangokoya, et al., 2010), and this would further support their feasibility in the eMV 
studied during this PhD research.     
The general analysis of miRNA expression in circulating erythrocytes can contribute 
towards mechanistic insights into the disease phenotypes of erythrocyte, adding a new 
feature to erythrocyte characterisation, and can potentially enhance the interpretation of 
their phenotypic alterations in physiological and pathological adjustment.  For example, 
hsa-miR-223-3p was demonstrated as being present in erythrocytes and all eMV samples, 
but not in HeLa or their derived MV. This is a haematopoietic particular miRNA with 
essential functions in myeloid lineage development. It performs a crucial part in 
promoting granulocytic differentiation (O'Connell, et al., 2011), while also being 
affiliated with the suppression of erythrocytic and megakaryocytic distinction of K562 
cells (myelogenous leukaemia cell line) (Yuan, et al., 2009).  
It is important to note that, each and every miRNA present in the samples utilised during 
this PhD research expresses different characteristics, and can also provide insights into 
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post-transcriptional regulation of gene expression. For example, Pinatel, et al., (2014) 
predicted that miR-223 targets revealed enrichment in cell death and survival-related 
genes and in pathways commonly altered in breast cancer. Their results demonstrated that 
protein levels for Signal transducer and activator of transcription 5A (STAT5A), Integrin 
alpha-3 (ITGA3), and NRAS proto-oncogene GTPase were modulated by miR-223. They 
evidenced that STAT5A is a direct miR-223 target and underlined a feasible correlation 
between miR-223 and STAT5A in migration and chemotherapy response, and that miR-
223 has an influential role in breast malignancy that could possibly be investigated 
therapeutically. 
 In haematopoiesis, a term used for the formation of blood cellular components, hsa-miR-
150-5p (present in eMV but not in erythrocytes) regulates genes whose downstream 
products encourage differentiating stem cells to become megakaryocytes rather than 
erythrocytes. It also, induces T-cell differentiation (miRBase database). Blood cell-
derived EV, containing miR-150, have been shown to enter human endothelial cells 
delivering miR-150, which reduced c-Myb (gene- proto-oncogene protein also known as 
transcriptional activator) expression. This enhanced cell migration of human endothelial 
cells (Zhang, et al., 2010). This expression is of interest because it suggests a different 
characteristic and yet another potential use for eMV because once inside neighbouring 
cells they can potentially share this information with a variety of sources in circulation.  
Furthermore, hsa-miR-146a-5p (present in eMV control and eMV CaCl2) has been 
observed to be involved in the regulation of inflammation, and other biological processes 
that operate in the innate immune system. This has been reported to be highly upregulated 
in osteoarthritis cartilage, and could be involved in its pathogenesis (miRBase database). 
Lopez, et al., (2017) suggested that miR-146a-5p, and miR-24-3p (present in all samples), 
are consistent blood markers of antidepressant response and regulators of psychiatrically 
relevant signalling pathways, and functional annotation clustering analysis disclosed an 
enrichment of calcium signalling pathways. This is interesting because eMV CaCl2 
demonstrated a particular expression of these these miRNAs. Their results, imply 
influential implications for the clarification of biological mechanisms involved in 
clinically relevant antidepressant effects, and propose that these miRNAs could 
potentially act as correlates or state biomarkers of treatment response. This highlights the 
potential for the development of diagnostic tools, precautionary approaches, and 
successful pharmacological interventions for major depressive disorder. 
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hsa-miR-221-3p is an oncogenic miRNA that targets CD117 (receptor tyrosine 
kinase protein), which then prevents cell migration and proliferation in endothelial cells. 
It is also known to be involved in the induction of angiogenesis (miRBase database). This 
miRNA was present in eMV control, eMV CaCl2, HeLa, HRV16iHc and their derived 
MV but not in erythrocytes and eMV CaCl2 +NHS.  
Additionally, several cell-preferentially expressed miRNAs are worth noting.  hsa-miR-
342-3p was present in all samples apart from erythrocytes. This miRNA targets the 
nuclear factor kappa-light-chain-enhancer of activated B cells known as the NF-κB 
pathway, and it has a significant role in cell proliferation. Hence it’s suitability for the 
investigation of therapeutic targets (Zhao & Zhang, 2015).  
Likewise, HeLa, HRV16iHc and their derived MV also expressed some miRNA 
specificity, in comparison with erythrocytes and eMV samples. For instance, hsa-miR-
23a was highly expressed in HeLa and their MV, it was weakly present in eMV control 
and eMV CaCl2, but absent in erythrocytes and eMV CaCl2 + NHS samples. This miRNA 
is known to regulate the transcriptional repressor Hairy enhancer of split 1 (Kawasaki & 
Taira, 2003).   
In a study by Ru, et al., (2014), miR-23a stimulated the replication of human herpes 
simplex virus type 1 (HSV-1) in HeLa cells. The interferon regulatory factor 1 (IRF1), an 
innate antiviral molecule is selected by miR-23a to advance viral replication. This is 
because miR-23a attaches to the 3'UTR of IRF1 and down-regulates its expression. The 
suppression of IRF1 expression minimises RSAD2 gene expression, augmenting HSV-1 
replication. The ectopic expression of IRF1 abrogated the advancement of HSV-1 
replication which is led by miR-23a, and the IRF1 advances to innate antiviral immunity 
by binding to IRF-response elements to control the expression of interferon-stimulated 
genes (ISGs) and apoptosis, disclosing a complex interaction between miR-23a and HSV-
1. They hypothesised that miR-23a eases HSV-1 replication by regulating IRF1-mediated 
antiviral signal pathway, and  IRF1 mRNA have also demonstrated to be up-regulated 
after HRV16 infection (Kim, et al., 2015) which may explain why HRV16iHMV are 
enriched with this miRNA.  
miR-23a has also been observed to be proportionately stable in plasma and serum 
(Komatsu, et al., 2016) and this is not affected by haemolysis. Therefore it is important 
to note the possible effects of miRNA profiling when conducting data normalisation and 
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analysis, so that systematic biases are discarded and detection of disease associated with 
miRNA biomarkers even from samples affected by haemolysis, are detectable (Blondal, 
et al., 2013).  
In terms of chronic obstructive pulmonary disease (COPD), a pilot study by Fawzy et al., 
(2016), observed the affiliation of the miR-196a2 rs11614913 polymorphism with COPD 
susceptibility and bronchodilator response to short-acting β2-agonist. Where, 108 COPD 
male patients and 116 unrelated controls were used for genotyping rs11614913 
polymorphism. When compared with controls COPD patients did not express notable 
differences in the genotype distribution and allele frequencies of the studied miRNA, but 
COPD patients with homozygote genotype (CC) results correlated to those with the 
smallest bronchodilator response post Salbutamol inhalation. The heterozygotes (CT) had 
an intermediate response, while those with the TT genotype (homozygote dominant) 
showed the highest response. miR-196a2 rs11614913 polymorphism is associated with 
the bronchodilator response of COPD patients, generating a hypothesis of the potential 
use of miR-196a2 variant as a pharmacogenetic marker for COPD which also provides an 
explanation of why miR-196a was present in Hela and their derived MV and absent in 
erythrocytes and eMV samples. 
hsa-miR-181b was present only on HeLa, HRV16iHc and their derived MV. In an 
investigation by Yang, et al., (2013) into the clinical significance of miR-181b expression 
in non-small cell lung cancer (NSCLC), it was revealed that there was an association of 
miR-181b expression with clinicopathological factors or prognosis of patients analysed. 
In the beginning of the investigation, miR-181b expression was remarkably down-
regulated in NSCLC tissues, in comparison with their normal counterparts. Subsequently, 
the low miR-181b expression was observed to be associated with larger tumour size, 
higher p-TNM stage and positive lymph node metastasis of NSCLC patients. Then, 
survival analysis revealed that the general survival and disease-free survival of NSCLC 
patients with low miR-181b expression decreased in comparison to those patients with 
increased miR-181b expression. Thus, their study indicates that down-regulation of miR-
181b may be affiliated with aggressive disease progression and poor prognosis of NSCLC 
patients. For this PhD research it may indicate that miR-181b involvement in lung 
carcinogenesis could potentially be favourable for MV to be used as a potential prognostic 
marker for NSCLC. 
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HRV16 show alteration in the microRNAome of HeLa cells indicating an area for 
research into infectivity and a potential target for prevention (Gutierrez , et al., 2016). 
MV can also exert effects on cells by stimulating specific signalling pathways 
(Mathivanan, et al., 2010). This may suggest that MV may have the ability to alter the 
transcriptome and signalling activity within recipient cells, allowing them to induce 
specific phenotypic changes, which support MV as potential therapeutic agents.  
miRNAs are highly important because they contribute significantly to the turnover of 
many proteins, thus inducing effects that may be either stimulatory or inhibitory for target 
cells which can change gene expression.  
The incorporation of miRNAs in eMV may allow them to circulate in the blood while 
avoiding degradation from blood RNAse activity because they are encapsulated (Arroyo, 
et al., 2011). This is important because miRNAs may contribute significantly to the 
turnover of many proteins, thus inducing effects that may be either stimulatory or 
inhibitory for target cells which can change gene expression.  
It is interesting that, not all miRNA present in MV samples were present in their parent 
cells during this PhD research, and so far, there is no clear evidence whether associated 
miRNA are either inside or just adhere to EV under in vivo conditions (Bala, et al., 2015).    
After assessing the pattern of miRNAs detected in the eMV samples, further analysis 
focused on their reported target genes using the miRTarBase database. The analysis 
generated a list of candidate genes with >14.165 target genes for the miRNA present in 
eMV samples, with >7.358 being redundant genes (see Appendix VI). The FunRich 
software classified their functional role in clusters of genes that are not mutually exclusive. 
The principle here is that previously stated for the GO enrichments produced in chapter 
3.2.4, where the product of a single gene could have one or more cellular components 
(Fig. 3.3.3.1), molecular functions (Fig. 3.3.3.2), be associated with different biological 
processes (Fig. 3.3.3.3), and be involved in several biological pathways (Fig. 3.3.3.4). 
The GO enrichments for the cellular component revealed over 635 locations, with  an 
important representation of genes with functions involved in the nucleus and the 
cytoplasm. The rest of the categories evaluated here showed lower scores <25% with no 
specific enrichments. 
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In terms of molecular functions, the wide range of genes showed an overall heterogeneous 
distribution with low frequencies (0-25%) and no specific enrichments, with DNA 
binding and transcription showing the highest scores among the miscellaneous single 
cluster. 
Fig. 3.3.3.1. Cellular component enrichment for target genes of miRNA observed in eMV.  Frequency of target genes 
involved in similar cellular  components. 
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The biological processes enrichment showed a single cluster (0-25%) of overlapping 
categories with different levels of representation. Within this group, it is possible to detect 
the relevance of metabolic processes performed by this set of genes. 
Fig. 3.3.3.2. Molecular function enrichment for target genes of miRNA observed in eMV. Frequency of target genes involved 
in similar molecular functions. 
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In the case of biological pathways,  the genes were grouped in two main clusters, one of 
them involving gene expression only (0-25%) and the other (25-50%) covering a variety 
of process regulated by the same set of genes, including: signalling events, cell surface 
interactions, cell adhesion and essential signalling pathways for cell environment 
recognition such as the mTOR, AKT and IGF1 that control cell fate representing ~28% 
of the miRNA target genes data input. 
Fig. 3.3.3.3. Biological processes enrichment for target genes for miRNA observed in eMV. Frequency of target genes 
grouped by biological processes. 
  
  
 
 
137 
 
 
 
 
 
 
 
 
Fig. 3.3.3.4. Biological pathways enrichment for target genes of miRNA observed in eMV. Frequency of target genes grouped 
by biological pathways.Where, the impact of a series of interactions among genes that leads to a certain product or a change, 
which can trigger the assembly of neighbouring cells.  
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Taken together, the GO enrichments generated in this section with the target genes of the 
miRNAs identified in this study, indicate the prevalence of gene products located in the 
nucleus and cytoplasm with an involvement in translation according to their frequencies. 
In this sense, this transcriptional machinery may be responsible for regulating several 
cellular metabolic processes, which was further supported by the enrichment of a set of 
biological pathways that operate as rheostats of extracellular stimulus that control cell 
cycle proliferation and cellular outcome. This is highly relevant to this study since the 
information transported in the isolated eMV by the set of detected miRNA may be 
involved in the control of those fundamental cellular processes, also supported by the data 
collected in chapter 3.2.4. 
This association of genes according to categories of processes in which they are involved, 
facilitates the overview of their potential effects, which allows the tailoring of the 
subsequent analyses of the query gene list, and provides valuable insights with testable 
hypotheses for the development of future projects. GO annotations and analysis for 
HRV16iMV is presented in Appendix VII.   
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3.4 The interaction of MV on the selected cell lines  
3.4.1 Introduction 
Cell communication is a major aspect of cell biology because it allows the coordination 
of biological activities of the organism as a whole by using signalling pathways. The 
release of MV as free entities containing a variety of biological molecules allowing their 
engagement with and influencing neighbouring cells became a wide and targeted concept 
(see chapter 1.7). Cancer cell lines constitute key model systems widely used within 
biological research. To this end, a variety of cell lines were used to conduct the 
experiments to observe the effect of MV on their growth rate, including:  
1. THP-1, a human leukaemia monocytic cell line that has been extensively used 
to study monocyte/macrophage functions, mechanisms, signalling pathways, 
and nutrient and drug transport. It was originally isolated from the peripheral 
blood of a 1-year-old male patient suffering from acute monocytic 
leukaemia (Chanput, et al., 2014). This cell line has been widely used to study 
immune responses, not only in the monocyte state but also in the macrophage-
like state. In the monocyte state, it can be differentiated into a macrophage-like 
phenotype using either phorbol-12-myristate-13-acetate, 1α, 25-
dihydroxyvitamin D3 or macrophage colony-stimulating factor (Lund, et al., 
2016). Although the latter stimulus is biologically relevant in vivo, it is less 
frequently applied in vitro, and it does not apply to this PhD research.  
2. Jurkat cells are an immortalised line of T lymphocyte cells that are used to study 
acute T cell leukaemia, T cell signalling, and the expression of various chemokine 
receptors susceptible to viral entry, particularly HIV. They originally derived 
from the peripheral blood of a 14-year-old boy with T cell leukaemia which makes 
them useful in scientific research because of their ability to produce IL2, a type of 
cytokine signalling molecule which regulates the activities of white blood cells 
that are responsible for immunity. Their primary research use is in determining 
the mechanism of differential susceptibility of cancers to drugs and radiation 
(Abraham & Weiss, 2004).  
3. In 1979 Kaighn, et al., defined the  PC-3 a prostate cancer cell line, it was 
established, characterised and its tumourigenicity from a human prostatic 
adenocarcinoma metastatic to bone was reported. Culturing the transplanted 
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tumour cells resulted in a human cell line with features identical to those used 
initially causing tumour.  
PC-3 cells retain characteristics similar to epithelial neoplastic cells, including 
numerous microvilli, junctional complexes, abnormal nuclei and nucleoli, 
abnormal mitochondria, annulated lamellae, and lipoidal bodies.  However, 
when compared to normal prostatic epithelial cells, PC-3 cells have a 
substantially decreased dependence upon serum for growth, do not respond to 
androgens, glucocorticoids, or epidermal or fibroblast growth factors. As well as 
divergent morphological development and function, the unique canonical 
pathways reveal greater diversified features including metabolism, retinoic acid 
signalling pathway, cell proliferation, and differentiation pathways. The 
divergence of characteristics in PC-3 cells make them helpful when exploring 
the biochemical changes in advanced prostatic cancer cells, as well as, when 
assessing their response to chemotherapeutic agents (Dozmorov, et al., 2009).  
4.  In 1970 the human breast cancer MCF-7 cell line was first isolated from the 
breast tissue of a 69-year old Caucasian woman. MCF-7 and other human breast 
cancer cell lines are useful in many studies including investigating the response 
of hormone, drug screening, and/or development of multidrug resistance, and the 
activation, amplification, and overexpression of oncogenes (Vazquez, et al., 
2004). MCF-7 cells retained several pathological characteristics associated with 
the mammary epithelium, including cytokeratin sensitivity, unreceptive to 
desmin (protein), endothelin (amino acid peptide), and vimentin (protein). 
Through oestrogen receptors in the cell cytoplasm, PC-3 retain the ability to 
process oestrogen (as oestradiol), and are therefore useful for in vitro breast 
cancer studies because the cell line can be used as an oestrogen receptor positive 
control cell line  (Pinzone, et al., 2004).  
5. For the HRV16 viral infection and their derived MV studies, HeLa cells were 
used. HeLa cells were the first human cell line established in culture and has 
since become the most widely used human cell line in biological research. Its 
application as a model organism has contributed to the characterisation of 
important biological processes. This cell line originates from a cervical cancer 
tumour of a patient named Henrietta Lacks, and because it has been continuously 
sub-cultured (transformed), can now be used as an immortalised bronchial 
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epithelial cell line. One of the earliest uses of HeLa cells was in the development 
of the polio vaccine (Landry, et al., 2013).  
The study of life cycles of many different viruses, including the HRV (although 
the natural targets of HRV are original human bronchial epithelial cells) is 
generally more difficult to obtain and maintain in the relevant primary cell 
cultures and is normally conducted with HeLa cells. The kinetics of Ribonucleic 
Acid (RNA) replication, the synthesis and processing of viral proteins, and the 
general subcellular localisation of key non-structural proteins resembled HeLa 
cells makes them useful for in vitro studies (Amineva, et al., 2011).  
All of the cell lines mentioned above present particular and different surface markers, 
ligands and receptors that can regulate cell adhesion, cell signalling, and adaptive 
immunity (as previously mentioned in chapter 3.2.1). For instance, THP-1 and Jurkat cells 
are known to present/express CD9 (Reyes, et al., 2015), a member of the tetraspanin 
superfamily that interact with other tetraspanins and with different transmembrane and 
intracellular proteins to facilitate cellular activities in the different subtypes of leukocytes, 
including intracellular signalling, proliferation, activation, survival, and adhesion (Reyes, 
et al., 2018). CD9 is understood to interact with CD36 (Huang, et al., 2011; Park, 2014) 
(also see Fig. 3.2.2.3.1), which showed expression in all MV tested during this PhD 
research (Fig 3.2.1.3). This demonstrates the potential of MV interacting with cells that 
for example presents CD9.  
The biological significance of EV remains largely of interest, and there is still growing 
evidence that EV may be important mediators of cell-to cell communication (Karpman, 
et al., 2017). Their interactions with target cells may be suggested to occur directly by 
phenotypic, and functional characteristics of cells and may do so by a variety of 
mechanisms of possible interaction network (see Fig. 3.2.1.3.1, 3.2.2.3.1, and 3.2.3.3.1). 
This interaction may be accomplished by direct stimulation of target cells with vesicle-
based growth factors and/or bioactive lipids, the transfer of a variety of membrane surface 
receptors, epigenetic reprogramming by transfer of genetic material, and/or protein based 
transcription factors or the transfer of infectious particles (Ratajczak, 2006; Quesenberry 
& Aliotta, 2010). 
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3.4.2 Results  
Considering the diversity of the cell lines used during this research (set out in chapter 
3.4.1), the aim of this chapter is to observe whether MV interact with neighbouring cells 
in vitro. MV were isolated as set out in chapter 2.2.4 and the experimental design was 
followed as set out in chapters 2.2.11 and 2.2.12. 
To record the interaction between MV and cell lines the Lumascope 500 single colour 
fluorescence live cell imaging microscope was used. It uses light-emitting diode (LED) 
light sources, Semrock filters, advanced optical engineering, and complementary metal–
oxide–semiconductor sensors to provide near diffraction-limited (theoretical maximum) 
resolution. The Light Source is detected at 488 nm (bright field and fluorescence) and the 
excitation filter range between 457-493 nm bright line bandpass, and emission filter at 
508-552 nm bright line bandpass (for both fluorescence and bright field). It provides 
images in formats JPG, BMP, TIF, GIF, and PNG at 1280 x 800 pixels (Labtech, 2014). 
Due to its compact size, it was placed inside the biological safety cabinet for sample 
preparation and subsequently inside the tissue culture incubator (37°C in a 5% CO2) for 
the duration of the experiment.  
Incubation of eMV control (labelled with Annexin V) with THP-1 cells is shown in Fig. 
3.4.2.1, where the increase of fluorescence intensity observed in eMV (green fluorescence 
imaging) was accompanied by unlabelled THP-1 cells (white bright field). After 24 hours 
of THP-1 cells subculture and incubation, labelled eMV sample was added to the culture 
flask and observed for 15 minutes, because fluorescence intensity disappeared after 20 
minutes of exposure. The aggregation of eMV cluster was observed immediately after the 
incubation period began. eMV movement towards the THP-1 cell membrane initiated 
after 4 minutes of incubation (Fig. 3.4.2.1a and b), where the eMV aggregated at first, 
forming two different clusters, then moved towards the cell membrane. Subsequently, at 
approximately 7-8 minutes of incubation a single cluster of the eMV was formed, where 
eMV joined cluster interacts with the cell membrane and finally breaks through the cell 
membrane (Fig. 3.4.2.1c). The eMV cluster appears to be depositing its contents 
(engulfment) into the cell (Fig. 3.4.2.1d) at the 11 minute mark after the incubation period. 
A small cluster joins the previously formed cluster of eMV (bottom right), then the entire 
cluster moves away from the cell membrane, apparently leaving the deposited residues 
inside the cell. 
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Similarly, the phenomenon of eMV control (uninduced) aggregation and their movement 
towards the Jurkat cell membrane as well as their engulfment was observed. However, in 
this experiment (Fig. 3.4.2.2) eMV were not labelled with Annexin-V and images were 
taken under bright field settings only. Also, the eMV cluster does not appear to increase 
in size (aggregate) over time as observed in Fig. 3.4.2.1, even though the same amount of 
eMV (ratio 1:1 to cell number) was used.  Fig. 3.4.2.2a shows the eMV cluster 
approaching the cell membrane (at 4 minutes of incubation). Fig. 3.4.2.2b shows what it 
may be considered an interaction between the eMV cluster and cell membrane (at 7 
minutes of incubation), and Fig. 3.4.2.2c suggests the internalisation of the eMV cluster 
into the cell cytoplasm (at 14 minutes of incubation), but it is not clearly visible.   
 
d) c) 
b) a) 
Fig. 3.4.2.1. THP-1 cell and eMV interaction. Photography sequence of eMV interactions with THP-1 cells (100x oil objective 
lense images) recorded by alternating between bright field and fluorescence. The white arrows indicate the THP-1 cell and the 
black arrows indicate the eMV Annexin-V labelled. Fig a) and b) show eMV aggregating, and moving towards the cell, 
approaching the cell membrane (bright field and fluorescent respectively). Whereas Fig c) to d) show the eMV cluster breaching 
the THP-1 cell membrane and depositing eMV Annexin-V labelled material (bright field and fluorescent respectively)  leading 
to the incorporation of eMV within the cell. After this interaction the eMV cluster moved away from the cell.  
Cell-8000 
nm 
eMV Cluster- 
Individual range 
100-800 nm 
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The initial observation (eMV and cell interaction) led to the investigation of how eMV 
may affect the neighbouring cell, therefore eMV (ratio 1:1 with cell number) was added 
to the tissue culture flask (different cell lines) and observed to assess whether eMV have 
an impact on the growth rate of the cell lines FC analysis (see chapter 2.2.5). This is where 
cells on the exponential phase were seeded into sterile 24 well plates and growth rate (cell 
number and viability) was assessed by FC every 24 hours for 96 hours (total length of the 
experiment). 
At 0 hours THP-1 (Fig. 3.4.2.3a) and Jurkat cells (Fig. 3.4.2.3b) were ~16 x105/ mL (N=3), 
relatively similar by 24 hours of incubation there was evidence of the growth of both 
samples (control against eMV treated) but no major differences were observed. There was 
only a slight decrease in eMV treated cells (~19 x105 / mL) in comparison to the control 
with ~26 x105 / mL. At 48 hours, the difference in cell number/ mL between control and 
treated eMV appears more obvious (P> * for THP-1 and P> ** for Jurkat cells). The trend 
of the growth rate (number/ mL) decreasing for eMV treated cells continued from 72 
hours of observation.  
Despite aggregation of eMV being observed in culture, there was no notable migration 
towards the PC-3 and MCF-7 cell lines, and engulfment was not observed (images not 
provided here). In contrast to THP-1 and Jurkat cells (decreased effect on the growth rate), 
no significant effect on the growth rate of PC-3 (Fig. 3.4.2.3c) and MCF-7 (Fig. 3.4.2.3d) 
cell lines was observed, where the rate of growth was almost at the same rate as control 
samples.  
Cluster- individual 
range 100-800nm 
c) b) a) 
Fig. 3.4.2.2. Jurkat cell and eMV interaction. Time lapse sequence eMV interactions with Jurkat cells (60x objective lense 
images were taken for 15minutes). Fig. a) shows the eMV cluster approaching the cell membrane, Fig. b) shows the eMV cluster 
reaching the cell membrane and Fig. c) shows eMV cluster going through the Jurkat cell membrane and depositing the eMV 
cluster in the cell. The black arrows represent the activity of eMV cluster.  
Cell 12000nm 
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a) 
b) 
c) 
d) 
Fig. 3.4.2.3. Growth rate of cell lines - control against eMV treated cells. Where a) represents THP-1, b) Jurkat, c) PC-3 and 
d) MCF-7 cell lines concentration (x10
5 
/ mL) (N=3) over a 96 hour observation period. Statistical analyses were obtained using 
GraphPad Prism version 7.2, using multiple T test (one unpaired t test per row- per period of time) and statistical significance 
was determined using the Holm-Sidak method, with alpha = 0.05. The p values (comparison between controls against eMV 
treated) were considered significant if P<0.05.   
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In addition to cell number analyses, the percentage viability was also assessed. eMV 
treated cells had an insignificant effect on the viability of any of the cell lines analysed 
(Fig. 3.4.2.4). There is no spike in cell death centred on the samples containing the eMV 
or control samples with general % viability lessening across all the samples from 72 hours 
into the study, which is expected if cells are left CGM untreated for the period of 96 hours. 
This demonstrates that eMV clearly have an inhibitory effect, rather than acting as a 
necrotic protagonist, indicating that they are active players in cell cycle regulation. 
 
 
Similarly to the eMV and THP-1 cell interaction experiment, Annexin-V-FITC-
Conjugated was also used to label the HeLaMVC and HRV16iHMV samples. The 
labelled MV were added to fully confluent culture dishes (ratio 1:1) after 12 hours of 
subculture and incubation and MV to cell interaction was observed. This was achieved 
by utilising an automated system, alternating between bright field and fluorescence which 
was also visualised using LumaScope™ 500 Series Fluorescence Microscope LED 
imaging analyses. Observation (by eye) of the outcomes were recorded for 15 minutes.  
Fig. 3.4.2.4. % Cell viability of control and eMV treated cell lines. Cell % viability was observed every 24 hours for 96 hours 
(5 days) in total. The graph highlights the similarites between all samples, where a slight decrease in %viability is observed over 
time. The P value of all paired data (control vs eMV treated) were all above (P<0.05) which were considered insignificant.  
Statistical analyses were obtained from GraphPad Prism version 7.2.  
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In Fig. 3.4.2.5, MV involvement/interaction with cell membrane was observed. 
HeLaMVC (Fig. 3.4.2.5a) and HRV16iHMV (Fig. 3.4.2.5b) show a certain degree of 
membrane interaction with HeLa cells, but in contrast to Fig. 3.4.2.1, does not clearly 
show the cell membrane breakthrough observed with the eMV samples. Also, these MV 
appear to act as single particles, as aggregation was not observed here at early stages (< 
5 minutes) into the experiment. Nevertheless, some aggregation was observed once MV 
started to approach the cell membrane. The images presented here were taken after 12 
minutes of the incubation period and no further MV action could be observed.  
 
To test the effects of HRV16 infection rate on the growth rate of HeLa  cells, the 
morphological effect/appearance of MV treated HeLa cells was further investigated after 
24 hours of initial infection (Fig. 3.4.2.6), in order to observe whether the HRV16iHMV 
(ratio 1:1 to cells) would also infect cells, in comparison to the cells infected with the 
HRV16 only. Fig. 3.4.2.6a represents healthy cells and did not produce plaques, Fig. 
3.4.2.6b HeLa cells were infected with HRV16 (MOI 0.2) and plaques arising due to the 
infection are shown demonstrating distinguishable characteristics on HeLa monolayers 
 
a) b) 
c) d) 
Fig. 3.4.2.5. HeLa cell and their derived MV interaction. Interactions were observed (60x objective lense images) for 
15minutes. Fig. a) and b) shows HeLaMVC moving towards the cell and approaching the cell membrane (brightfield and 
fluorescence) and c) and d) shows HRV16iHMV surrounding the  HeLa cell (bright field and fluorescence respectively) but no 
major activities were observed.  
Cell -20000nm 
Cluster- MV individual 
range 100-800nm 
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under these conditions, in comparison to healthy cells. To understand the morphology 
further, HeLaMVC were introduced to a culture flask and no plaques were visible (no 
HRV16 particles) in Fig. 3.4.2.6c, in contrast to Fig. 3.4.2.6d where HRV16iHMV appear 
to also infect healthy cells, showing a significant amount of plaques.   
  
 
In order to compare the infection rate of HRV16iHMV with HRV16iHc accordantly it 
would be required to titrate HRV16iHMV samples in the same manner as in chapter 2.2.3. 
However, it was not the aim of this PhD research project. HeLa and their derived MV act 
as a parallel sample to understand the differences and similarities of MV types and 
characteristics in comparison to eMV samples.  
To further investigate the potential impact of HeLaMVC and HRV16iHMV on the growth 
of HeLa cells, cells on the exponential phase were seeded into sterile 24 well plates. Then 
MV were quantified (FC) and diluted (ratio 1:1) in DMEM and were added to each well 
d) HRV16iHMV (ratio 1:1) c) HeLaMVC 
b) HRV16iHc (MOI 0.2)  a) HeLa control 
Fig. 3.4.2.6. The impact of HRV16 and MV on the growth of HeLa cells. Where images (bright field) were taken after 24 hours 
of the initial incubation period showing and comparing the differences and similarities of the samples used. Healthy cells can be 
observed in Fig. a where no plaques can be observed. Whereas Fig. b shows the HRV16 infection of HeLa cells with the presence 
of plaques. In addition, HeLa cells were treated with HeLaMVC and no changes in cell morphology can be observed in Fig. c, 
demonstrating similar morphology/characteristics to Fig.a. In contrast, Fig. d indicates a stronger infection rate of HRV16iHMV 
infected HeLa cells than those treated with HRV16 itself, where plaques are strongly presented.  
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(except controls) containing the HeLa cells. Plates were incubated at 37°C in a 5% CO2 
incubator and left untreated for 24 hours. The cells were counted and viability was 
determined every 4 hours, after 12 hours of infection (Fig. 3.4.2.7).  
In Fig. 3.4.2.7a, no significance in growth rate was observed when comparing HeLa cells 
with HeLaMVC samples. Whereas Fig. 3.4.2.7b shows statistical significance in the 
growth rate of HRV16iHMV treated cells after 16 hours of treatment. In addition, Fig. 
3.4.2.7c compares both sets of treated HeLa cells, where HeLa treated with HRV16iHMV 
shows a decline of growth after 16 hours into the experiment. Fig. 3.4.2.7d suggests that 
HRV16iHMV has an effect on treated cells showing a faster infection rate (P**) after 16 
hours of the initial experiment when compared to HeLa infected with HRV16.  
 
Fig. 3.4.2.7. Growth rate of HeLa cells - control against HeLa cells treated with HeLaMVC and HRV16iHMV. Where a) 
represents HeLa cells against HeLa treated with HeLaMVC, b) represents HeLa cells against HeLa cells treated with 
HRV16iHMV, and c) comparing HeLa treated with HeLaMVC and HeLa cells treated with HRV16iHMV. All experiments 
were performed using triplicates of each sample (N=3). Statistical analyses were obtained using GraphPad Prism version 7.2, 
using multiple T test and statistical significance was determined using the Holm-Sidak method, with alpha = 0.05. The P values 
(HeLa cells against HeLa MV treated) were considered significant if P<0.05.   
  
a) b) 
c) d) 
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The % viability of HeLa cells against MV treated cells was also observed (Fig. 3.4.2.8), 
demonstrating a large number of HeLa cells dying with the time of HRV16 infection 
increasing (after 16 hours of the experiment- 50% infection rate expected after 24hours 
of initial infection). Healthy HeLa cells treated with HeLaMVC did not demonstrate 
statistical significance during the experiment. On the other hand, HeLa cells treated with 
HRV16 and HRV16iHMV demonstrated a decline in % viability (P>**) after 16 hours 
of treatment/infection in comparison to HeLa on its own, and those treated with 
HeLaMVC. However, despite a slight decrease in HRV16iHMV treated cells no 
statistical significance was observed. This was also used as a control factor to investigate 
the effect of HRV16 on the growth rate of HeLa cells for the extraction of MV (to avoid 
apoptotic bodies). 
 
 
 
 
 
 
Fig. 3.4.2.8. % Cell viability of HeLaMVC and HRV16IHMV treated HeLa cells. Where % viability was observed every 4 
hours for 24 hours in total after initial incubation period of 12 hours (N=3). The P values of all paired data were considered 
significant if P<0.05. As stated in the table (below graph) only samples compared against HRV16iHMV treated cells 
demonstrated statistical significance, where statistical analyses were obtained using GraphPad Prism version 7.2.  
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3.4.3 Discussion  
During this PhD research eMV did not interact and/or did not have an effect on the growth 
of PC-3 and MCF-7, which are epithelial cell lines. That may be because these cells lines 
are widely different cell types (location, form, and function), forming different types of 
tissues in animals and are derived from different embryonic layers, making them 
fundamentally unrelated. It is well understood that epithelium refers to a general class of 
cells that are found throughout the body in various linings of organs including glands, 
skin, digestive system, breast and prostate. Whereas, endothelial cells are a lining layer 
of cells or tissue (endothelium- blood vessels and lymphatic’s) (Alberts, et al., 2002), 
particularly present in the interior of the blood vessels at the same location of eMV 
isolation.  
The common structure of the adherens junctions and tight junctions in the endothelium is 
relatively similar with that of epithelial cells, but there are some cell-specific 
characteristics. For example, VE-cadherin, claudin-5, and PECAM-1 are endothelial 
markers, and have not been found in epithelial cells and the morphology of the 
intercellular cleft in the endothelium vary from that of many epithelia, as tight junction 
are not only located on the apical side, but may also be united with adherens junctions 
(Dejana, et al., 2009). Nevertheless, altered tight junction permeability in co-cultures 
have indicated that these cell types can work conjointly as an operating part of the 
mucosal barrier (Chowdhury, et al., 2010). However, eMV did not have an impact on the 
growth rate of PC-3 and/or MCF-7 cell lines during this PhD project and this may be due 
to the lack of matchable molecules between cell and MV required for the interaction. 
However, this is an assumption and it requires further investigations to understand the 
lack of interaction between MV with these cells.  
As previously mentioned (chapter 3.4.1) the THP-1 and Jurkat cell lines used here present 
particular and different surface markers, ligands and receptors that can regulate cell 
adhesion, cell signalling and adaptive immunity  for example, CD9 to CD36 interaction. 
Other receptors and ligands may have been involved, facilitating the interaction of THP-
1 and Jurkat cells with eMV. For instance, the adhesion involving CD2 (a surface antigen 
found on all peripheral blood T-cells) - CD58 (expressed in all MV tested here Fig. 
3.2.1.3e), antigen-specific T-cell receptor interactions with peptides bound 
MHC molecules (Wang & Reinherz, 2000). 
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Also, annexin-V was expressed on the surface of all MV tested during this PhD research 
(see Fig. 3.2.1.2) which may enable MV recognition by PS, a marker for apoptosis 
receptors on the surface of specific types of target cells. This interaction has been 
previously described within the context of phagocytosis of apoptotic cells by 
mononuclear cells using PS receptors including T-cell immunoglobulin and mucin 
domain (Tim)-1, Tim-4, Stabilin 2, and Brain-specific angiogenesis inhibitor (BAI)-1 
(Park, et al., 2007). This could be involved in the uptake of MV. This proposes that 
Tim1/4 receptors on two adjacent cells could allow the formation of MV/exosome bridges, 
thereby promoting additional/indirect intercellular interactions (Zhou, 2007). Also, the 
transfer of PS from vesiculating cells to erythrocytes was implicated in tagging these cells 
for destruction by phagocytes (Liu, et al., 2009), showing that vesicular transfer of several 
molecules emerges as a relatively widespread process, that may complement intercellular 
communication by different mechanisms.  
Indeed, PS has been demonstrated to play a critical part in the internalisation of MV 
derived from cells including monocytes and platelets into endothelial cells (Morelli, et al., 
2004; Bruno, et al., 2009). PS has also demonstrated involvement in the uptake of 
exosomes by dendritic cells (Lima, et al., 2013), but it does not appear to be the case in 
this PhD study because PS was blocked with Annexin-V label for microscopy analyses. 
Therefore, the Annexin-V blocking of PS receptors indicates that this may not be the entry 
site, despite research that has identified a high concentration of PS as one route (Feng, et 
al., 2010; Mulcahy, et al., 2014). Wei, et al., (2016), demonstrated that blockage of PS 
sites on hypoxia-induced mesenchymal stem cells (MSC)-MV with Annexin V 
significantly lowers the incorporation into human umbilical cord endothelial cells 
(HUVECs). Blocking PS often obliterates MV incorporation at least by endothelial cells, 
platelets and cancer cells (Del Conde, et al., 2005; Al-Nedawi, et al., 2008). Also, 
blockage of PS from neuron-derived exosomes using Annexin V not only prevented 
exosome uptake but also suppressed amyloid β-peptide and Aβ incorporation into 
microglia (Yuyama, et al., 2012). 
A proposition that follows would be that phagocytes could be particularly susceptible to 
molecular influences of PS positive MV, beyond their simple destruction. For example, 
the presence of P-selectin (cell adhesion molecule) ligand on the surface of procoagulant 
MV, could direct them to P-selectin expressing platelets and endothelial cells (Thomas, 
et al., 2009). Just as the role of protein milk fat globule-epidermal growth factor 8 (MFG-
E8) in promoting the phagocytosis of apoptotic cells, by acting as a bridging molecule 
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between apoptotic cells and phagocytes has been elucidated (Fricker, et al., 2012). It is 
believed to facilitate the phagocytic uptake of apoptotic cells by binding PS through 1 
domain and with cell surface proteins including CD51 and CD61 through a second 
domain (Hanayama, et al., 2002 ) and during macrophage phagocytosis of aged 
erythrocytes (Föller, et al., 2008). 
Nevertheless, the enrichment in signalling molecules alone is not enough to facilitate the 
signalling functions of EV. In fact, EV also have active lipolytic moieties, including 
phospholipases, resulting in the the formation of bioactive lipid mediators (fatty acids and 
prostaglandins). This may interact with peripheral G-protein-coupled receptors and the 
nuclear receptors in neighbouring cells (Subra, et al., 2010).  
The aggregation phenomenon observed in Fig. 3.4.2.1 could be explained by the presence 
of ADAMTS13 in eMV samples (Fig. 3.2.3.2) simply due to its general function (Zheng, 
2013). It processes a large protein called von Willebrand factor, this protein plays a role 
in clot formation and its unprocessed form of von Willebrand factor interacts easily with 
cell fragments, that circulate in the bloodstream and are essential for blood clotting. It 
helps cell fragments attach together and stick to the walls of blood vessels, leading to 
temporary clots. 
Fig. 3.4.2.2 also demonstrated some aggregation (not as much as in Fig. 3.4.2.1). The 
major differences between the experiments is that the eMV sample in this case was not 
labelled with Annexin V. Cells and EV membranes present vastly heterogeneous lipid 
compositions that vary between cell types (van Meer, et al., 2008; Osteikoetxea, et al., 
2015), and such variety of lipid composition in membranes is crucial in modulating the 
interactions of amphipathic proteins with membranes (not studied during this PhD 
research). Particularly, negatively charged phospholipid including PS (not blocked in 
this case) and phosphatidylglycerol are well known to impact the kinetics of  
aggregation and fibril formation of a variety of amyloidogenic proteins on the 
membrane surface (Galvagnion, et al., 2015; Zhu, et al., 2003; Mizuguchi, et al., 2018).  
In addition, while cell lines were undergoing apoptosis/proliferation, they could also have 
released their own MV or similar properties affecting the neighbouring cells. In a study 
of MV isolated from THP-1 and Jurkat cells, it was shown that they carry high levels of 
transforming growth factor-β1. This suggest that they could have the ability to 
promote/inhibit the control of cell cycle, cell proliferation, cell differentiation and 
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apoptosis which caused significantly greater reductions in the growth rate of THP-1 cells 
(Ansa-Addo, et al., 2010).  
In relation to HRV16 and HRV16iHMV treated HeLa cells, it did not increase/decrease 
in concentration/number, and this may be due to the HRV16 infection dose decreasing 
their chance of survival, and cell growth rate/effect could therefore not be observed. As 
for HeLaMVC, no major differences in growth rate were observed within the 24 hours of 
the experiment. However, HRV16iHMV treated cells showed an advanced infection rate 
of treated HeLa cells, suggesting that HRV16 particles may be carried in the sample, 
because according to Lisco, et al., (2009), EV can in general (in vivo), interact with 
viruses and with each other. Either directly or via modulation of host responses by 
participating in a “War and Peace” interaction between viruses and host.  
Some viruses, including HIV, induce the infected cells to release modified EV that 
facilitate further infection by increasing the pool of susceptible target cells. This is 
promoted by increasing the number of activated cells, or their susceptibility to viral 
infection, or by serving as decoys that absorb antiviral antibodies. The capacity of EV to 
regulate the lifespan of permissive cells and to modify antiviral immune responses may 
give additional flexibility to the host in responding to viral infection, suggesting that EV 
formed during viral infection may play either pro- or counter-viral roles (Hoen, et al., 
2016).  
In this study only much higher infection rate is presented visually in Fig. 3.4.2.6 and 
3.4.2.7, and further work is required before any assumptions are made. For example, 
several HIV proteins and RNAs having already been detected in EV released from HIV-
infected cells. One of the viral components released via EV is the HIV transactivation 
response (TAR) element RNA. The TAR is an RNA stem-loop structure located at the 5′ 
ends of HIV-1 transcripts, which in infected cells is found in TAT (gene that provides 
instructions for making the liver enzyme, tyrosine aminotransferase), thereby facilitating 
recruitment of elongation factors and increased production of viral RNA (He, et al., 2010). 
When transferred via EV, TAR RNA can increase the population of susceptible target 
cells. Inside EV-targeted cells, the full-length TAR RNA is processed into miRNAs, 
which silence messenger RNA (mRNA) coding for B-cell lymphoma 2- interacting 
Protein. The consequential increase in resistance to apoptosis, allows the cell to produce 
the virus for a longer period, thereby facilitating HIV infection (Narayanan, et al., 2013; 
Hoen, et al., 2016). 
 
 
155 
4. A model proposition: eMV may act as delivery vectors in 
circulation 
 
 
Human erythrocytes have a flexible biconcave shape and are approximately 7000 nm in 
size. Their main functions are the transport of oxygen and carbon dioxide. They are also 
involved in the release of ATP, which may participate in vessel dilation by triggering 
nitric oxide production (Olearczyk, et al., 2004; Bakhtiari, et al., 2012). Erythrocytes are 
known to secrete MV and their presence has been observed in a number of diseases by 
different researchers (see chapter 1.2.1)  
eMV range between 100-800 nm in size (Fig. 3.1.2.3) and their biogenesis has been 
described as a part of erythrocyte senescence and have also been proposed as part of an 
apoptosis-like process (eryptosis) (Rubin, et al., 2012). An increase of intracellular 
calcium levels leads to disruption of the erythrocyte membrane asymmetry with 
concomitant biogenesis. Erythrocytes exposure to inducing agents including CaCl2 and 
CaCl2 + NHS leads to a loss of plasma membrane deformability (see chapter 1.2.2), and 
an increase of their release (amount) was observed during this PhD research (see chapter 
3.1.2). 
According to the literature used during this PhD research, MV are suggested as being 
involved in cellular communication (see chapter 1.7). An umbrella term that allows the 
understanding of how different types of cells can cooperatively perform important bodily 
processes that are necessary for cell proliferation and their survival. It may also help to 
understand the binding of eMV to the external surface of their target cells, in which a 
specific pathway remains unclear. Nevertheless, a number of possible interactions have 
been suggested by protein interaction networks (Fig. 3.2.1.3.1, 3.2.2.3.1, and 3.2.3.3.1).  
 
EV-cell communication has been proposed as occurring during a variety of processes, 
which may take place inside the cell, protein-to-protein interaction, endocytosis and other 
events (chapters 1.4 and 1.7). Intracellular binding and fusion require the involvement of 
various proteins, including cytoskeletal proteins (actin). Among the latter processes, the 
ones intensely investigated are EV-virus fusions, which occur with the participation of 
specific proteins (chapter 1.3.1).  
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The initial interactions of EV with cells are expected to require specific, high affinity 
binding of at least two surface proteins (principles of cell communication). One 
protruding from the EV, and the other from the plasma membrane of the target cells. The 
investigation into key biomolecules conducted during this PhD research (chapter 3.2), 
provided the identification of molecules which may play an important role on how eMV 
may interact with the recipient cell or at least a starting point for further experiments.   
To better understand the mechanism by which MV may enter the cells, further analysis is 
required including the characterisation of potential target cells. For now, the process 
remains a major challenge and is necessary for elucidating the underlying mechanisms as 
well as for identifying cell targets.  
As the cell travels and circulates in the bloodstream, its trajectory is influenced by 
viscoelastic and frictional properties, the latter of which is governed by cell surface 
interactions as well as normal forces exerted by the cell on the channel wall (Byun, et al., 
2013). This may also be occurring with MV due to its cargo (surface markers).  
After receptor-ligand interaction takes place, which may occur through CD36-CD9, 
CD58-CD2 and CD63-TIMP1 interactions (see Fig. 3.2.1.3.1), some of these 
receptors/ligands were present in eMV and ligands/receptors known to be present in THP-
1 and Jurkat cells (Wang & Reinherz, 2000; Reyes, et al., 2015; Trim, et al., 2000) . Then 
the ligand-receptor pair relocates as a single component on the plasma membrane. The 
assembly binds together and diffuses with the receptor, which leads to a chemical 
environment for the ligand and receptor to adapt. They are then accepted or rejected by 
each other as allies. The alliance may transduce extracellular signals across the plasma 
membrane and, through the activation of intracellular signalling pathways, bring about 
the appropriate functional response (Uings & Farrow, 2000).  
For example, integrin-dependent cell adhesion, through integration of cell signalling 
pathways and cytoskeletal reorganisation are understood to influence cell growth, death, 
and differentiation (Clark & Brugge, 1995). But, integrin signalling may not simply 
require cytoplasmic domain associations, it may also use lateral interactions through 
integrin transmembrane and ectodomains (Wary, et al., 1996), because they tend to 
assemble into protein complexes (Hotchin & Hall, 1995). This is where they might recruit 
other molecules including growth factor ligands and phosphatidylinositol 4-kinase, into 
proximity with integrins (Nakamura, et al., 1995; Berditchevski, et al., 1997).  
 
 
157 
Furthermore, as previously suggested in chapter 3.2.2.3, integrin proteins may also link 
specific integrins to Protein Kinase C (PKC) (Zhang, et al., 2001). This is important 
because understanding of the mechanisms underlying PKC-mediated control of the cell 
cycle can provide valuable insight into its role in inhibiting cell growth and transformation 
(Black, 2000). This is of interest because an inhibition of THP-1 and Jurkat cell lines 
treated with eMV was observed during this research, which may suggest that the 
activation of PKC on the recipient cell could be the catalyst for this observed inhibition. 
This is relevant because members of the PKC family have been widely implicated in the 
regulation of cell growth/cell cycle progression and differentiation (Frey, et al., 2000). 
Also, PKC was present in eMV samples, see Fig. 3.2.2.2. 
The GO enrichment indicated that PKC is heavily involved in these biological functions 
and pathways (Appendix III; Tables 5 and 6).  Using G1 and G2 as checkpoints in vitro 
and in vivo systems point to PKC as a key regulator of critical cell cycle transitions, 
including cell cycle entry and exit. Most of the mechanistic information available relates 
to the involvement of the PKC enzyme family in negative regulation of these transitions. 
Cip/Kip cyclin-dependent kinase (known as CDK) inhibitor p21waf1/cip1 (cyclin-
dependent kinase inhibitor 1 or CDK-interacting protein 1) are the major target for PKC-
mediated inhibition of cell cycle progression (see Appendix VIII). CDK2 activity in the 
G1 phase is blocked by increased expression of p21waf1/cip1, this leads to hypo-
phosphorylation of the retinoblastoma protein and inhibition of cell cycle progression into 
the S phase. Whereas in G2, p21waf1/cip1 expression blocks cdc2/cyclin B activity, 
likely through an indirect mechanism involving inhibition of the CDK2/cyclinA complex, 
and in turn prevents progression into the M phase. PKC signalling can also activate a 
coordinated program of pocket protein regulation activities leading to cells leave G1 and 
enter an alternative G0 state (Chambard, et al., 2007).  
Regig & Platanias (2008), summarised the work in this field based on the relevance of 
distinct members of the PKC family in the pathophysiology of myeloid and lymphoid 
Leukaemias. Although most members of PKC promote leukaemic cell survival and 
growth, others exhibit opposing effects and participate in the generation of anti-leukaemic 
responses. They concluded that the clinical-therapeutic potential of ongoing work in the 
future development of novel approaches for the treatment of different types of leukaemias 
is developing. 
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The results that are presented in the results chapters of this PhD thesis have provided 
helpful information into eMV cargo, which opened a range of possibilities for eMV to be 
involved in different biological processes, due to the large number of molecules identified 
(chapters 3.2 and 3.3). This may lead to responses to a number of different biological 
pathways that have been linked to the group of molecules/genes analysed here 
(proteins/genes and miRNA target genes GO enrichment). The analysed target genes can 
be regulated in many different ways since a single gene demonstrated involvement in 
many processes which may be under the regulation of other entities including mutation, 
repair, and the recombination of the genome (Brown, 2002). During the analysis of these 
genes, it was possible to distinguish the group of those that were able to regulate the 
expression of all of the target genes from the miRNAs identified in chapter 3.3.  
The universal mechanism of the post-transcriptional regulation of a gene activity through 
miRNAs indicates they may adapt to a variety of routes (Engels & Hutvagner, 2006). The 
data obtained during this PhD project, suggests that eMV contain miRNAs which can 
possibly be involved in up- or down-regulation of the different components. This is 
because biosynthesis pathways are necessary in some aspects of growth regulation or 
adaptation to environmental stimuli to cells (Lloyd, 2013).  
A deregulation of miRNA expression can result from increased or decreased transcription 
from their respective miRNA genes by aberrant transcription factor activity. For example, 
miR-21 (present in all samples tested here) has been reported at high levels in 
glioblastomas, pancreas, and breast cancer (Garzon, et al., 2010). When miR-21 was 
blocked, an increased activation of caspases and apoptosis was observed in glioblastoma 
cell lines (Chan, et al., 2005). 
Taken together, the study based on eMV characterisation, biomolecules identified and the 
GO enrichment analyses obtained during this PhD project, a relevant biological model is 
proposed in Fig. 4.2.1. The proposed model overviews eMV being released from the 
parent cell, biological molecules which may help eMV to communicate with target cells 
and, their potential to change gene expression. This is where potential 
suggestions/conclusions related to the impact of eMV in neighbouring cells may be 
understood which may be due to a variety of molecular and cellular molecules identified. 
The model presents information that is currently absence from the EV/MV field. 
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Fig. 4.2.1. Schematic summary of eMV biogenesis, contents, mechanism of communication and potential impact on a THP-1 
cell. A representation of the key features identified in eMV during this PhD research. It demonstrates eMV budding directly from the 
plasma membrane during an increase of intracellular calcium due to the introduction of inducing agents. eMV contains proteins of 
interest, including tetraspanins CD36, CD58 and CD63 (allows receptor-mediated endocytosis fusion with neighbouring cells) and 
CD47 (protection against phagocytosis). After MV are secreted, they may be taken up by neighbouring/ target cells via fusion with 
the plasma membrane, a receptor-ligand interaction. Once inside the cell, eMV can then release their contents including miRNAs, 
therefore transporting key molecules in which may have an effect on the recipient cell proliferation and overall fate.  
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5. Conclusions and further work 
 
 
This PhD research was designed to characterise MV released from uninduced 
erythrocytes, erythrocytes induced with CaCl2, and erythrocytes induced with CaCl2 
+NHS. The characterisation was based on their amount of release (concentration), their 
size, and the identification of potential molecules which could allow these MV (eMV) to 
communicate with cells in vitro. And lastly to investigate whether eMV could act as a 
potential delivery vector. In parallel, HeLa cells, HeLa derived MV, and HeLa infected 
with HRV16 derived MV were used as a comparative source for all experiments 
The first step included the comparison of the amount of MV released from uninduced and 
induced erythrocytes. This was to investigate whether the induced agents would provide 
a higher amount of release. The investigation was assessed by FC analyses using samples 
obtained from the ultracentrifugation procedure compared with SEC. It was observed that 
erythrocytes released a greater amount of MV when induced with CaCl2 and CaCl2+NHS. 
Classic ultracentrifugation proved to be a faster and more accurate method of isolation 
when compared to SEC. These findings are helpful and further parameters should be 
included with these comparisons to gain a better understanding of eMV biogenesis.  
For example, to further the work of this PhD research, the inclusion and comparison of 
erythrocytes induced with NHS only, and other inducing agents including 4-bromo-
A23187, lysophosphatidic acid, or phorbol-12 myristate-13 acetate suggested by Nguyen, 
et al., (2016).  
It would also be of interest to take an opposite approach by using Calcium Channel 
Blockers that are examples of agents that attenuate eMV biogenesis (Harisa, et al., 2017).   
A potential clinical application for eMV can be the design of MV modulating therapy 
based on inhibiting MV biogenesis, by inhibiting their cellular uptake, and/or inhibiting 
their active components. Mulcahy, et al., (2014), listed several agents that inhibit EV 
cellular entry including heparin, chlorpromazine, amiloride, Annexin-V and proton pump 
inhibitor which could be considered for further experiments. 
The characterisation of eMV sizes was addressed in this study using different techniques 
that included FC analyses and qNano. The eMV samples obtained during this PhD 
research were concluded to be of a size range of between 100-800 nm. The qNano 
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provided a more accurate measurement of size distribution, but the FC analyses proved 
to be a faster approach, particularly because the comparison of the size of eMV was not 
further assessed during subsequent experiments. Alternative techniques are proposed in 
chapter 3.1.3 (page 66 and 67). 
In addition, to compare the MV isolation methods, the classic ultracentrifugation 
procedure was compared to the Size Exclusion Chromatography column method. This 
decreased the recovery rate of MV and it added an extra step to the lengthy 
ultracentrifugation procedure, without demonstrating any advantages in this PhD research. 
As discussed in chapter 3.1.3 (page 69) alternative approaches are available. Further 
assessment including proteomic analysis could potentially advance this approach.    
Furthermore, random sampling (variability) was not used in this study despite being 
convenient when the population members are similar to one another on variables, and it 
ensures a high degree of representativeness for the data obtained because it can critically 
construct the “representativeness of study samples and generalisability of study results’’. 
These key concepts often can be misconstrued and blended, concealing the general 
drawbacks of internal and external validity (Kukull & Ganguli, 2012). For this study, 
eMV samples were derived from the same blood donor and are not to be presented as 
representative data of the general type of EV population (MV). The results should not be 
generalised as such, they are derived from uninduced and induced erythrocytes designed 
samples. Sample size, concentration and isolation methodology were key variables 
considered in chapter 3.1 when studying the heterogeneity of eMV. This should minimize 
the possibility that selection factors will have unintended adverse consequences in results, 
since any effect measured depends on the stimuli used rather than on the comparison of 
different blood groups as eMV types (control and induced). Factors including sex, age 
(sample and donor), and total time of isolation may provide different EV yield (total 
population) because it is noticeable that eMV are composed of diverse subpopulations in 
relation to size and concentration. It may expand the known EV subpopulation 
classification, but instead the focus was on eMV derived from uninduced and induced 
samples. 
Nevertheless, random sampling (variability) is an approach recommended for further 
experiments, especially eMV derived from donors presenting medical conditions that are 
known to affect erythrocytes. Examples of these conditions include hemolytic anaemia, 
hemochromatosis, hereditary spherocytosis, iron deficiency anaemia and polycythemia. 
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This is because elevated levels of eMV release have also been associated with numerous 
diseases (see chapter 1.2.1, page 13). 
The characterisation and optimisation of MV size and concentration mentioned above 
was a requirement to be able to proceed with the characterisation of the samples in relation 
to the present of biological molecules, therefore it acted as a starting point.   
Subsequently, this study focused on the identification of key biomolecules. This was 
performed by using immunoblotting techniques including immunophenotyping (surface 
markers), Western blotting analyses (total proteins) and Proteome Profiler Array 
(proteases). This is provided in chapter 3.2.  
The identification of surface markers, general proteins and proteases within eMV 
provided an insightful recognition of their biological potential. For example, the potential 
interaction of CD2 with CD58 among other ligands/receptors identified in chapter 3.2 
may facilitate communication/exchange of information by using ligand-receptor 
molecules to initiate the process. Whereas, by using CD47 (the “do not eat me” signal) 
eMV may be able to protect themselves in the extracellular environment. 
The in silico analyses performed in chapter 3.2 (protein interaction network and GO 
enrichment), provided a detailed set of information that can help unravel the biological 
functions of eMV. This is because each of the interaction network, biological process 
and/or pathways identified may form the basis of subsequential research projects, which 
can support and further this PhD research. The options for further experiments are endless, 
but the data collected can act as a starting point to understand the complex processes of 
and biological features of the eMV interacting with neighbouring/target cells.  
For example, CD36 was detected in the surface of all eMV samples tested here and it is 
well understood that CD36 interacts with CD9, a highly conserved cell surface 
protein CD9 (Wang, et al., 2011). CD9 is known to be expressed on the surface of white 
blood cells in general, including THP-1 cells (Reyes, et al., 2015). CD9 is relevant 
for signal transduction, proliferation/apoptosis, cell adhesion and migration among other 
processes (Sumiyoshi, et al., 2016).  
Experiments with THP-1 cells for example, could include the functional assessment and 
localisation of CD9 on the cell. Functional analyses involving the downregulation 
of CD9 through genetic manipulation using either Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9-based approaches (Gilbert, et al., 2013) or 
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transient knock-down by means of mRNA degradation (Fire, et al., 1998), could shed 
light on the role of CD9 as a rheostat of cell/eMV adhesion and homotypic aggregation. 
This was previously described as integrin-dependent, which is a critical regulator of vital 
processes such as fertilisation, where the absence of the protein in oocytes produces 
a deficient fusion among sperm and egg (Wang, et al., 2011). The knockdown of CD9 
from THP-1 cells would prove whether eMV interaction with the cell is dependent on the 
CD9-CD36 ligand/receptor interaction. This is just one example of an interaction network, 
but these type of functional analyses are relevant for this study to further elucidate the 
postulated pathway of cell to eMV interaction.           
Then, the identification of immune related miRNA’s was conducted using the Firefly 
particle technology. This was investigated because the presence of miRNAs that function 
to regulate cellular processes, including cell proliferation, could be a major characteristic 
that may support MV activities. The data obtained in chapter 3.3.2 provided a detailed set 
of information that can help to reveal additional biological functions that eMV may be 
involved with. The options for further investigations here are inestimable, each of the 
identified miRNA and each of their target genes can provide enough interest for extensive 
research projects. This is because it has been reported that the presence of miRNAs 
patterns characterised by their over-/under expression in specific pathologies (Ha, 
2011).  For example, let-7 is a tumour suppressor miRNA and its overexpression results 
in oncogenic loss of differentiation/cell identity (Johnson, et al., 2005), it also prevents 
early cancer progression by suppressing expression of the embryonic gene HMGA2 (Park, 
et al., 2007).  Therefore, restoring let-7 levels in cancer is an appealing therapeutic option 
(Jansson & Lund, 2012). 
The use of CRISPR (Chang, et al., 2016) in the case of eMV miRNAs is not feasible 
because the miRNA found in these samples are as a result of the MV biogenesis, and the 
erythrocytes lack nuclei and are unable to transcribe mRNA (Warren, 2017). Whether 
these identified miRNAs were inherited from the erythrocytes membrane or collected in 
circulation is unknown. Therefore, miRNA biogenesis cannot be edited because MV do 
not have the cell machinery (including the genome) to carry out this function. Instead, 
another functional approach can be achieved by the incorporation of locked nucleic acids 
(LNAs) into a biological model (Pritchard, et al., 2012). After miRNAs purification, 
miRNAs can be tagged with fluorophore-labelled nucleotides (Nilsen, 2007), leading to 
the design of oligonucleotides that result in either degradation or steric hindrance of the 
target mRNA in the recipient cell (Braasch, et al., 2002). This method for specific 
 
 
164 
inhibition of miRNA function through the interaction with LNA-modified antisense 
oligonucleotides (Ørom, et al., 2006), has been proved to specifically inhibit both 
endogenous and exogenously introduced miRNA in Drosophila melanogaster cells using 
a heterologous reporter assay. The method showed stoichiometric and reliable inhibition 
of the targeted miRNA being applicable to functional studies of miRNA and validation 
of putative target genes. 
Another example is the approach used by Elmén, et al., (2008) that systemically 
administered LNA-antimiR oligonucleotide complementary to the 5' end of miR-122, it is 
relevant to this study because it suggested that miRNA antagonists comprised of LNA 
are valuable tools for identifying miRNA targets in vivo. Such miRNA antagonists can 
be used to elucidade the biological role of miRNAs and miRNA-associated gene-
regulatory networks in  physiological conditions. Their results suggested that this 
incorporation leads to specific, dose-dependent silencing of miR-122 without 
hepatotoxicity in mice.  
Following active miRNA load release inside the recipient cell, MV may have the ability 
to alter the transcriptome and signalling activity within the recipient cells, resulting inthe 
induction of specific phenotypic changes (Camussi, et al., 2010; Bronisz, et al., 2016; van 
Dongen, et al., 2016), after endocytic activity that can separate properties to be recycled 
from those that will be degraded in lysosomes (Piper & Katzmann, 2007).  
In chapter 1.3, HRV16 was suggested as having a strategy that has evolved to evade cells. 
For MV to have similar functionality, it may involve alterations in the content of the 
HRV16iHMV so that it includes components of innate defence against selected viral gene 
products to be able to replicate, but his was not studied during this PhD research. See GO 
enrichment, set out in Appendix IV for information regarding molecules identified in 
chapters 3.1, 3.2, 3.2 and their target genes. It can be hypothesised that the reorganisation 
of the HRV16 is part of the mission of the HRV16iHMV, and this is to alter the 
environment in the recipient cells so that it is able to control its dissemination in the host 
as suggested in Herpes Simplex Virus type 1 infection (Kalamvoki & Deschamps, 2016). 
This is by restricting its dissemination within the human body, it can propose long-term 
interactions with the host and increases its chance of transmission, showing potential 
mechanisms to hijack MV and this could be suggested to be possibly occurring with the 
HRV16iHMV. However further experiments are required to ascertain this possibility, 
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which is not a mechanism in which eMV may use, because they are not infectious 
particles that require a host for survival.  
Therefore, it is logical that the next step for this PhD research is to further study the 
potential to harness the capability of MV to transfer their contents into target cells. This 
is to confirm whether eMV might be convertible into vehicles for the delivery of 
therapeutic agents. In addition, because it is well established that cells can be manipulated 
and have drugs introduced into them, MV may also be manipulated in the same way and 
thus represent a promising candidate for delivery vectors (Perteghellaa, et al., 2017), 
without immune rejection following in vivo allogenic administration as suggested for 
exosomes (Yu, et al., 2014). This is because after being delivered to the target cells, the 
miRNAs may be able to regulate the translation of the target genes and the function of 
the recipient cells (Valadi, et al., 2007; Tkach & Théry, 2016).  
Despite clinical investigations being in their infancy, the relevance of miRNA transfer in 
several physiological settings has been postulated in this field. There is emerging 
evidence that miRNAs transported in EV may be responsible for intercellular 
communication, but it is yet to be established if the amounts of miRNAs necessary to 
process that effect are appropriate to confer relevant effects, with regard to physiological 
impacts in vivo.  
EV in general demonstrate several possible advantages in terms of their use in 
regenerative medicine (Beer, et al., 2017) and as delivery vehicles/vectors, because they 
are stable (membrane bound vesicles), potentially capable inducers of strong signalling 
pathways due to their cargo (surface markers for instance), and can be produced in higher 
concentrations when induced compared to uninduced samples (see Fig. 3.1.2.2).  
One of the most exciting outcomes of this PhD research was the identification of key 
molecules in eMV that may contribute to their postulated identity of being genuine 
biological entities, that are, therefore able to transfer information and substances to 
recipient cells. The observed membrane interaction with the THP-1 cell and their 
inhibitory impact (chapter 3.4) during this study demonstrates their potential as a delivery 
agent.  
At this stage, the exact biological mechanisms which eMV use to communicate with 
neighbouring cells is difficult to predict. Nevertheless, MV have been shown to be an 
integral part of various immunological systems, as a result of their enriched cargo 
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consisting of proteins and miRNAs. It is possible they might be able to indirectly activate 
immune stimulation factors and act as carriers, but this hypothesis needs to be tested in 
further studies. 
eMV are promising biological vectors for drug delivery because they could overcome 
restrictions of synthetic micro carrier and considered self-molecules due to their ability 
to permeate the plasma membrane of target cells, as a result of their membrane being able 
to be amenable to improve specific cell targeting that can deliver their contents to 
neighbouring cells. Therefore, MV may be suitable for the development of drug delivery 
cargo, and can be produced at a high level using inducing agents such as CaCl2 and CaCl2 
+ NHS. EV has shown the capability to deliver drugs to specific tissues, thereby reducing 
therapeutic doses and decreasing side effects (Sun, et al., 2010).  
The results obtained in this study are consistent with knowledge in the EV field, 
hypothesising that MV not only interact but also have an impact on cell lines in vitro 
(García-Manrique, et al., 2018; Koniusz, et al., 2016). Indeed, results from some studies 
show that fluorescently labelled EV can be taken up by cells (Svensson, et al., 2013), but 
others suggest that EV uptake is a particularly specific affair that requires the right 
combination of ligand and receptor (Mulcahy, et al., 2014; Tomasetti, et al., 2017). This 
is an assertion this PhD research supports (combination of ligand and receptor- Fig. 
3.2.1.3.1).  
However, strong evidence about the mechanism of MV influencing other cells in vivo is 
still absent. Implying that more investigation is required to validate these suggestions, 
including the targeted binding of specific receptors, in order for MV to act as a natural 
delivery vector. Nevertheless, the characterisation of the MV properties was explored in 
this research and the data obtained can positively contribute towards the EV field, and 
further work to identify their true potential for use in the medical field.   
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Appendices 
 
 
Appendix I 
Abcam miRNA profiling protocol  
Sample’s volume were adjusted in water such that 5 ng/ μL was in a 25μL volume.  Then, 
for each sample, 35μL of the Firefly particles were added to a well of a 96-well filter plate 
and filtered. Three additional wells for no-sample controls were also prepared.  
Subsequently, 25 μL of hybridization buffer was added to each well followed by 25μL of 
sample (or water in the case of no-sample controls). The plate was incubated at 37°C for 
60 minutes while shaking at 750 rpm. Then, the wells were rinsed twice with 175μL of 
1X Buffer A, and 75 μL of 1X labelling buffer was added to each well. The plate was 
incubated at RT for 60 minutes while shaking at 750rpm.  The wells were rinsed twice 
with Buffer B followed by one rinse with 1X Buffer A. A catch plate was added to the 
vacuum manifold (ab204067) and the filter plate was placed under constant vacuum. A 
65 μL of 95°C RNAse-free water was added twice to each well and the eluant was retained 
in the catch plate. The particles were stored in the filter plate at 4°C with 75 μL Rinse A 
for a short period of time until needed.  
A 30 μL of the eluant was added to a clean polymerase chain reaction (PCR) plate and 
mixed with 20 μL PCR master mix. The mixture underwent 27 cycles of PCR 
amplification followed by 6 cycles of asymmetric amplification.  
Then, suction was used to remove the rinse A from the particles that was stored in the 
filter plate at 4°C with 75 μL rinse A. Next, 60 μL of hybridization Buffer was added to 
each well followed by 20 μL of the PCR product. The plate was incubated at 37°C for 30 
minutes while shaking at 750rpm.  
The plate was then rinsed twice with 175 μL of 1X buffer A and 75 μL of 1X reporting 
buffer was added to each well and the plate was incubated at RT for 15 mins while shaking 
at 750 rpm followed by two rinses with 175 μL of 1X buffer A and then 175 μL of run 
buffer was added to each well. Samples were then scanned using an EMD Millipore 
Guava 6HT or 8HT flow cytometer.  
Buffers were not specified by manufacturer. 
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Appendix II 
The complement pathway 
 
“Complement can be activated through three pathways: classical, lectin, and alternative. 
The classical pathway is activated when C1q binds to antibody attached to antigen, 
activating C1r and C1s, which cleave C4 and C2. The lectin pathway is activated when 
mannose-binding lectin (MBL) encounters conserved pathogenic carbohydrate motifs, 
activating the MBL-associated serine proteases (MASPs) and again cleaving C4 and C2. 
C4 and C2 cleavage products form the classical and lectin pathway C3 convertase, 
C4bC2a, which cleaves C3 into C3b and C3a. A second molecule of C3b can associate 
with C4bC2a to form the C5 convertase of the classical and lectin pathways, C4bC2aC3b. 
The alternative pathway (AP) is activated when C3 undergoes spontaneous hydrolysis 
and forms the initial AP C3 convertase, C3 (H2O) Bb, in the presence of Factors B and 
D, leading to additional C3 cleavage and eventual formation of the AP C3 convertase 
(C3bBb) and AP C5 convertase (C3bBbC3b). Properdin facilitates AP activation by 
stabilizing AP convertases.” retrieved from Dunkelberger & Song (2010). 
Moreover, opsonins (C3b, iC3b, and C3d - induces phagocytosis of opsonized targets and 
also serves to amplify complement activation through the alternative pathway) is essential 
for the induction of the terminal pathway of complement effector generation. The 
increasing density of C3b during complement activation and amplification leads to a 
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substrate specificity shift in the generated convertases from C3 to its paralog C5 (terminal 
pathway at the stage of cleavage) (Janeway, et al., 2001). C3a and C5a, which are potent 
anaphylatoxins (proinflammatory molecules derived from the cleavage-C4a/C3a/C5a) 
and has chemotactic activities leaves the large fragment C5b to form the nest of a MAC 
(terminal assembly of complement components C5b through C9, which can directly lyse 
targeted surfaces) ) (Janeway, et al., 2001; Noris & Remuzzi, 2013; Towner, et al., 2016).  
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Appendix III 
Table 1.  Protein name to gene name conversion 
Surface markers  Gene name  
Cluster differentiation 36 
Cluster differentiation 58 
Cluster differentiation 63 
Glycophorin A & B 
 
CD36 
CD58 
CD63 
GYPA and GYPB 
 
Total proteins  Gene name 
Glycophorin A   
Band 3 anion transport protein 
Spectrin beta chain 
 
Protein Kinase C 
 
Cluster differentiation 47 
 
GYPA 
SLC4A1 
SPTBN2 
PRKC 
CD47 
 
Proteases  Gene name  
  Disintegrin Metallopeptidase Domain 8 
  Disintegrin-like Metallopeptidase with thrombospondin motif 1, 13 
Cathepsin A 
 
Cathepsin B 
 
Cathepsin D 
 
Cathepsin E 
 
Cathepsin V 
 
Cathepsin Z 
 
Dipeptidyl peptidase 4 
Matrix Metalloproteinase 2  
Matrix Metalloproteinase 3 
Matrix Metalloproteinase 8 
Matrix Metalloproteinase 9 
Matrix Metalloproteinase 12 
Matrix Metalloproteinase 13 
Kallikrein 10 
 
Proprotein convertase 9 
Proteinase 3 
  
  ADAM8 
  ADAMTS13 
  CTSA 
  CTSB 
  CTSD 
  CTSE 
  CTSV 
  CTSZ 
  DPP4 
  MMP2 
  MMP3 
  MMP8 
  MMP9 
  MMP12 
  MMP13 
  KLK10 
  PCSK9 
  PRTN3 
 
 
 
 
 
 
Protein names were converted into gene names in order to allow GO enrichment analysis, where column 1 indicates the protein name 
and column 2 indicates the name of the gene of interest.  
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The functional enrichments among the multiple proteins/genes present in eMV samples  
Table 2. Description of mapped items for protein/gene expression data 
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Table 3. Description of cellular components for protein/gene present in eMV samples 
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Table 4. Description of molecular functions for protein/gene present in eMV samples 
 
 
 
Table 5. Description of biological processes involved in protein/gene present in eMV 
samples 
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Table 6. Description of biological pathways involved in protein/gene present in eMV 
samples 
Biological pathway No. of genes  in the data set Percentage of genes Genes mapped from  input data set
Hemostasis 5 35.71428571 CD58,CD36,CD63,CD47,PRKC
LPA receptor mediated events 3 21.42857143 MMP2,MMP9,PRKC
Osteopontin-mediated events 2 14.28571429 MMP2,MMP9
Response to elevated platelet cytosolic Ca2+ 2 14.28571429 CD63,PRKC
Validated transcriptional targets of AP1 family members Fra1 and Fra2 3 21.42857143 MMP2,MMP9,PRKC
amb2 Integrin signaling 2 14.28571429 MMP2,MMP9
Integrin family cell surface interactions 8 57.14285714 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,CD47,PRKC
Regulation of Insulin Secretion by Acetylcholine 1 7.142857143 PRKC
ATF-2 transcription factor network 2 14.28571429 MMP2,PRKC
Integrins in angiogenesis 2 14.28571429 MMP2,MMP9
Signaling by SCF-KIT 2 14.28571429 MMP9,PRKC
Syndecan-4-mediated signaling events 3 21.42857143 MMP2,MMP9,PRKC
Cell surface interactions at the vascular wall 2 14.28571429 CD58,CD47
Syndecan-2-mediated signaling events 2 14.28571429 MMP2,MMP9
Posttranslational regulation of adherens junction stability and dissassembly 3 21.42857143 MMP2,MMP3,MMP9
Class I PI3K signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
EGF receptor (ErbB1) signaling pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
PDGFR-beta signaling pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Internalization of ErbB1 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Signaling events mediated by focal adhesion kinase 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Arf6 downstream pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Arf6 trafficking events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
S1P1 pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Insulin Pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
ErbB1 downstream signaling 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Class I PI3K signaling events mediated by Akt 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
mTOR signaling pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Arf6 signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
EGFR-dependent Endothelin signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
IGF1 pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
IL5-mediated signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
GMCSF-mediated signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
PDGF receptor signaling network 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
IL3-mediated signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Nectin adhesion pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
IFN-gamma pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Signaling events mediated by VEGFR1 and VEGFR2 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
PAR1-mediated thrombin signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Glypican 1 network 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Thrombin/protease-activated receptor (PAR) pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Syndecan-1-mediated signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Plasma membrane estrogen receptor signaling 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
VEGF and VEGFR signaling network 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Alpha9 beta1 integrin signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
LKB1 signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Endothelins 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
ErbB receptor signaling network 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Sphingosine 1-phosphate (S1P) pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
N-cadherin signaling events 3 21.42857143 MMP2,MMP3,MMP9
Stabilization of mRNA by HuR 1 7.142857143 PRKC
TRAIL signaling pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Glypican pathway 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Proteoglycan syndecan-mediated signaling events 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Bicarbonate transporters 1 7.142857143 SLC4A1
Regulation of KIT signaling 1 7.142857143 PRKC
Beta1 integrin cell surface interactions 7 50 MMP2,MMP3,MMP9,MMP12,CTSD,MMP13,PRKC
Stabilization and expansion of the E-cadherin adherens junction 3 21.42857143 MMP2,MMP3,MMP9
E-cadherin signaling in the nascent adherens junction 3 21.42857143 MMP2,MMP3,MMP9
E-cadherin signaling events 3 21.42857143 MMP2,MMP3,MMP9
Signal regulatory protein (SIRP) family interactions 1 7.142857143 CD47
Interaction between L1 and Ankyrins 1 7.142857143 SPTBN2
Cell-Cell communication 2 14.28571429 SPTBN2,CD47
Platelet Adhesion to exposed collagen 1 7.142857143 CD36
Regulation of Insulin-like Growth Factor (IGF) Activity by Insulin-like Growth Factor Binding Proteins (IGFBPs) 1 7.142857143 MMP2
FAS (CD95) signaling pathway 2 14.28571429 CTSD,PRKC
Regulation of nuclear beta catenin signaling and target gene transcription 2 14.28571429 MMP2,MMP9
Platelet activation, signaling and aggregation 2 14.28571429 CD63,PRKC
Direct p53 effectors 2 14.28571429 MMP2,CTSD
CD28 dependent Vav1 pathway 1 7.142857143 SPTBN2
Canonical Wnt signaling pathway 2 14.28571429 MMP2,MMP9
CaM pathway 1 7.142857143 PRKC
Calmodulin induced events 1 7.142857143 PRKC
Phospholipase C-mediated cascade 1 7.142857143 PRKC
Ca-dependent events 1 7.142857143 PRKC
DAG and IP3 signaling 1 7.142857143 PRKC
Platelet degranulation 1 7.142857143 CD63
p75(NTR)-mediated signaling 2 14.28571429 MMP3,PRKC
IL8- and CXCR1-mediated signaling events 1 7.142857143 PRKC
EGFR interacts with phospholipase C-gamma 1 7.142857143 PRKC
VEGFR1 specific signals 1 7.142857143 PRKC
Noncanonical Wnt signaling pathway 2 14.28571429 MMP2,MMP9
PLC-gamma1 signalling 1 7.142857143 PRKC
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samples continued... 
 
Nephrin interactions 1 7.142857143 SPTBN2
p53 pathway 2 14.28571429 MMP2,CTSD
CXCR4-mediated signaling events 2 14.28571429 MMP9,PRKC
IL8- and CXCR2-mediated signaling events 1 7.142857143 PRKC
Wnt signaling network 2 14.28571429 MMP2,MMP9
Canonical NF-kappaB pathway 1 7.142857143 PRKC
a6b1 and a6b4 Integrin signaling 1 7.142857143 PRKC
RhoA signaling pathway 2 14.28571429 MMP2,PRKC
Regulation of RAC1 activity 2 14.28571429 MMP2,PRKC
Regulation of RhoA activity 2 14.28571429 MMP2,PRKC
RAC1 signaling pathway 2 14.28571429 MMP2,PRKC
Glypican 3 network 2 14.28571429 MMP2,MMP9
CD28 co-stimulation 1 7.142857143 SPTBN2
IL8-mediated signaling events 1 7.142857143 PRKC
PLC beta mediated events 1 7.142857143 PRKC
G-protein mediated events 1 7.142857143 PRKC
FOXM1 transcription factor network 1 7.142857143 MMP2
Ras signaling in the CD4+ TCR pathway 1 7.142857143 PRKC
Beta3 integrin cell surface interactions 1 7.142857143 CD47
Retinoic acid receptors-mediated signaling 1 7.142857143 PRKC
FGF signaling pathway 1 7.142857143 MMP9
Alpha6Beta4Integrin 1 7.142857143 PRKC
Regulation of Insulin Secretion 1 7.142857143 PRKC
Ceramide signaling pathway 1 7.142857143 CTSD
Angiopoietin receptor Tie2-mediated signaling 1 7.142857143 MMP2
ATR signaling pathway 2 14.28571429 MMP2,CTSD
Opioid Signalling 1 7.142857143 PRKC
Costimulation by the CD28 family 1 7.142857143 SPTBN2
Thromboxane A2 receptor signaling 1 7.142857143 PRKC
KitReceptor 1 7.142857143 PRKC
Endogenous TLR signaling 1 7.142857143 PRKC
NCAM signaling for neurite out-growth 1 7.142857143 SPTBN2
CD40/CD40L signaling 1 7.142857143 PRKC
Aurora A signaling 1 7.142857143 PRKC
Downstream signaling in na&#xef;ve CD8+ T cells 1 7.142857143 PRKC
Validated nuclear estrogen receptor alpha network 1 7.142857143 CTSD
Downstream signaling of activated FGFR 1 7.142857143 PRKC
IL23-mediated signaling events 1 7.142857143 PRKC
IL2 signaling events mediated by PI3K 1 7.142857143 PRKC
Signaling events regulated by Ret tyrosine kinase 1 7.142857143 PRKC
Transcriptional Regulation of White Adipocyte Differentiation 1 7.142857143 CD36
TNF receptor signaling pathway 2 14.28571429 CTSD,PRKC
ATM pathway 2 14.28571429 MMP2,CTSD
Downstream signal transduction 1 7.142857143 PRKC
Signaling by PDGF 1 7.142857143 PRKC
AP-1 transcription factor network 3 21.42857143 MMP2,MMP9,PRKC
Validated targets of C-MYC transcriptional activation 1 7.142857143 MMP9
L1CAM interactions 1 7.142857143 SPTBN2
Wnt 1 7.142857143 PRKC
Integration of energy metabolism 1 7.142857143 PRKC
C-MYB transcription factor network 1 7.142857143 PRTN3
Integrin-linked kinase signaling 3 21.42857143 MMP2,MMP9,PRKC
Role of Calcineurin-dependent NFAT signaling in lymphocytes 1 7.142857143 PRKC
Transport of inorganic cations/anions and amino acids/oligopeptides 1 7.142857143 SLC4A1
Signaling by FGFR 1 7.142857143 PRKC
Signaling by EGFR 1 7.142857143 PRKC
Signaling by Aurora kinases 1 7.142857143 PRKC
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements 1 7.142857143 PRKC
PLK1 signaling events 1 7.142857143 PRKC
NGF signalling via TRKA from the plasma membrane 1 7.142857143 PRKC
IL12-mediated signaling events 1 7.142857143 PRKC
Polo-like kinase signaling events in the cell cycle 1 7.142857143 PRKC
IL2-mediated signaling events 1 7.142857143 PRKC
CDC42 signaling events 3 21.42857143 MMP2,MMP9,PRKC
TCR signaling in na&#xef;ve CD8+ T cells 1 7.142857143 PRKC
Regulation of CDC42 activity 3 21.42857143 MMP2,MMP9,PRKC
Developmental Biology 2 14.28571429 CD36,SPTBN2
TCR signaling in na&#xef;ve CD4+ T cells 1 7.142857143 PRKC
EGFR1 1 7.142857143 PRKC
Signalling by NGF 1 7.142857143 PRKC
C-MYC pathway 1 7.142857143 MMP9
Regulation of p38-alpha and p38-beta 1 7.142857143 PRKC
p38 MAPK signaling pathway 1 7.142857143 PRKC
Diabetes pathways 1 7.142857143 MMP2
Axon guidance 1 7.142857143 SPTBN2
BMP receptor signaling 1 7.142857143 PRKC
IL1-mediated signaling events 1 7.142857143 PRKC
Metabolism of mRNA 1 7.142857143 PRKC
Adaptive Immune System 1 7.142857143 SPTBN2
SLC-mediated transmembrane transport 1 7.142857143 SLC4A1
Metabolism of RNA 1 7.142857143 PRKC
Regulation of cytoplasmic and nuclear SMAD2/3 signaling 1 7.142857143 PRKC
TGF-beta receptor signaling 1 7.142857143 PRKC
Regulation of nuclear SMAD2/3 signaling 1 7.142857143 PRKC
ALK1 signaling events 1 7.142857143 PRKC
ALK1 pathway 1 7.142857143 PRKC
Transmembrane transport of small molecules 1 7.142857143 SLC4A1
Immune System 1 7.142857143 SPTBN2
Signal Transduction 2 14.28571429 MMP9,PRKC
Signaling by GPCR 1 7.142857143 PRKC
Metabolism 1 7.142857143 PRKC
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Appendix IV 
GO assessment of proteins/genes present in HRV16iHMV 
The primary focus on GO annotations was associated with human proteins/genes only. 
After assessing the pattern of protein expression on HRV16iHMV samples, further 
analyses was focused on the protein to gene name conversion (actual protein coding 
sequence is often only a small part), using String and UniProt databases and then the 
cellular component (Fig. a), molecular function (Fig. b), biological processes (Fig. c), and 
specific biological pathways involved (Fig. d), using the same methodology used in 
chapter 3.2.4.  
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The functional enrichments among the multiple proteins present in HRV16iHMV 
samples  
Table 1. Description of mapped items for protein/gene expression data 
 
Table 2. Description of cellular components for protein/gene present in HRV16iHMV 
samples 
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Table 3. Description of molecular functions for protein/gene present in HRV16iHMV 
samples 
 
Table 4. Description of biological processes involved in protein/gene present in 
HRV16iHMV samples  
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Table 5. Description of biological pathways involved in protein/gene present in 
HRV16iHMV samples  
 
Biological pathway No. of genes  in the data setPercentage of genes Genes mapped from  input data set
Hemostasis 5 50 CD58,CD36,CD63,CD47,PRKCA
Response to elevated platelet cytosolic Ca2+ 2 20 CD63,PRKCA
Interferon gamma signaling 2 20 ICAM1,HLA-A
Thromboxane A2 receptor signaling 2 20 PRKCA,ICAM1
Downstream signaling in na&#xef;ve CD8+ T cells 2 20 PRKCA,HLA-A
Regulation of Insulin Secretion by Acetylcholine 1 10 PRKCA
Cell surface interactions at the vascular wall 2 20 CD58,CD47
Interferon Signaling 2 20 ICAM1,HLA-A
Integrin family cell surface interactions 6 60 CTSD,MMP13,CD47,PRKCA,ICAM1,HLA-A
Stabilization of mRNA by HuR 1 10 PRKCA
IL12-mediated signaling events 2 20 PRKCA,HLA-A
Endosomal/Vacuolar pathway 1 10 HLA-A
Regulation of KIT signaling 1 10 PRKCA
Cell-Cell communication 2 20 SPTBN2,CD47
TCR signaling in na&#xef;ve CD8+ T cells 2 20 PRKCA,HLA-A
Signal regulatory protein (SIRP) family interactions 1 10 CD47
FAS (CD95) signaling pathway 2 20 CTSD,PRKCA
Validated transcriptional targets of AP1 family members Fra1 and Fra2 2 20 PRKCA,HLA-A
Interaction between L1 and Ankyrins 1 10 SPTBN2
Platelet activation, signaling and aggregation 2 20 CD63,PRKCA
Platelet Adhesion to exposed collagen 1 10 CD36
CD28 dependent Vav1 pathway 1 10 SPTBN2
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 1 10 HLA-A
Cytokine Signaling in Immune system 2 20 ICAM1,HLA-A
Calmodulin induced events 1 10 PRKCA
CaM pathway 1 10 PRKCA
PDGFR-beta signaling pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
mTOR signaling pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
ErbB1 downstream signaling 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Arf6 signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Class I PI3K signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
EGF receptor (ErbB1) signaling pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Arf6 downstream pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Arf6 trafficking events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Insulin Pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Signaling events mediated by focal adhesion kinase 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Internalization of ErbB1 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
S1P1 pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Class I PI3K signaling events mediated by Akt 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
EGFR-dependent Endothelin signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
IGF1 pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
GMCSF-mediated signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
IL5-mediated signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
PDGF receptor signaling network 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Phospholipase C-mediated cascade 1 10 PRKCA
Ca-dependent events 1 10 PRKCA
DAG and IP3 signaling 1 10 PRKCA
Nectin adhesion pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
IL3-mediated signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
IFN-gamma pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Signaling events mediated by VEGFR1 and VEGFR2 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Glypican 1 network 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
PAR1-mediated thrombin signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Thrombin/protease-activated receptor (PAR) pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Syndecan-1-mediated signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Plasma membrane estrogen receptor signaling 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
VEGF and VEGFR signaling network 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Alpha9 beta1 integrin signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Platelet degranulation 1 10 CD63
Endothelins 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
LKB1 signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
ErbB receptor signaling network 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Sphingosine 1-phosphate (S1P) pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Beta2 integrin cell surface interactions 1 10 ICAM1
IL8- and CXCR1-mediated signaling events 1 10 PRKCA
VEGFR1 specific signals 1 10 PRKCA
EGFR interacts with phospholipase C-gamma 1 10 PRKCA
TRAIL signaling pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
PLC-gamma1 signalling 1 10 PRKCA
Nephrin interactions 1 10 SPTBN2
Immune System 3 30 SPTBN2,ICAM1,HLA-A
Glypican pathway 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Proteoglycan syndecan-mediated signaling events 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
Beta1 integrin cell surface interactions 5 50 CTSD,MMP13,PRKCA,ICAM1,HLA-A
IL8- and CXCR2-mediated signaling events 1 10 PRKCA
Adaptive Immune System 2 20 SPTBN2,HLA-A
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Table 5. Description of biological pathways involved in protein/gene present in 
HRV16iHMV samples continued... 
Canonical NF-kappaB pathway 1 10 PRKCA
a6b1 and a6b4 Integrin signaling 1 10 PRKCA
CD28 co-stimulation 1 10 SPTBN2
IL8-mediated signaling events 1 10 PRKCA
PLC beta mediated events 1 10 PRKCA
G-protein mediated events 1 10 PRKCA
amb2 Integrin signaling 1 10 ICAM1
Ras signaling in the CD4+ TCR pathway 1 10 PRKCA
Beta3 integrin cell surface interactions 1 10 CD47
AP-1 transcription factor network 3 30 PRKCA,ICAM1,HLA-A
Retinoic acid receptors-mediated signaling 1 10 PRKCA
Regulation of Insulin Secretion 1 10 PRKCA
Alpha6Beta4Integrin 1 10 PRKCA
Ceramide signaling pathway 1 10 CTSD
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 1 10 HLA-A
Costimulation by the CD28 family 1 10 SPTBN2
Opioid Signalling 1 10 PRKCA
TNF receptor signaling pathway 2 20 CTSD,PRKCA
Integrin-linked kinase signaling 3 30 PRKCA,ICAM1,HLA-A
KitReceptor 1 10 PRKCA
Endogenous TLR signaling 1 10 PRKCA
NCAM signaling for neurite out-growth 1 10 SPTBN2
CD40/CD40L signaling 1 10 PRKCA
ATF-2 transcription factor network 1 10 PRKCA
Validated nuclear estrogen receptor alpha network 1 10 CTSD
Aurora A signaling 1 10 PRKCA
Downstream signaling of activated FGFR 1 10 PRKCA
Signaling by SCF-KIT 1 10 PRKCA
IL23-mediated signaling events 1 10 PRKCA
IL2 signaling events mediated by PI3K 1 10 PRKCA
Signaling events regulated by Ret tyrosine kinase 1 10 PRKCA
Transcriptional Regulation of White Adipocyte Differentiation 1 10 CD36
Downstream signal transduction 1 10 PRKCA
CDC42 signaling events 3 30 PRKCA,ICAM1,HLA-A
Interferon alpha/beta signaling 1 10 HLA-A
Signaling by PDGF 1 10 PRKCA
L1CAM interactions 1 10 SPTBN2
Regulation of CDC42 activity 3 30 PRKCA,ICAM1,HLA-A
ER-Phagosome pathway 1 10 HLA-A
Glucocorticoid receptor regulatory network 1 10 ICAM1
Wnt 1 10 PRKCA
Integration of energy metabolism 1 10 PRKCA
Glucocorticoid receptor signaling 1 10 ICAM1
Antigen processing-Cross presentation 1 10 HLA-A
Signaling by FGFR 1 10 PRKCA
Role of Calcineurin-dependent NFAT signaling in lymphocytes 1 10 PRKCA
Signaling by EGFR 1 10 PRKCA
Signaling by Aurora kinases 1 10 PRKCA
LPA receptor mediated events 1 10 PRKCA
Class I MHC mediated antigen processing & presentation 1 10 HLA-A
Developmental Biology 2 20 CD36,SPTBN2
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements 1 10 PRKCA
PLK1 signaling events 1 10 PRKCA
NGF signalling via TRKA from the plasma membrane 1 10 PRKCA
Polo-like kinase signaling events in the cell cycle 1 10 PRKCA
IL2-mediated signaling events 1 10 PRKCA
TCR signaling in na&#xef;ve CD4+ T cells 1 10 PRKCA
Direct p53 effectors 1 10 CTSD
EGFR1 1 10 PRKCA
Signalling by NGF 1 10 PRKCA
Regulation of p38-alpha and p38-beta 1 10 PRKCA
p75(NTR)-mediated signaling 1 10 PRKCA
p53 pathway 1 10 CTSD
p38 MAPK signaling pathway 1 10 PRKCA
CXCR4-mediated signaling events 1 10 PRKCA
Regulation of RhoA activity 1 10 PRKCA
RAC1 signaling pathway 1 10 PRKCA
RhoA signaling pathway 1 10 PRKCA
Regulation of RAC1 activity 1 10 PRKCA
Syndecan-4-mediated signaling events 1 10 PRKCA
Axon guidance 1 10 SPTBN2
BMP receptor signaling 1 10 PRKCA
IL1-mediated signaling events 1 10 PRKCA
Metabolism of mRNA 1 10 PRKCA
ATR signaling pathway 1 10 CTSD
Metabolism of RNA 1 10 PRKCA
Regulation of nuclear SMAD2/3 signaling 1 10 PRKCA
Regulation of cytoplasmic and nuclear SMAD2/3 signaling 1 10 PRKCA
TGF-beta receptor signaling 1 10 PRKCA
ATM pathway 1 10 CTSD
ALK1 signaling events 1 10 PRKCA
ALK1 pathway 1 10 PRKCA
Signaling by GPCR 1 10 PRKCA
Metabolism 1 10 PRKCA
Signal Transduction 1 10 PRKCA
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Appendix V 
Ribonucleic acid (RNA) is a linear molecule composed of four types of smaller molecules 
called ribonucleotide bases: adenine (A); cytosine (C); guanine (G); and uracil (U). Each 
ribonucleotide base consists of a ribose sugar, a phosphate group, and a nitrogenous base. 
Unlike Deoxyribonucleic Acid (DNA), RNA is single-stranded. Additionally, RNA in 
comparison to DNA contains ribose sugars rather than deoxyribose sugars, resulting in 
RNA being unstable and more prone to degradation (Alberts, et al., 2014). The primary 
role of RNAs is to convert the genetic information stored in DNA into proteins (Berg, et 
al., 2002). 
RNA is synthesized from DNA by an enzyme known as RNA polymerase, during a 
process called transcription (DNA is copied to messenger RNA). The new RNA 
sequences are complementary to their DNA template, rather than being identical copies 
of the template. RNA is then translated into proteins by structures called ribosomes. While 
some RNA molecules are passive copies of DNA, many play crucial, active roles in the 
cell. For example, some RNA molecules are involved in switching genes on and off, and 
other RNA molecules make up the critical protein synthesis machinery in ribosomes 
(Alberts, et al., 2014).  
There are three major types of RNA involved in the translation process (protein synthesis) 
where Messenger RNA (mRNA) carries the genetic information copied from DNA in the 
form of a series of three bases, each of which specifies a particular amino acid; Transfer 
RNA (tRNA) is the key to deciphering the code words in mRNA, where each type 
of amino acid has its own type of tRNA, which binds it and carries it to the growing end 
of a polypeptide chain if the next code word on mRNA calls for it. Then correct tRNA 
with its attached amino acid is selected at each step, because each specific tRNA molecule 
contains a three-base sequence that can base-pair with its complementary code word in 
the mRNA; and  Ribosomal RNA (rRNA) associates with a set of proteins to 
form ribosomes. These complex structures physically move along an mRNA molecule, 
catalyse the assembly of amino acids into protein chains. They also bind tRNAs and 
various accessory molecules that are necessary for protein synthesis (Griffiths, et al., 
2000; Lodish , et al., 2000). 
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Small ncRNAs function by guiding sequence-specific gene silencing at the transcriptional 
and/or post-transcriptional level, through a mechanism known as RNA interference 
(RNAi) (Felekkis & Deltas, 2006). 
Briefly, the RNAi pathway involves two phases: 
1. During the initiation phase, the double stranded RNA (dsRNA) molecules are 
either in the form of a hairpin or a longer dsRNA is processed into an short, 
interfering RNA (siRNA) by the RNase II enzymes Dicer, a helicase with RNase 
motif- functions as a molecular ruler to produce dsRNA fragments 25 nucleotides 
in length (Macrae, et al., 2006) and Drosha, a ribonuclease (RNase) III double-
stranded RNA-specific ribonuclease and subunit of the microprocessor protein 
complex that generate staggered cuts on each side of the RNA helix (Nicholson, 
2014) and,  
2. During the execution phase, siRNAs are loaded into the effector complex RNA-
induced silencing complex (RISC), disentangled during and the single-stranded 
RNA hybridizes with mRNA target (Leuschner, et al., 2006).  The gene specific 
inactivation occurs by hybridization to and degradation of the target mRNA or by 
translation inhibition (Felekkis, et al., 2010). 
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The animal miRNA synthesis pathway  
 
 
 
 
“The miRNA genes are transcribed by RNA 
polymerase II (Pol II), which results in the 
production of a pri-miRNA. Drosha, along 
with DiGeorge syndrome critical region 
gene-8 (DGCR-8; Pasha in flies), mediates 
the initial processing step (primary 
processing) that produces a ~ 65 nucleotide 
(nt) pre-miRNA. The pre-miRNA has a short 
stem of 2–3 nt 3′ overhangs, which is 
recognised by exportin 5 (EXP5) that 
mediates transport to cytoplasm. In the 
cytoplasm, RNase III Dicer is thought to 
catalyse the second processing step 
(secondary processing), which generates the 
miRNA/miRNA* duplex. Dicer, TRBP or 
PACT (LOQS in flies), and Argonaute1–4 
(Ago 1–4) (Argonaute 1 in flies) are 
responsible for pre-miRNA processing and 
RISC (RNA-induced silencing complex) 
assembly. An unknown helicase is thought to 
mediate unwinding of the duplex. One strand 
of the duplex remains the mature miRNA 
(miRNA) on Ago, whereas the miRNA* or 
passenger strand is degraded. The figure 
shows the mammalian miRNA synthesis 
pathway and fly factors are in the squares.” 
Retrieved from Wahid, et al., (2010). 
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Appendix VI 
Gene ontology methodology for miRNA data 
Due to a large number of target genes generated by each miRNA, only instructions on 
how to produce the data and graphs can be provided, which is readily available as follows:   
1. In order to obtain the target genes for each miRNA of interest, please go to 
miRTarBase website (http://mirtarbase.mbc.nctu.edu.tw/php/search.php). On 
the home page select Search by miRNA, then select Human for species available 
from the drop down menu.  
 
This step will generated a large list for the miRNA of interest (each miRNA 
generally targets > 500 genes). 
2. Download FunRich software for free at http://www.funrich.org/download.  
3. Upload the data or copy and paste the target gene name/code retrieved from 
miRTarBase website to create a data set using FunRich software.  
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This step will allow the generation of enrichment analysis of the target genes for 
each, or for multiple miRNAs of interest.  
4. In order to obtain the full report of the enrichment analysis, simply save the 
generated report on the ExportExcel option available from the menu.  
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Appendix VII 
GO assessment of target genes for miRNA present in HRV16iHMV 
After assessing the pattern of expression of miRNAs in HRV16iHMV samples, further 
analyses was focused on the reported target genes using miRTarBase database. The 
analyses generated a list of candidate genes with >15.866 target genes for the 29 miRNA 
present in the MV samples, with >8.880 being redundant genes. The FunRich software 
classified their targets in clusters of genes that are not mutually exclusive, the reason for 
this is that the product of a single gene could have one or more cellular components (Fig. 
a), molecular functions (Fig. b), be associated with different biological processes (Fig. c) 
and be involved in several biological pathways (Fig. d). 
The graphs were created with the use of the FunRich functional enrichment analysis tool 
software, which performs functional enrichment analyses on background databases that 
are integrated from heterogeneous genomic and proteomic resources. The 
Hypergeometric distribution test was performed to check the statistical significance of 
enriched and depleted terms. In addition, the Bonferroni and Benjamini-Hochberg (BH) 
(also known as the False Discovery Rate (FDR)) method was also implemented to correct 
for multiple testing, each associated with a p-value (p <0.05). 
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Appendix VIII 
Protein kinase C  inhibits Caco-2 cell proliferation by selective changes in cell cycle and 
cell death regulators 
 
“A Proposed model for PKC-  antiproliferative functions in Caco-2 cells. PKC-
 signalling suppresses G1–S progression by inhibiting the expression levels of G1 cell 
cycle activators, cyclin D1 and cyclin E, and upregulating G1 cell cycle inhibitor 
p21Waf1 as well as p27Kip1–cdk4 complex. PKC-  signals also inhibit cell survival by 
downregulating antiapoptotic Bcl-2 and increasing proapoptotic Bax. These tumour 
suppressor pathways inhibit mitogenic signalling and enhance cell death that result in 
decreased cellular proliferation of colon cancer cells. Suppresses G1–S progression by 
inhibiting the expression levels of G1 cell cycle activators, cyclin D1 and cyclin E, and 
upregulating G1 cell cycle inhibitor p21Waf1 as well as p27Kip1–cdk4 complex. PKC-
 signals also inhibit cell survival by downregulation.” Retrieved from Cerda, et al., 
(2006). 
